



MALABAR CANCER CENTRE

[Postgraduate Institute of Oncology Sciences & Research]
(An Autonomous Institution under Govt. of Kerala)

THALASSERY

HOSPITAL BASED CANCER REGISTRY REPORT

2023

FUNDED BY NCDIR, ICMR



icmr
INDIAN COUNCIL OF
MEDICAL RESEARCH
Serving the nation since 1913





MALABAR CANCER CENTRE

[Postgraduate Institute of Oncology Sciences & Research]

THALASSERY



HOSPITAL BASED CANCER REGISTRY REPORT 2023

Funded by NCDIR, ICMR



Published on August 2025



ACKNOWLEDGEMENT

The Hospital Based Cancer Registry of Malabar Cancer Centre expresses its sincere thanks and gratitude to the following Institutions/Departments/Individuals for supporting and promoting the activities of the Registry.

- National Cancer Registry Programme, Indian Council of Medical Research, Bangalore
 - Medical Records Division, Malabar Cancer Centre, Thalassery
 - Department of Radiation Oncology, Malabar Cancer Centre, Thalassery
 - Department of Clinical Hematology & Medical Oncology, Malabar Cancer Centre, Thalassery
 - Department of Pathology, Malabar Cancer Centre, Thalassery
 - Department of Surgical Oncology, Malabar Cancer Centre, Thalassery
 - General Administration, Malabar Cancer Centre, Thalassery
- 

FROM DIRECTOR'S DESK



It is our pleasure to present the 14th report of Hospital Based Cancer Registry (HBCR) for the year 2023 in the silver jubilee year of Malabar Cancer Centre-Post Graduate Institute of Oncology Sciences and Research (MCC-PGIOSR). It is prudent to state that the HBCR reports over the years helped us understand trends in referral patterns and possible cancer burden in the regions. As a postgraduate institution, it is our responsibility to inform the public and the government about the burden of cancer and enable the government to make appropriate policy decisions. The highlights of the HBCR Annual Report for the year 2023 are as follows. A total of 5622 new cancer patients were registered at Malabar Cancer Centre (PGIOSR) during the year 2023. Among them 2885 (51.3 %) were males and 2737 (48.7%) were females. The proportion of leading cancers in males are lung (15.9%), mouth (6.2%), liver (5.9%), prostate (5.7%) and stomach (5.3%). Similarly the leading cancers in females are breast (30.7%), thyroid (9.1%), ovary (6.2%), cervix uteri (5.4%) and corpus Uteri (5.3%). Total proportion of tobacco related cancer (TRC) relative to all sites is 43% in males and 12.2 % in females. Lung, mouth, laryngeal, tongue, oropharynx, and esophageal cancers account for the majority of tobacco-related cancers. Special appreciation should be given to the registry Team leadership Dr. Saina Sunilkumar, Dr. Bindu and Dr. Ratheesan and all the members of their teams for the diligent work they put into this report. The Director of NCDIR, Bangalore and his august and energetic team deserve our sincere gratitude and appreciation for their support and assistance during the preparation of this report. Cancer researchers and students can use our reports to learn about the trend, distribution, and nature of cancer in these areas.

Dr. Satheesan Balasubramanian

DIRECTOR

PREFACE



It is with great pride and commitment that we present the 14th Annual Report of the Hospital-Based Cancer Registry (HBCR) for the year 2023, coinciding with the silver jubilee year of Malabar Cancer Centre – Post Graduate Institute of Oncology Sciences and Research (MCC–PGIOSR). This milestone is a testament to our institution's legacy of excellence in oncology care, research, and education.

Over the years, the HBCR has played a pivotal role in helping us understand regional cancer patterns, referral dynamics, and the growing burden of cancer in our catchment area. As a postgraduate academic and research institution, it is both our duty and privilege to make this information accessible to the public and relevant authorities, thereby contributing to informed health policy and cancer control planning.

In 2023, a total of 5,622 new cancer cases were registered at MCC–PGIOSR, comprising 2,885 (51.3%) males and 2,737 (48.7%) females. Tobacco-related cancers (TRC) remain a significant concern, accounting for 43% of all cancers in males and 12.2% in females., underscoring the importance of sustained public health efforts in tobacco cessation and prevention.

We hope this report continues to serve as a valuable reference for healthcare professionals, researchers, students, and policymakers, offering a clear picture of the local cancer landscape and guiding future interventions.

We express our heartfelt gratitude and appreciation to our Director, Dr. Satheesan Balasubramanian, for his unwavering support, visionary leadership, and continuous encouragement in advancing the objectives of the Hospital-Based Cancer Registry. His guidance has been instrumental in the successful compilation and dissemination of this report.

We also extend sincere thanks to all departments and cancer registry staff involved in data collection, validation, and analysis—your dedicated efforts make this work possible.

Dr. Saina Sunilkumar

Principal investigator

Hospital Based Cancer Registry

Malabar Cancer Centre – PGIOSR

TABLE OF CONTENTS

Sl. No	Contents	Page No.
I	Introduction	06
	Department of Cancer Registry & Epidemiology	06
	Hospital Based Cancer Registry	07
	National Cancer Registry Programme	08
II	Summary of Results	
	Patterns of Cancer Registration	09
	District wise Cancer Registration	10
	Leading Site of Cancers	11
	Cancer sites by Age and Gender	13
	Tobacco Related Cancers	16
	Method of Diagnosis	17
	Clinical Extent of Disease	18
	Cancer Directed Treatment	19
	Childhood Cancer	21
	Demographic Details	23
III	Detailed Information : Diagnostic, Clinical & Demographic	25-49
IV	Detailed Information - MCC	
	New /Old Cases	52
	System wise Cancers	52
	Habits & System wise Cancer	53
V	Ten Leading Cancers – Irrespective of Sex	54-81
	Breast	54
	Lung	57
	Thyroid	60
	Mouth	63
	Rectum	66
	NHL	69
	Colon	71
	Liver	74
	Stomach	77
	Tongue	79
VI	References	82

INTRODUCTION

Malabar Cancer Centre, Thalassery (MCC), Postgraduate institute of oncology sciences and research (PGIOSR) is an autonomous institution under Health and Family Welfare Department, Government of Kerala, started with an aim to establish a comprehensive cancer centre, providing the much-required oncology care to the population of Northern region of Kerala and neighbouring parts of Karnataka and Tamilnadu states and Union Territory of Pondicherry (Mahe). The main objective being establishing a modern cancer hospital, research and training centre of international standard in the treatment and prevention of cancer. MCC is providing a full spectrum of oncological care as an autonomous not-for-profit institution (200+bedded Hospital) funded by the State Government and other sources. Despite this, MCC provides a variety of patient support systems to assist them in getting treatment in time and completing the treatment. As per the clinical data of MCC, 96% of patients are treated free of cost or through subsidized rates, at MCC, through

various finance supporting schemes of Government and through donations from various NGO's, philanthropists etc;-. It has been undertaken by MCC, that no patients will be denied treatment for financial reasons. The control and management of the Centre are vested in the Governing Body consisting of 23 members. The routine activities and functions of the Centre are supervised by an Executive Committee, with the Secretary, Health & Family Welfare Department, being the Chairman of the Committee. All cancer survivors should have follow-up care. Follow-up care for cancer means consulting a Health care provider for regular medical checkups, once you have finished with treatment. These checkups may include blood tests as well as other tests and procedures that may require for your health, or any problems that may occur due to cancer treatment. These visits are also a time to check for physical and emotional problems that may develop, for months or years for prevention.

DEPARTMENT OF CANCER REGISTRY & EPIDEMIOLOGY

Department of Cancer Registry and Epidemiology was established in the year 2010 and started Hospital Based Cancer Registry partially supported by National Cancer Registry Programme (ICMR), Bangalore. The department routinely published the Hospital Based Cancer Registry reports and this is

the 14th report of Hospital Based Cancer Registry. The Hospital Based Cancer registry project was renamed as Hospital Based Cancer Registry in India- NCDIR/ICMR and funded by ICMR, Bengaluru, 01.04.2022 to 31.03.2027.

STAFF [Department of Cancer Registry & Epidemiology]

Sl. No	Name	Designation
1.	Dr. Saina Sunil Kumar	Lecturer [HOD in charge]
2.	Dr. Bindu T	Lecturer in Biostatistics
3.	Dr. Ratheesan K	Lecturer in Biostatistics
4.	Sri. Prachith K S	Coding Clerk
5.	Smt. Sheena E	Data Entry Operator [Outsource]
6.	Smt. Nisha K	Data Entry Operator [Outsource]

PROJECT STAFF

Sl. No	Name	Designation
1.	Nijin P	Social Worker[HBCR]
2.	Rejisha R	Registry Data Entry Operator [HBCR]
3.	Shibin Mathew	Social worker [POCSS]
4.	Akshaj E	Registry Data Entry Operator [POCSS]
5.	Athira M	Data Entry Operator [POCSS]

Currently, the department has the following programmes.

- **Hospital based cancer registry in India [Under the network of NCDIR/ ICMR]**
- **Population Based Cancer Registry [Under the network of NCDIR/ ICMR]**

The department launched Malabar Population Based Cancer Registry partially supported by NCDIR, Bangalore in 2014 for three districts of Kannur, Kasaragod & Mahe. The department also published four PBCR reports for years 2015, 2016, 2017 and 2018. The department expanded the PBCR area to five other neighboring districts of Wayanad, Kozhikode, Malappuram, Thrissur and Palakkad in 2018.

- **A study on patterns of care and survival of head and neck, breast and cervical cancers in India under the Hospital Based Cancer Registries of National Cancer Registry Program [Under the network of NCDIR/ICMR]**

Funded project of NCRP/ICMR, Patterns of Care & Survival Studies in Breast, Cervix & Head & Neck cancers started in 2014. The project was renamed as “**A study on Patterns of Care & Survival of Breast, Cervix and Head & Neck Cancers in India**”.

Hospital based cancer registry in India [Under the network of NCDIR/ ICMR]:

Hospital based cancer registries collect information of cancers reported in a given hospital, regardless of where that person with cancer resides. Hospital based registries help in assessing cancer patient care in a given hospital and aid in hospital administration including the individual hospital's cancer control programmes. Hospital registries help in planning and monitoring survival studies and clinical trials. Hospital registries contribute cases to the population based cancer registry in the area. The primary purpose of Hospital Based Cancer Registries is to contribute to patient care by providing readily accessible information on the patients with cancer, the treatment received and its results. The data is also used for clinical research and for epidemiological purposes. Hospital based cancer registries are concerned with recording of information on the cancer patients seen in a particular hospital (Isabel dos Santos Silva et al, 1999). Within the hospital, a registry is often considered to be an integral part of the hospital's cancer Programme or health care delivery system.

In hospital based cancer registry, the data abstraction and entry are done using the hospital files. The core proforma contains the demographic details, diagnostic, treatment and follow up details. The details of the ICMR core proforma are entered using the ICMR software after retrieving case sheets from the MCC Medical Records division. All variables in the core pro forma except age and various dates are directly selected. The selection box contains all the codes along with their descriptions for each variable. Hence, this helps to avoid mistakes beyond the range of values for each variable. The selection box corresponding to the variable topography and morphology contains the third edition of international classification of diseases for oncology (ICD-O-3) and the international classification of diseases (ICD-10).

After abstraction, coding and data entry the data were sent to the coordinating unit of the NCRP of ICMR, Bangalore in an electronic format and the data was subjected to various range, consistency, unlikely combinations, and duplicate checks. Necessary corrections are done based on the error list of the cases sent by the coordinating unit and this report is generated.

NATIONAL CANCER REGISTRY PROGRAMME [INDIAN COUNCIL OF MEDICAL RESEARCH]

The Indian Council of Medical Research initiated a network of cancer registries across the country under the National Cancer Registry Programme (NCRP) in December 1981. This move followed the recognition that there was an urgent need for strengthening the existing cancer registries and organization of new cancer registries in different regions of the country.

The Programme had commenced with the following objectives:

1. To generate reliable data on the magnitude and patterns of cancer – this would be based on morbidity and mortality rates including incidence rates according to gender, age and residence of the patient, anatomical site of cancer and proportion of histological type or microscopic confirmation for each site; pattern of different types of cancer according to relative proportions or ratios in various population sub-groups such as religion, language spoken, educational status; clinical stage of disease when patients come to hospital for treatment and where possible the nature of treatment received and outcome;
2. To undertake epidemiologic studies in the form of case control or cohort studies based on observations of registry data;
3. Provide research base for developing appropriate strategies to aid in National Cancer Control Programme; this would be in the form of planning, monitoring and evaluation of activities under this Programme;
4. Develop human resource in cancer registration and Epidemiology.

SUMMARY OF RESULTS

- During the year 2023, a total of 5622 cancer patients were registered at MCC and among them 2885 (51.3%) were males and 2737 (48.7%) were females.
- Average age at diagnosis was 60.4 years (SD: 15.1) in males and 56.2 years (SD: 14.7) in females.
- Among the cancer cases reported for the year 2023, date of diagnosis was 2023 itself for 4831 (85.9%) cases and the remaining cases had their date of diagnosis was in the previous years.
- Among males Lung cancer (15.9%) was the leading site followed by Mouth cancer (6.2%). The third leading cancer was liver (5.9%).
- Among females, Breast cancer (30.7%) was the leading site of cancer followed by thyroid (9.1%). The third leading cancer was ovary (6.2%).
- Considering the five year age group, the peak age group was 60-64 years in males and 55-59 years in females.
- Children (0-14 years) constitute 1.8% of all cancers and in children leukaemia was the leading cancer in both genders.
- 4.4% of all cancers were in age group 15-34 years. In this age group thyroid cancer was the leading cancer in both males (16.3%) and females (31.5%).
- 55.7% of all cancers were in age group 35-64 years. In 35-64 age group lung cancer (12.7%) was the leading cancer in males and breast cancer (36.1%) was the leading cancer in females.
- 38.1% of all cancers were in age group 65+ years. In this age group lung cancer (21.4%) was the leading cancer in males and breast cancer (23.2%) was the leading cancer in females.
- The proportion of tobacco related cancer relative to all cancers was 43.0% in males and 12.2% in females.
- The peak age group for tobacco related cancer was 60-64 years in males (19.4%) and 75+ years in females (21.3%).
- Among 5622 registered cases, 90.7% of males and 96.3% of females were microscopically diagnosed.


- Among the microscopically diagnosed cases, histology of primary was available in 82.6% of males and 86.6% of females
- Among 5622 cancer cases, 895(15.9%) of patients received prior treatment only, 874(15.5%) of patients received prior treatment and treatment at MCC and 2299(40.9%) of patients received treatment only at MCC.
- Among 2299 patients who received treatment only at MCC 1144(39.7%) were males and 1155(42.2%) were females.
- The system wise leading cancer was digestive organ (64.5% in males and 35.5% in females) followed by breast cancer (99.5% in females).

Patterns of Patient Registration, 2023

Type	Total
Total Registration	7650
Malignant [including multiple primaries]	5622
Non malignant	2028

Table 1: Patterns of Patient Registration

Figure 1: Annual Number of Cancer patients, HBCR (2010-2023)



DISTRICT WISE CANCER REGISTRATION HBCR 2023**Table 2: Districtwise Patients Registration**

District	Patients	%
Kannur	2774	49.34%
Kasaragod	895	15.92%
Kozhikode	838	14.91%
Malappuram	446	7.93%
Wayanad	312	5.55%
Palakkad	103	1.83%
Thrissur	61	1.09%
Ernakulam	13	0.23%
Idukki	6	0.11%
Kottayam	6	0.11%
Pathanamthitta	4	0.07%
Alappuzha	9	0.16%
Kollam	7	0.12%
Thiruvananthapuram	20	0.36%
Other states		
Pondicherry	50	0.89%
Karnataka	47	0.84%
Tamilnadu	19	0.34%
Other states	12	0.21%



NATIONAL CENTER FOR DISEASE INFORMATICS AND RESEARCH NATIONAL CANCER REGISTRY PROGRAMME


(Indian Council of Medical Research)
Hospital Based Cancer Registry
524 - Malabar Cancer Centre, Kannur

Report Based on Year of Registration: 2023 MAGNITUDE OF CANCERS

During the year 2023, the total number of cancer patients registered in the HBCR was 5622
[Male: 2885, Female: 2737] and the male to female ratio was 1.05:1

Table 3: Number (#) and Proportion (%) according to Sex and Sex Ratio Percent

Males		Females		Total Cases
#	%	#	%	
2885	51.3	2737	48.7	5622



LEADING SITE OF CANCERS

Leading site of cancer among males was Lung cancer followed by mouth
Leading site of cancer among females was Breast cancer followed by Thyroid

Table 4: Rank, Number(#) and Relative Proportion(%) of Leading Sites of Cancer- Males

Relative proportion of Ten leading site of cancer – Males

Rank	Sites(ICD 10)	#	%
1	Lung etc.	460	15.9
2	Mouth	179	6.2
3	Liver	169	5.9
4	Prostate	164	5.7
5	Stomach	152	5.3
6	Rectum	142	4.9
7	NHL	137	4.7

8	Larynx	126	4.4
9	Tongue	124	4.3
10	Oropharynx	108	3.7
	All Sites	2885	100





Table 5: Rank, Number(#) and Relative Proportion(%) of Leading Sites of Cancer- Females

Rank	Sites (ICD-10)	#	%
1	Breast	840	30.7
2	Thyroid	248	9.1
3	Ovary	170	6.2
4	Cervix	148	5.4
5	Corpus Uteri	146	5.3
6	Colon	110	4.0
7	Lung	110	4.0
8	Rectum	101	3.7
9	NHL	94	3.4
10	Mouth	79	2.9
	All Sites	2737	100



CANCER SITES BY AGE AND GENDER

Five year age group

- Peak age group : 60-64in males and females
- Mean age at diagnosis : 60.4 years for males and 56.2 years for females

Table 6: Five Year Age Distribution

Age in years	Male(N=2885)		Female(N=2737)		Total(5622)	
	#	%	#	%	#	%
00-04	25	0.9	18	0.7	43	0.8
05-09	22	0.8	7	0.3	29	0.5
10-14	15	0.5	12	0.4	27	0.5
15-19	21	0.7	19	0.7	40	0.7
20-24	26	0.9	27	1.0	53	0.9
25-29	19	0.7	37	1.4	56	1.0
30-34	38	1.3	60	2.2	98	1.7
35-39	68	2.4	126	4.6	194	3.5
40-44	124	4.3	227	8.3	351	6.2
45-49	145	5.0	301	11.0	446	7.9
50-54	273	9.5	344	12.6	617	11.0
55-59	321	11.1	372	13.6	693	12.3
60-64	489	16.9	342	12.5	831	14.8
65-69	460	15.9	327	11.9	787	14.0
70-74	478	16.6	264	9.6	742	13.2
75+	361	12.5	254	9.3	615	10.9

Broad age group

□ 49.2% of males and 62.6% females were in the age group 35-64 years


Table 7: Number and Proportion of Patients according to Broad age group

Broad Age Groups	Males(N=2885)		Females(N=2737)		Total(N=5622)	
	#	%	#	%	#	%
00-14	62	2.1	37	1.4	99	1.8
15-34	104	3.6	143	5.2	247	4.4
35-64	1420	49.2	1712	62.6	3132	55.7
65+	1299	45.0	845	30.9	2144	38.1

Table 8 :Number(#) and proportion of leading site of cancer and broad age group

Age	Male				Female			
	Rank	Leading sites	#	%	Rank	Leading sites	#	%
0-14	1	Lymphoid Leukaemia	21	33.9	1	Lymphoid Leukaemia	13	35.1
	2	Brain, Nervous system	10	16.1	2	Myeloid Leukaemia	7	18.9
	3	Bone	5	8.1	3	Brain, Nervous system	4	10.8
	4	NHL	5	8.1	4	NHL	2	5.4
	5	Hodgkins disease	4	6.5	5	Bone,Ovary	2	5.4
15-34	1	Thyroid	17	16.3	1	Thyroid	45	31.5
	2	Bone	13	12.5	2	Breast	26	18.2
	3	Myeloid Leukaemia	11	10.6	3	Ovary	14	9.8
	4	Brain, Nervous system	10	9.6	4	Myeloid Leukaemia	10	7.0
	5	Lymphoid Leukaemia	9	8.7	5	NHL	7	4.9
35-64	1	Lung	180	12.7	1	Breast	618	36.1
	2	Mouth	116	8.2	2	Thyroid	169	9.9
	3	NHL	87	6.1	3	Ovary	116	6.8
	4	Tongue	86	6.1	4	Corpus Uteri	107	6.3
	5	Liver	81	5.7	5	Cervix Uteri	95	5.5
65+	1	Lung	278	21.4	1	Breast	196	23.2
	2	Prostate	117	9.0	2	Cervix Uteri	51	6.0
	3	Liver	87	6.7	3	Corpus Uteri	38	4.5
	4	Stomach	86	6.6	4	Ovary	38	4.5
	5	Rectum	70	5.4	5	Thyroid	33	3.9

Five Leading Cancer Sites by broad age group



TOBACCO RELATED CANCERS

Table 9: Number (#) and Proportion (%) of Cancers associated with Tobacco Relative to all sites of Cancer

Males			Females		
All Sites	#	%	All Sites	#	%
2885	1241	43.0	2737	334	12.2

Table 10: Number (#) and Proportion (%) of Tobacco Related Cancers (TRC) relative to all sites of Cancer

Sites of Cancer	Males		Females	
	#	%	#	%
Lip (C00)	12	0.4	11	0.4
Tongue (C01-02)	124	4.3	47	1.7
Mouth (C03-06)	179	6.2	79	2.9
Oropharynx (C10)	108	3.7	8	0.3
Hypopharynx (C12-13)	60	2.1	16	0.6
Pharynx (C14)	1	0.03	-	-
Oesophagus (C15)	87	3.0	35	1.3
Larynx (C32)	126	4.4	11	0.4
Lung (C33-34)	460	15.9	110	4.0
Urinary Bladder (C67)	84	2.9	17	0.6
TRC	1241	43.0	334	12.2
All Sites	2885	100.0	2737	100

Table 11: Number (#) and Proportion (%) of Specific Sites of Cancers among Tobacco Related Cancers (TRC)

Sites of Cancer	Males		Females	
	#	%	#	%
Lip (C00)	12	1.0	11	3.3
Tongue (C01-02)	124	10.0	47	14.1
Mouth (C03-06)	179	14.4	79	23.7
Oropharynx (C10)	108	8.7	8	2.4
Hypopharynx (C12-13)	60	4.8	16	4.8
Pharynx (C14)	1	0.1	-	-

Oesophagus (C15)	87	7.0	35	10.5
Larynx (C32)	126	10.2	11	3.3
Lung (C33-34)	460	37.1	110	32.9
Urinary Bladder (C67)	84	6.8	17	5.1
TRC	1241	100	334	100

Table 12 :Number (#) and Proportion (%) of Tobacco Related Cancers (TRC) by Five year age group

Age group	Males		Females	
	#	%	#	%
00-14	1	0.1	-	-
15-19	-		1	0.3
20-24	-		1	0.3
25-29	-		1	0.3
30-34	8	0.6	3	0.9
35-39	30	2.4	8	2.4
40-44	42	3.4	13	3.9
45-49	54	4.4	20	6.0
50-54	104	8.4	31	9.3
55-59	135	10.9	41	12.3
60-64	241	19.4	48	14.4
65-69	220	17.7	46	13.8
70-74	234	18.9	50	15.0
75+	172	13.9	71	21.3
All Ages	1241	100	334	100

Peak age group of tobacco related cancer was 60-64 in males and 75+ in females

METHOD OF DIAGNOSIS

Table 13 : Number (#) and Proportion (%) of Cancers by Method of Diagnosis

Method of Diagnosis	Males (N=2885)		Females (N=2737)		Total (N=5622)	
	#	%	#	%	#	%
Microscopic	2618	90.7	2637	96.3	5255	93.5
All imaging Techniques	251	8.7	88	3.2	339	6.0
Clinical	10	0.3	7	0.3	17	0.3
Others	6	0.2	5	0.2	11	0.2

Table 14: Number (#) and Proportion (%) of Cancers by Different Types of Microscopic Diagnosis

Types of Microscopic Diagnosis	Males (N=2618)		Females (N=2637)		Total (N=5255)	
	#	%	#	%	#	%
Histology of Primary	2163	82.6	2283	86.6	4446	84.6
Histology of Metastasis	147	5.6	103	3.9	250	4.8
Cytology of Primary	34	1.3	66	2.5	100	1.9
Cytology of Metastasis	64	2.4	31	1.2	95	1.8
Blood Film	7	0.3	2	0.1	9	0.2
Bone Marrow	203	7.8	152	5.8	355	6.8

Table 15: Number (#) and Proportion (%) of Cancers by Different Types of Microscopic Diagnosis (Includes Non-Microscopic Cases)

Types of Microscopic Diagnosis	Males (N=2885)		Females (N=2737)		Total (N=5622)	
	#	%	#	%	#	%
Histology of Primary	2163	75.0	2283	83.4	4446	79.1
Histology of Metastasis	147	5.1	103	3.8	250	4.4
Cytology of Primary	34	1.2	66	2.4	100	1.8
Cytology of Metastasis	64	2.2	31	1.1	95	1.7
Blood Film	7	0.2	2	0.1	9	0.2
Bone Marrow	203	7.0	151	5.5	354	6.3
Non Microscopic	267	9.3	101	3.7	368	6.5

CLINICAL EXTENT OF DISEASE

Table 16: Number (#) and Proportion (%) of Cancers by Clinical Extent of Disease (Treatment only at RI)

Clinical Extent	Males(N=1144)		Females(N=1155)		Total(N=2299)	
	#	%	#	%	#	%
Localised (L)	258	22.6	386	33.4	644	28.0
Regional (R)	427	37.3	440	38.1	867	37.7
Distant	277	24.2	188	16.3	465	20.2
Others	182	15.9	141	12.2	323	14.0

Table 17: Number (#) and Proportion (%) of Cancers by Clinical Extent of Disease (Prior Treatment Only)

Clinical Extent	Males (N=465)		Females (N=430)		Total (N=895)	
	#	%	#	%	#	%
Localised (L)	7	1.5	12	2.8	19	2.1
Regional(R)	10	2.2	16	3.7	26	2.9
Distant	23	4.9	19	4.4	42	4.7
Others	425	91.4	383	89.1	808	90.3

Table 18: Number (#) and Proportion (%) of Cancers by Clinical Extent of Disease (Prior & Treatment at MCC)

Clinical Extent	Males (N=335)		Females (N=539)		Total (N=874)	
	#	%	#	%	#	%
Localised	14	4.2	38	7.1	52	5.9
Regional	20	5.9	26	4.8	46	5.3
Distant	24	7.2	23	4.3	47	5.4
Others	277	82.7	452	83.9	729	83.4

Table 19: Number (#) and Proportion (%) of Cancers by Clinical Extent of Disease (No Treatment)

Clinical Extent	Males (N=941)		Females (N=613)		Total (N=1554)	
	#	%	#	%	#	%
Localised	162	17.2	115	18.8	277	17.8
Regional	238	25.3	155	25.3	393	25.3
Distant	379	40.3	226	36.9	605	38.9
Others	158	16.8	112	18.3	270	17.4
Unknown	4	0.4	5	0.8	9	0.6

CANCER DIRECTED TREATMENT

Prior Treatment Only:

Patients who received partial or complete cancer directed treatment before registration at MCC and not received any further treatment at MCC.

Prior and Treatment at MCC:

Patients who received some cancer directed treatment prior to registration at MCC and also at MCC.

Treatment Only at MCC:

Patients reporting for the first time at MCC with or without a confirmed diagnosis of malignancy and receiving cancer directed treatment at MCC

No Treatment:

Patients who have not received any cancer directed treatment before registration at MCC and not received any further treatment at MCC.

Table 20: Number (#) and Relative Proportion (%) of Patients by Broad Treatment Group

Treatment	Males (N=2885)		Females (N=2737)		Total (N=5622)	
	#	%	#	%	#	%
Prior treatment Only	465	16.1	430	15.7	895	15.9
Prior treatment & treatment at MCC	335	11.6	539	19.7	874	15.5
Treatment Only at MCC	1144	39.7	1155	42.2	2299	40.9
No treatment	941	32.6	613	22.4	1554	27.6

Table 21: Number (#) and Relative Proportion (%) of Patients according to type of treatment given (Treatment Only at MCC)

	Males (N=1144)		Females (N=1155)		Total (N=2299)	
	#	%	#	%	#	%
Surgery (S)	109	9.5	105	9.1	214	9.3
Radiotherapy ®	323	28.2	133	11.5	456	19.8
Chemotherapy©	230	20.1	182	15.8	412	17.9
S + R	97	8.5	64	5.5	161	7.0
S + C	61	5.3	100	8.7	161	7.0
R + C	191	16.7	125	10.8	316	13.7
S + R + C	64	5.6	96	8.3	160	6.9
Hormonotherapy	22	1.3	20	1.7	42	1.8
S+H	5	0.4	52	4.5	57	2.5
R+H	19	1.7	6	0.5	25	1.1
C+H	6	0.5	12	1.0	18	0.8
S+R+H	12	1.0	55	4.8	67	2.9
S+C+H	1	0.1	44	3.8	45	1.9
R+C+H	3	0.3	2	0.2	5	0.2
S+R+C+H	-	-	159	13.8	159	6.9
Others	1	0.1	-	-	1	0.04

Table 22: Number (#) and Relative Proportion (%) of Cancer Patients according to Any Specific Treatment relative to all Treatment Procedures (Treatment Only at RI)

Treatments	Males (N=1683)		Females (N=2385)		Total (N=4068)	
	#	%	#	%	#	%
Any Surgery	349	20.7	675	28.3	1024	25.2
Any Radiotherapy	709	42.1	640	26.8	1349	33.2
Any Chemotherapy	556	33.0	720	30.2	1276	31.4
Any Hormone Therapy	68	4.0	350	14.7	418	10.3
Others	1	0.1	-	-	1	0.02

Table 23: Number(#) and Proportion(%) of Treatment Status at Reporting Institution (Excluding the Cancers Previously Treated)

Treatment Status	Males (N=2085)		Females (N=1768)		Total (N=3853)	
	#	%	#	%	#	%
Received	1144	54.9	1155	65.3	2299	59.7
Not Received	663	31.8	408	23.1	1071	27.8
Not Accepted	175	8.4	108	6.1	283	7.3
Incomplete	103	4.9	97	5.5	200	5.2

Intention to Treat:

Table 24: Number (#) and Relative Proportion (%) of Cancers by intent to treat [Excluding Previously treated]

Intention to treat	Male (N=1144)		Female (N=1155)		Total (N=2299)	
	#	%	#	%	#	%
Radical	699	61.1	914	79.1	1613	70.2
Palliative	445	38.9	241	20.9	686	29.8

CHILDHOOD CANCER

Table 25: Number (#) and Proportion (%) of Cancers in Childhood relative to all Cancers

Boys			Girls		
All Cancers	#	%	All Cancers	#	%
2885	62	2.1	2737	37	1.4

Table 26: Number (#) and Proportion(%) of Childhood Cancers by Five-year Age Group

Age Groups	Boys		Girls		Total	
	#	%	#	%	#	%
00-04	25	40.3	18	48.6	43	43.4
05-09	22	35.5	7	18.9	29	29.3
10-14	15	24.2	12	32.4	27	29.3
All Childhood Cancers	62	100	37	100	99	100

Table 27: Number(#) and Relative Proportion(%) of Broad Types of Cancers in-Childhood (0-14 years)

Broad Type of Cancers in Childhood	Boys		Girls	
	#	%	#	%
Leukaemias	22	35.5	20	54.1
Lymphomas &ReticuloendothelialNeop	9	14.5	3	8.1
CNS &Misc Intracranial &IntraspinalNeop	9	14.5	4	10.8
Sympathetic Nervous System Tumors	5	8.1	1	2.7
Retinoblastoma	2	3.2	1	2.7
Renal Tumors	-		1	2.7
Hepatic Tumours	-		1	2.7
Malignant Bone Tumours	5	8.1	2	5.4
Soft Tissue (S-T) Sarcomas(S)	6	9.7	1	2.7
Carcinoma &Oth Malignant Epithelial Neop.	1	1.6	-	-
Others (Not Classified)	3	4.8	3	8.1
All Types	62	100	37	100

Table 28 :Number (#) and Relative Proportion (%) of Specific Types of Cancers in Childhood (0-14 years)

Specific Types of Cancers in Childhood	Boys		Girls	
	#	%	#	%
LEUKAEMIAS	22	35.5	20	54.1
Lymphoid Leukaemias	19	30.6	11	29.7
Acute non-lymphocytic Leukaemias	1	1.6	6	16.2
Unsp. Leukaemias	2	3.2	3	8.1
LYMPHOMAS & RETICULOENDOTHELIAL NEOP.	9	14.5	3	8.1
Hodgkin"s Disease	4	6.5	1	2.7
Non-Hodgkin"s Disease	3	4.8	2	5.4
Burkitt"s Lymphoma	1	1.6	-	-
MiscLymphoreticularneop.	1	1.6	-	-
C.N.S & MISC. INTRACRANIAL & INTRASPINAL NEOP.	9	14.5	4	10.8
Ependymoma	3	4.8	1	2.7
Primitive NeuroectodermalTumours	2	3.2	2	5.4
Other Gliomas	4	6.5	1	2.7

SYMPATHETIC NERVOUS SYSTEM TUMOURS	5	8.1	1	2.7
Neuroblastoma and Ganglioneuroblastoma	5	8.1	1	2.7
RETINOBLASTOMA	2	3.2	1	2.7
RENAL TUMOURS	-	-	1	2.7
Wilms's Tumour, Rhabdoid and clear cell Sarcoma	-	-	1	2.7
HEPATIC TUMOURS	-	-	1	2.7
Hepatoblastoma	-	-	1	2.7
MALIGNANT BONE TUMOURS	5	8.1	2	5.4
Osteosarcoma	3	4.8	1	2.7
Ewing's Sarcoma	2	3.2	1	2.7
SOFT-TISSUE(S-T) SARCOMAS(S)	6	9.7	1	2.7
Rhabdomyosarcoma and embryonal Sarcoma	3	4.8	-	-
Fibros. neurofibros. and othFibromatousneop	-	-	1	2.7
Other Specified Soft Tissue Sarcoma	2	3.2	-	-
Unsp. soft tissue Sarcoma	1	1.6	-	-
CARCINOMA & OTH MALIGNANT EPITHELIAL NEOP.	1	1.6	-	-
Nasopharyngeal Carcinoma	1	1.6	-	-
OTHERS (Not Classified)	3	4.8	3	8.1
All Types	62	100	37	100

DEMOGRAPHIC DETAILS

TABLE 29: NUMBER (#) AND RELATIVE PROPORTION OF CANCERS BY MARITAL STATUS

Marital Status	Males (N=2885)		Females (N=2737)		Total (N=5622)	
	#	%	#	%	#	%
Unmarried	183	6.3	158	5.8	341	6.1
Married	2672	92.6	2171	79.3	4843	86.1
Widowed	21	0.7	380	13.9	401	7.1
Divorced	9	0.3	28	1	37	0.7

Table 30: Number (#) and Relative Proportion of Cancers by Education

Education	Males (N=2885)		Females (N=2737)		Total (N=5622)	
	#	%	#	%	#	%
Middle	1026	35.6	869	31.8	1895	33.7
Secondary	769	26.7	711	26.0	1480	26.3
Primary	497	17.2	470	17.2	967	17.2
Literate	241	8.4	279	10.2	520	9.2
College	172	6	200	7.3	372	6.6
Others	180	6.2	208	7.6	388	6.9

Table 31: Number (#) and Relative Proportion of Cancers by Religion

Religion	Males (N=2885)		Females (N=2737)		Total (N=5622)	
	#	%	#	%	#	%
Hindu	1740	60.3	1670	61	3410	60.7
Muslim	896	31.1	844	30.8	1740	30.9
Christian	249	8.6	223	8.1	472	8.4

**DETAILED
INFORMATION
NCRP-ICMR
DIAGNOSTIC,
CLINICAL AND
DEMOGRAPHIC**

**NATIONAL CENTRE FOR DISEASE INFORMATICS AND RESEARCH
NATIONAL CANCER REGISTRY PROGRAMME**

(Indian Council of Medical Research)



**Hospital Based Cancer Registry
524 HBCR - Malabar Cancer Centre, Kannur**

Report Based on Year of Registration : 2023

TABLE 1(a): Number of cancers by site (ICD-10) and Five Year Age Group - Males

As on: 11/06/2025

ICD 10	Site	00-04	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	Unk	Total	%
C00	Lip	-	-	-	-	-	-	-	-	-	3	1	1	3	1	2	1	-	12	0.4
C01-02	Tongue	-	-	-	-	-	-	4	13	14	8	22	16	13	14	10	10	-	124	4.3
C03-06	Mouth	1	-	-	-	-	-	1	12	14	19	24	27	20	15	21	25	-	179	6.2
C07-08	Salivary Gland	-	-	-	-	1	-	-	1	2	2	5	3	3	-	-	-	-	19	0.7
C09	Tonsil	-	-	-	-	-	-	-	-	-	-	-	1	1	-	-	-	-	2	0.1
C10	Oth. Oropharynx	-	-	-	-	-	-	-	1	5	6	11	9	25	19	20	12	-	108	3.7
C11	Nasopharynx	1	-	1	-	-	1	1	-	1	1	1	2	1	-	-	-	-	10	0.3
C12-13	Hypopharynx	-	-	-	-	-	-	-	2	2	1	2	5	14	10	14	10	-	60	2.1
C14	Pharynx Unspecified	-	-	-	-	-	-	-	-	-	-	-	1	-	-	-	-	-	1	0.0
C15	Oesophagus	-	-	-	-	-	-	-	-	1	2	5	10	26	14	14	15	-	87	3.0
C16	Stomach	-	-	-	-	-	-	-	2	6	10	9	10	29	30	29	27	-	152	5.3
C17	Small Intestine	-	-	-	-	-	-	-	-	-	-	-	3	2	-	1	1	-	7	0.2
C18	Colon	-	-	-	1	1	-	2	1	5	5	14	10	18	16	17	11	-	101	3.5
C19-20	Rectum	-	-	-	-	1	-	-	-	7	11	17	15	21	21	24	25	-	142	4.9
C21	Anus & Anal Canal	-	-	-	-	-	-	-	-	-	-	-	2	5	1	1	1	-	10	0.3
C22	Liver	-	1	-	-	-	-	-	3	4	3	12	25	34	37	30	20	-	169	5.9
C23-24	Gallbladder etc.	-	-	-	-	-	-	1	-	-	-	7	6	5	5	4	5	-	33	1.1
C25	Pancreas	-	-	-	-	-	-	1	-	2	6	9	5	8	4	7	1	-	43	1.5
C30-31	Nose, Sinuses etc.	-	-	-	-	-	1	1	1	1	1	-	-	-	1	3	-	-	9	0.3
C32	Larynx	-	-	-	-	-	-	-	-	2	3	5	15	35	27	24	15	-	126	4.4
C33-34	Lung etc.	-	-	-	-	-	-	2	1	3	12	30	46	88	103	113	62	-	460	15.9
C37-38	Other Thoracic Organs	1	-	-	-	-	-	-	-	1	-	1	-	2	-	1	-	-	6	0.2
C40-41	Bone	-	2	3	9	3	1	-	-	2	-	2	-	-	1	1	2	-	26	0.9
C43	Melanoma of Skin	-	-	-	-	-	-	-	1	-	-	-	1	-	2	-	4	-	8	0.3
C44	Other Skin	-	-	-	-	-	-	2	-	1	-	9	6	8	7	6	12	-	51	1.8
C45	Mesothelioma	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C46	Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C47+C49	Conn. & Soft Tissue	1	1	1	-	2	-	-	2	3	2	2	3	-	1	2	3	-	23	0.8
C50	Breast	-	-	-	-	-	-	-	-	-	-	1	-	-	2	1	-	-	4	0.1
C60	Penis	-	-	-	-	-	-	-	-	-	-	4	1	-	-	2	2	-	9	0.3
C61	Prostate	-	-	-	-	-	-	-	-	1	1	4	14	27	33	52	32	-	164	5.7
C62	Testis	-	-	-	-	3	2	-	2	-	-	3	-	-	-	-	2	-	12	0.4
C63	Other Male Genital	-	-	-	-	-	-	-	-	-	-	-	-	-	1	-	-	-	1	0.0
C64	Kidney etc.	-	-	-	-	-	1	-	2	2	2	6	8	17	10	7	2	-	57	2.0
C65	Renal Pelvis	-	-	-	-	-	-	-	-	1	-	1	-	-	1	-	-	-	3	0.1
C66	Ureter	-	-	-	-	-	-	-	-	-	-	-	-	2	-	-	-	-	2	0.1
C67	Bladder	-	-	-	-	-	-	1	1	1	-	4	5	17	17	16	22	-	84	2.9
C68	Uns. Urinary Organs	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C69	Eye	2	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2	0.1
C70-72	Brain, Nervous System	6	2	2	3	3	1	3	2	4	6	7	9	9	10	3	-	-	70	2.4
C73	Thyroid	-	1	-	-	3	5	9	2	9	12	13	8	5	5	10	3	-	85	2.9
C74	Adrenal Gland	1	2	-	-	-	-	-	-	-	-	-	-	-	1	-	-	-	4	0.1
C81	Hodgkins Disease	1	2	1	-	2	3	1	1	4	1	-	2	-	-	2	-	-	20	0.7
C82-85,C96	NHL	2	2	1	-	1	1	4	9	14	11	16	19	18	15	17	7	-	137	4.7
C88	Malig Imn.Prol D	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C90	Multiple Myeloma	-	-	-	-	-	-	-	1	3	4	7	12	12	14	6	14	-	73	2.5
C91	Lymphoid Leuk.	8	9	4	5	2	-	2	1	1	1	2	6	3	2	3	4	-	53	1.8
C92-94	Myeloid Leukaemia	1	-	2	3	2	3	3	6	3	10	15	6	7	6	6	3	-	76	2.6
C95	Leukaemia Uns	-	-	-	-	-	-	-	-	-	-	-	-	1	-	-	-	-	1	0.0
O&U	Other and Uns	-	-	-	-	2	-	-	1	5	2	5	7	10	11	9	8	-	60	2.1
	All Sites	25	22	15	21	26	19	38	68	124	145	273	321	489	460	478	361	-	2885	100.0

O & U : C26, C39, C48, C75, C76, C77, C78, C79, C80, C97

**NATIONAL CENTRE FOR DISEASE INFORMATICS AND RESEARCH
NATIONAL CANCER REGISTRY PROGRAMME**



(Indian Council of Medical Research)
Hospital Based Cancer Registry
524 HBCR - Malabar Cancer Centre, Kannur

Report Based on Year of Registration : 2023

TABLE 1(b): Number of cancers by site (ICD-10) and Five Year Age Group - Females

As on: 11/06/2025

ICD 10	Site	00-04	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	Unk	Total	%
C00	Lip	-	-	-	-	-	-	-	-	1	-	1	1	3	1	2	2	-	11	0.4
C01-02	Tongue	-	-	-	-	-	-	1	2	3	1	3	6	5	7	4	15	-	47	1.7
C03-06	Mouth	-	-	-	1	1	-	1	2	1	4	4	7	10	10	16	22	-	79	2.9
C07-08	Salivary Gland	-	-	-	1	-	1	-	1	-	1	2	-	2	-	1	3	-	12	0.4
C09	Tonsil	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C10	Oth. Oropharynx	-	-	-	-	-	1	-	-	1	1	-	1	1	-	-	3	-	8	0.3
C11	Nasopharynx	-	-	-	-	-	-	-	-	-	-	-	-	1	-	-	-	-	1	0.0
C12-13	Hypopharynx	-	-	-	-	-	-	-	-	2	-	5	3	2	-	-	4	-	16	0.6
C14	Pharynx Unspecified	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C15	Oesophagus	-	-	-	-	-	-	-	2	1	3	-	3	4	5	7	10	-	35	1.3
C16	Stomach	-	-	-	-	-	1	2	4	7	6	4	7	8	4	5	2	-	50	1.8
C17	Small Intestine	-	-	-	-	-	-	-	-	1	-	1	1	-	2	1	1	-	7	0.3
C18	Colon	-	-	-	1	1	-	1	3	17	12	11	11	14	21	10	8	-	110	4.0
C19-20	Rectum	-	-	-	-	-	1	1	-	-	10	9	12	12	17	17	22	-	101	3.7
C21	Anus & Anal Canal	-	-	-	-	-	-	-	-	-	-	-	-	2	1	1	-	-	4	0.1
C22	Liver	1	-	-	-	-	-	1	2	-	2	4	3	1	8	4	7	-	33	1.2
C23-24	Gallbladder etc.	-	-	-	-	-	-	-	-	2	1	2	4	2	5	10	3	-	29	1.1
C25	Pancreas	-	-	-	-	-	-	-	1	2	3	9	9	6	3	5	1	-	39	1.4
C30-31	Nose, Sinuses etc.	-	-	-	-	-	-	-	-	-	2	1	1	1	1	2	-	-	8	0.3
C32	Larynx	-	-	-	-	-	-	-	1	1	1	2	-	3	-	2	1	-	11	0.4
C33-34	Lung etc.	-	-	-	-	-	-	1	1	3	9	16	19	19	19	12	11	-	110	4.0
C37-38	Other Thoracic Organs	-	-	-	-	-	-	-	-	1	-	1	2	-	-	1	-	-	5	0.2
C40-41	Bone	1	-	1	1	-	1	-	1	-	-	3	1	-	-	-	1	-	10	0.4
C43	Melanoma of Skin	-	-	-	-	-	-	-	-	-	1	4	2	1	-	2	2	-	12	0.4
C44	Other Skin	1	-	-	-	2	-	-	1	3	2	1	3	4	4	7	9	-	37	1.4
C45	Mesothelioma	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C46	Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C47+C49	Conn. & Soft Tissue	-	-	-	1	1	-	-	2	3	1	2	1	1	3	3	3	-	21	0.8
C50	Breast	-	-	-	-	3	9	14	46	91	125	133	118	105	91	62	43	-	840	30.7
C51	Vulva	-	-	-	-	-	-	-	-	-	-	1	-	1	-	-	2	-	4	0.1
C52	Vagina	-	-	-	-	-	-	-	1	-	-	1	-	1	1	1	1	-	6	0.2
C53	Cervix Uteri	-	-	-	-	-	-	2	6	7	13	18	29	22	24	15	12	-	148	5.4
C54	Corpus Uteri	-	-	-	-	1	-	-	4	10	13	26	29	25	24	6	8	-	146	5.3
C55	Uterus Unspecified	-	-	-	-	-	-	-	1	-	1	1	4	-	-	1	-	-	8	0.3
C56	Ovary etc.	-	1	1	1	1	6	6	10	14	21	16	27	28	15	12	11	-	170	6.2
C57	Other Female Genital	-	-	-	-	-	-	-	1	-	-	-	1	1	-	-	-	-	3	0.1
C58	Placenta	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C64	Kidney etc.	1	-	-	1	-	-	-	-	-	-	1	1	3	1	3	1	-	12	0.4
C65	Renal Pelvis	-	-	-	-	-	-	-	-	-	-	-	-	1	-	1	-	-	2	0.1
C66	Ureter	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C67	Bladder	-	-	-	-	-	-	-	-	-	1	-	1	1	4	7	3	-	17	0.6
C68	Uns.Urinary Organs	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C69	Eye	1	-	-	-	-	-	-	-	-	-	-	-	-	1	-	-	-	2	0.1
C70-72	Brain, Nervous System	3	-	1	-	-	2	-	3	4	10	4	5	5	4	2	3	-	46	1.7
C73	Thyroid	-	1	-	5	11	8	21	23	30	40	34	25	17	15	10	8	-	248	9.1
C74	Adrenal Gland	-	-	1	-	-	-	-	-	-	-	1	1	-	-	-	-	-	3	0.1
C81	Hodgkins Disease	-	1	-	-	1	2	2	2	-	1	-	2	-	-	-	1	-	12	0.4
C82-85,C96	NHL	-	-	2	2	2	2	1	3	10	6	8	12	10	14	12	10	-	94	3.4
C88	Malig Imn.Prol D	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C90	Multiple Myeloma	-	-	-	-	-	-	1	1	1	4	4	10	7	13	12	7	-	60	2.2
C91	Lymphoid Leuk.	6	3	4	3	1	1	1	2	2	1	2	3	3	3	2	5	-	42	1.5
C92-94	Myeloid Leukaemia	4	1	2	2	2	2	4	-	7	4	7	3	3	2	5	4	-	52	1.9
C95	Leukaemia Uns	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
O&U	Other and Uns	-	-	-	-	-	-	-	-	2	1	2	4	7	4	1	5	-	26	0.9
	All Sites	18	7	12	19	27	37	60	126	227	301	344	372	342	327	264	254	-	2737	100.0

O & U : C26, C39, C48, C75, C76, C77, C78, C79, C80, C97

NATIONAL CENTRE FOR DISEASE INFORMATICS AND RESEARCH
NATIONAL CANCER REGISTRY PROGRAMME



(Indian Council of Medical Research)
Hospital Based Cancer Registry
524 HBCR - Malabar Cancer Centre, Kannur

Report Based on Year of Registration : 2023

TABLE 2(a): Number(#) and Proportion(%) of cancers by site (ICD-10) and Method of Diagnosis - Males

As on: 11/06/2025

ICD 10	Site Name	Microscopic		X-Ray / Imaging		Clinical		Others		Unknown		Total	
		#	%	#	%	#	%	#	%	#	%	#	%
C00	Lip	12	100.0	-	-	-	-	-	-	-	-	12	100.0
C01-02	Tongue	120	96.8	1	0.8	3	2.4	-	-	-	-	124	100.0
C03-06	Mouth	177	98.9	1	0.6	1	0.6	-	-	-	-	179	100.0
C07-08	Salivary Gland	19	100.0	-	-	-	-	-	-	-	-	19	100.0
C09	Tonsil	2	100.0	-	-	-	-	-	-	-	-	2	100.0
C10	Oth. Oropharynx	107	99.1	-	-	1	0.9	-	-	-	-	108	100.0
C11	Nasopharynx	10	100.0	-	-	-	-	-	-	-	-	10	100.0
C12-13	Hypopharynx	56	93.3	3	5.0	-	-	1	1.7	-	-	60	100.0
C14	Pharynx Unspecified	1	100.0	-	-	-	-	-	-	-	-	1	100.0
C15	Oesophagus	85	97.7	2	2.3	-	-	-	-	-	-	87	100.0
C16	Stomach	144	94.7	8	5.3	-	-	-	-	-	-	152	100.0
C17	Small Intestine	7	100.0	-	-	-	-	-	-	-	-	7	100.0
C18	Colon	95	94.1	6	5.9	-	-	-	-	-	-	101	100.0
C19-20	Rectum	137	96.5	4	2.8	1	0.7	-	-	-	-	142	100.0
C21	Anus & Anal Canal	9	90.0	1	10.0	-	-	-	-	-	-	10	100.0
C22	Liver	65	38.5	104	61.5	-	-	-	-	-	-	169	100.0
C23-24	Gallbladder etc.	30	90.9	3	9.1	-	-	-	-	-	-	33	100.0
C25	Pancreas	39	90.7	4	9.3	-	-	-	-	-	-	43	100.0
C30-31	Nose, Sinuses etc.	8	88.9	1	11.1	-	-	-	-	-	-	9	100.0
C32	Larynx	123	97.6	1	0.8	-	-	2	1.6	-	-	126	100.0
C33-34	Lung etc.	389	84.6	71	15.4	-	-	-	-	-	-	460	100.0
C37-38	Other Thoracic Organs	6	100.0	-	-	-	-	-	-	-	-	6	100.0
C40-41	Bone	26	100.0	-	-	-	-	-	-	-	-	26	100.0
C43	Melanoma of Skin	8	100.0	-	-	-	-	-	-	-	-	8	100.0
C44	Other Skin	51	100.0	-	-	-	-	-	-	-	-	51	100.0
C45	Mesothelioma	-	-	-	-	-	-	-	-	-	-	-	-
C46	Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-	-	-
C47+C49	Conn. & Soft Tissue	23	100.0	-	-	-	-	-	-	-	-	23	100.0
C50	Breast	4	100.0	-	-	-	-	-	-	-	-	4	100.0
C51	Vulva	-	-	-	-	-	-	-	-	-	-	-	-
C52	Vagina	-	-	-	-	-	-	-	-	-	-	-	-
C53	Cervix Uteri	-	-	-	-	-	-	-	-	-	-	-	-
C54	Corpus Uteri	-	-	-	-	-	-	-	-	-	-	-	-
C55	Uterus Unspecified	-	-	-	-	-	-	-	-	-	-	-	-
C56	Ovary etc.	-	-	-	-	-	-	-	-	-	-	-	-
C57	Other Female Genital	-	-	-	-	-	-	-	-	-	-	-	-
C58	Placenta	-	-	-	-	-	-	-	-	-	-	-	-
C60	Penis	9	100.0	-	-	-	-	-	-	-	-	9	100.0
C61	Prostate	152	92.7	9	5.5	2	1.2	1	0.6	-	-	164	100.0
C62	Testis	11	91.7	1	8.3	-	-	-	-	-	-	12	100.0
C63	Other Male Genital	1	100.0	-	-	-	-	-	-	-	-	1	100.0
C64	Kidney etc.	46	80.7	11	19.3	-	-	-	-	-	-	57	100.0
C65	Renal Pelvis	3	100.0	-	-	-	-	-	-	-	-	3	100.0
C66	Ureter	2	100.0	-	-	-	-	-	-	-	-	2	100.0
C67	Bladder	78	92.9	5	6.0	1	1.2	-	-	-	-	84	100.0
C68	Uns.Urinary Organs	-	-	-	-	-	-	-	-	-	-	-	-
C69	Eye	2	100.0	-	-	-	-	-	-	-	-	2	100.0
C70-72	Brain, Nervous System	65	92.9	5	7.1	-	-	-	-	-	-	70	100.0
C73	Thyroid	85	100.0	-	-	-	-	-	-	-	-	85	100.0
C74	Adrenal Gland	3	75.0	1	25.0	-	-	-	-	-	-	4	100.0
C81	Hodgkins Disease	20	100.0	-	-	-	-	-	-	-	-	20	100.0
C82-85,C96	NHL	137	100.0	-	-	-	-	-	-	-	-	137	100.0
C88	Malig Imn.Prol D	-	-	-	-	-	-	-	-	-	-	-	-
C90	Multiple Myeloma	71	97.3	-	-	-	-	2	2.7	-	-	73	100.0
C91	Lymphoid Leuk.	53	100.0	-	-	-	-	-	-	-	-	53	100.0
C92-94	Myeloid Leukaemia	76	100.0	-	-	-	-	-	-	-	-	76	100.0
C95	Leukaemia Uns	1	100.0	-	-	-	-	-	-	-	-	1	100.0
O&U	Other and Uns	50	83.3	9	15.0	1	1.7	-	-	-	-	60	100.0
	All Sites	2618	90.7	251	8.7	10	0.3	6	0.2	-	-	2885	100.0

O & U : C26, C39, C48, C75, C76, C77, C78, C79, C80, C97

NATIONAL CENTRE FOR DISEASE INFORMATICS AND RESEARCH
NATIONAL CANCER REGISTRY PROGRAMME



(Indian Council of Medical Research)
Hospital Based Cancer Registry
524 HBCR - Malabar Cancer Centre, Kannur

Report Based on Year of Registration : 2023

TABLE 2(b): Number(#) and Proportion(%) of cancers by site (ICD-10) and Method of Diagnosis - Females

As on: 11/06/2025

ICD 10	Site Name	Microscopic		X-Ray / Imaging		Clinical		Others		Unknown		Total	
		#	%	#	%	#	%	#	%	#	%	#	%
C00	Lip	11	100.0	-	-	-	-	-	-	-	-	11	100.0
C01-02	Tongue	45	95.7	-	-	2	4.3	-	-	-	-	47	100.0
C03-06	Mouth	74	93.7	2	2.5	3	3.8	-	-	-	-	79	100.0
C07-08	Salivary Gland	11	91.7	-	-	1	8.3	-	-	-	-	12	100.0
C09	Tonsil	-	-	-	-	-	-	-	-	-	-	-	-
C10	Oth. Oropharynx	8	100.0	-	-	-	-	-	-	-	-	8	100.0
C11	Nasopharynx	1	100.0	-	-	-	-	-	-	-	-	1	100.0
C12-13	Hypopharynx	15	93.8	1	6.2	-	-	-	-	-	-	16	100.0
C14	Pharynx Unspecified	-	-	-	-	-	-	-	-	-	-	-	-
C15	Oesophagus	34	97.1	1	2.9	-	-	-	-	-	-	35	100.0
C16	Stomach	49	98.0	1	2.0	-	-	-	-	-	-	50	100.0
C17	Small Intestine	6	85.7	1	14.3	-	-	-	-	-	-	7	100.0
C18	Colon	106	96.4	4	3.6	-	-	-	-	-	-	110	100.0
C19-20	Rectum	100	99.0	1	1.0	-	-	-	-	-	-	101	100.0
C21	Anus & Anal Canal	4	100.0	-	-	-	-	-	-	-	-	4	100.0
C22	Liver	18	54.5	15	45.5	-	-	-	-	-	-	33	100.0
C23-24	Gallbladder etc.	20	69.0	9	31.0	-	-	-	-	-	-	29	100.0
C25	Pancreas	27	69.2	12	30.8	-	-	-	-	-	-	39	100.0
C30-31	Nose, Sinuses etc.	8	100.0	-	-	-	-	-	-	-	-	8	100.0
C32	Larynx	11	100.0	-	-	-	-	-	-	-	-	11	100.0
C33-34	Lung etc.	96	87.3	14	12.7	-	-	-	-	-	-	110	100.0
C37-38	Other Thoracic Organs	5	100.0	-	-	-	-	-	-	-	-	5	100.0
C40-41	Bone	9	90.0	1	10.0	-	-	-	-	-	-	10	100.0
C43	Melanoma of Skin	12	100.0	-	-	-	-	-	-	-	-	12	100.0
C44	Other Skin	37	100.0	-	-	-	-	-	-	-	-	37	100.0
C45	Mesothelioma	-	-	-	-	-	-	-	-	-	-	-	-
C46	Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-	-	-
C47+C49	Conn. & Soft Tissue	21	100.0	-	-	-	-	-	-	-	-	21	100.0
C50	Breast	832	99.0	8	1.0	-	-	-	-	-	-	840	100.0
C51	Vulva	4	100.0	-	-	-	-	-	-	-	-	4	100.0
C52	Vagina	6	100.0	-	-	-	-	-	-	-	-	6	100.0
C53	Cervix Uteri	147	99.3	-	-	-	-	1	0.7	-	-	148	100.0
C54	Corpus Uteri	145	99.3	1	0.7	-	-	-	-	-	-	146	100.0
C55	Uterus Unspecified	8	100.0	-	-	-	-	-	-	-	-	8	100.0
C56	Ovary etc.	161	94.7	6	3.5	-	-	3	1.8	-	-	170	100.0
C57	Other Female Genital	3	100.0	-	-	-	-	-	-	-	-	3	100.0
C58	Placenta	-	-	-	-	-	-	-	-	-	-	-	-
C60	Penis	-	-	-	-	-	-	-	-	-	-	-	-
C61	Prostate	-	-	-	-	-	-	-	-	-	-	-	-
C62	Testis	-	-	-	-	-	-	-	-	-	-	-	-
C63	Other Male Genital	-	-	-	-	-	-	-	-	-	-	-	-
C64	Kidney etc.	11	91.7	1	8.3	-	-	-	-	-	-	12	100.0
C65	Renal Pelvis	2	100.0	-	-	-	-	-	-	-	-	2	100.0
C66	Ureter	-	-	-	-	-	-	-	-	-	-	-	-
C67	Bladder	17	100.0	-	-	-	-	-	-	-	-	17	100.0
C68	Uns.Urinary Organs	-	-	-	-	-	-	-	-	-	-	-	-
C69	Eye	2	100.0	-	-	-	-	-	-	-	-	2	100.0
C70-72	Brain, Nervous System	42	91.3	4	8.7	-	-	-	-	-	-	46	100.0
C73	Thyroid	247	99.6	1	0.4	-	-	-	-	-	-	248	100.0
C74	Adrenal Gland	3	100.0	-	-	-	-	-	-	-	-	3	100.0
C81	Hodgkins Disease	12	100.0	-	-	-	-	-	-	-	-	12	100.0
C82-85,C96	NHL	94	100.0	-	-	-	-	-	-	-	-	94	100.0
C88	Malign. Imm.Prol D	-	-	-	-	-	-	-	-	-	-	-	-
C90	Multiple Myeloma	59	98.3	-	-	-	-	1	1.7	-	-	60	100.0
C91	Lymphoid Leuk.	42	100.0	-	-	-	-	-	-	-	-	42	100.0
C92-94	Myeloid Leukaemia	52	100.0	-	-	-	-	-	-	-	-	52	100.0
C95	Leukaemia Uns	-	-	-	-	-	-	-	-	-	-	-	-
O&U	Other and Uns	20	76.9	5	19.2	1	3.8	-	-	-	-	26	100.0
	All Sites	2637	96.3	88	3.2	7	0.3	5	0.2	-	-	2737	100.0

O & U : C26, C39, C48, C75, C76, C77, C78, C79, C80, C97

NATIONAL CENTRE FOR DISEASE INFORMATICS AND RESEARCH
NATIONAL CANCER REGISTRY PROGRAMME

(Indian Council of Medical Research)



Hospital Based Cancer Registry

524 HBCR - Malabar Cancer Centre, Kannur

Report Based on Year of Registration : 2023

TABLE 3(a): Number(#) and Proportion(%) of cancers by site (ICD-10) and Detailed Microscopic Diagnosis - Males

As on: 11/06/2025

ICD 10	Site	Histology of Primary		Histology of Secondary		Cytology of Primary		Cytology of Metastasis		Blood Film		Bone Marrow		Total	
		#	%	#	%	#	%	#	%	#	%	#	%	#	%
C00	Lip	12	100.0	-	-	-	-	-	-	-	-	-	-	12	100.0
C01-02	Tongue	118	98.3	1	0.8	-	-	1	0.8	-	-	-	-	120	100.0
C03-06	Mouth	175	98.9	-	-	1	0.6	1	0.6	-	-	-	-	177	100.0
C07-08	Salivary Gland	17	89.5	-	-	1	5.3	1	5.3	-	-	-	-	19	100.0
C09	Tonsil	2	100.0	-	-	-	-	-	-	-	-	-	-	2	100.0
C10	Oth. Oropharynx	95	88.8	2	1.9	-	-	10	9.3	-	-	-	-	107	100.0
C11	Nasopharynx	9	90.0	-	-	-	-	1	10.0	-	-	-	-	10	100.0
C12-13	Hypopharynx	45	80.4	3	5.4	-	-	8	14.3	-	-	-	-	56	100.0
C14	Pharynx Unspecified	1	100.0	-	-	-	-	-	-	-	-	-	-	1	100.0
C15	Oesophagus	84	98.8	-	-	-	-	1	1.2	-	-	-	-	85	100.0
C16	Stomach	140	97.2	3	2.1	-	-	1	0.7	-	-	-	-	144	100.0
C17	Small Intestine	7	100.0	-	-	-	-	-	-	-	-	-	-	7	100.0
C18	Colon	88	92.6	7	7.4	-	-	-	-	-	-	-	-	95	100.0
C19-20	Rectum	133	97.1	3	2.2	-	-	1	0.7	-	-	-	-	137	100.0
C21	Anus & Anal Canal	9	100.0	-	-	-	-	-	-	-	-	-	-	9	100.0
C22	Liver	47	72.3	14	21.5	2	3.1	2	3.1	-	-	-	-	65	100.0
C23-24	Gallbladder etc.	26	86.7	3	10.0	-	-	1	3.3	-	-	-	-	30	100.0
C25	Pancreas	25	64.1	13	33.3	1	2.6	-	-	-	-	-	-	39	100.0
C30-31	Nose, Sinuses etc.	8	100.0	-	-	-	-	-	-	-	-	-	-	8	100.0
C32	Larynx	119	96.7	2	1.6	-	-	2	1.6	-	-	-	-	123	100.0
C33-34	Lung etc.	300	77.1	50	12.9	16	4.1	23	5.9	-	-	-	-	389	100.0
C37-38	Other Thoracic Organs	5	83.3	1	16.7	-	-	-	-	-	-	-	-	6	100.0
C40-41	Bone	25	96.2	-	-	1	3.8	-	-	-	-	-	-	26	100.0
C43	Melanoma of Skin	8	100.0	-	-	-	-	-	-	-	-	-	-	8	100.0
C44	Other Skin	51	100.0	-	-	-	-	-	-	-	-	-	-	51	100.0
C45	Mesothelioma	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C46	Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C47+C49	Conn. & Soft Tissue	23	100.0	-	-	-	-	-	-	-	-	-	-	23	100.0
C50	Breast	4	100.0	-	-	-	-	-	-	-	-	-	-	4	100.0
C51	Vulva	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C52	Vagina	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C53	Cervix Uteri	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C54	Corpus Uteri	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C55	Uterus Unspecified	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C56	Ovary etc.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C57	Other Female Genital	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C58	Placenta	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C60	Penis	8	88.9	1	11.1	-	-	-	-	-	-	-	-	9	100.0
C61	Prostate	147	96.7	5	3.3	-	-	-	-	-	-	-	-	152	100.0
C62	Testis	11	100.0	-	-	-	-	-	-	-	-	-	-	11	100.0
C63	Other Male Genital	1	100.0	-	-	-	-	-	-	-	-	-	-	1	100.0
C64	Kidney etc.	41	89.1	4	8.7	-	-	1	2.2	-	-	-	-	46	100.0
C65	Renal Pelvis	3	100.0	-	-	-	-	-	-	-	-	-	-	3	100.0
C66	Ureter	2	100.0	-	-	-	-	-	-	-	-	-	-	2	100.0
C67	Bladder	77	98.7	-	-	1	1.3	-	-	-	-	-	-	78	100.0
C68	Uns.Urinary Organs	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C69	Eye	2	100.0	-	-	-	-	-	-	-	-	-	-	2	100.0
C70-72	Brain, Nervous System	65	100.0	-	-	-	-	-	-	-	-	-	-	65	100.0
C73	Thyroid	72	84.7	2	2.4	10	11.8	1	1.2	-	-	-	-	85	100.0
C74	Adrenal Gland	3	100.0	-	-	-	-	-	-	-	-	-	-	3	100.0
C81	Hodgkins Disease	19	95.0	-	-	1	5.0	-	-	-	-	-	-	20	100.0
C82-85,C96	NHL	107	78.1	1	0.7	-	-	-	-	-	-	29	21.2	137	100.0
C88	Malig Imn.Prol D	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C90	Multiple Myeloma	10	14.1	-	-	-	-	-	-	-	-	61	85.9	71	100.0
C91	Lymphoid Leuk.	5	9.4	-	-	-	-	-	-	2	3.8	46	86.8	53	100.0
C92-94	Myeloid Leukaemia	5	6.6	-	-	-	-	-	-	5	6.6	66	86.8	76	100.0
C95	Leukaemia Uns	-	-	-	-	-	-	-	-	-	-	1	100.0	1	100.0
O&U	Other and Uns	9	18.0	32	64.0	-	-	9	18.0	-	-	-	-	50	100.0
	All Sites	2163	82.6	147	5.6	34	1.3	64	2.4	7	0.3	203	7.8	2618	100.0

**NATIONAL CENTRE FOR DISEASE INFORMATICS AND RESEARCH
NATIONAL CANCER REGISTRY PROGRAMME**



(Indian Council of Medical Research)
Hospital Based Cancer Registry
524 HBCR - Malabar Cancer Centre, Kannur

Report Based on Year of Registration : 2023

TABLE 3(b): Number(#) and Proportion(%) of cancers by site (ICD-10) and Detailed Microscopic Diagnosis - Females

As on: 11/06/2025

ICD 10	Site	Histology of Primary		Histology of Secondary		Cytology of Primary		Cytology of Metastasis		Blood Film		Bone Marrow		Total	
		#	%	#	%	#	%	#	%	#	%	#	%	#	%
C00	Lip	11	100.0	-	-	-	-	-	-	-	-	-	-	11	100.0
C01-02	Tongue	43	95.6	-	-	1	2.2	1	2.2	-	-	-	-	45	100.0
C03-06	Mouth	72	97.3	-	-	-	-	2	2.7	-	-	-	-	74	100.0
C07-08	Salivary Gland	9	81.8	-	-	2	18.2	-	-	-	-	-	-	11	100.0
C09	Tonsil	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C10	Oth. Oropharynx	7	87.5	1	12.5	-	-	-	-	-	-	-	-	8	100.0
C11	Nasopharynx	1	100.0	-	-	-	-	-	-	-	-	-	-	1	100.0
C12-13	Hypopharynx	14	93.3	-	-	1	6.7	-	-	-	-	-	-	15	100.0
C14	Pharynx Unspecified	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C15	Oesophagus	34	100.0	-	-	-	-	-	-	-	-	-	-	34	100.0
C16	Stomach	46	93.9	2	4.1	-	-	1	2.0	-	-	-	-	49	100.0
C17	Small Intestine	6	100.0	-	-	-	-	-	-	-	-	-	-	6	100.0
C18	Colon	95	89.6	10	9.4	-	-	1	0.9	-	-	-	-	106	100.0
C19-20	Rectum	99	99.0	1	1.0	-	-	-	-	-	-	-	-	100	100.0
C21	Anus & Anal Canal	4	100.0	-	-	-	-	-	-	-	-	-	-	4	100.0
C22	Liver	8	44.4	7	38.9	1	5.6	2	11.1	-	-	-	-	18	100.0
C23-24	Gallbladder etc.	18	90.0	1	5.0	1	5.0	-	-	-	-	-	-	20	100.0
C25	Pancreas	19	70.4	6	22.2	2	7.4	-	-	-	-	-	-	27	100.0
C30-31	Nose, Sinuses etc.	8	100.0	-	-	-	-	-	-	-	-	-	-	8	100.0
C32	Larynx	10	90.9	-	-	1	9.1	-	-	-	-	-	-	11	100.0
C33-34	Lung etc.	72	75.0	16	16.7	2	2.1	6	6.2	-	-	-	-	96	100.0
C37-38	Other Thoracic Organs	3	60.0	2	40.0	-	-	-	-	-	-	-	-	5	100.0
C40-41	Bone	9	100.0	-	-	-	-	-	-	-	-	-	-	9	100.0
C43	Melanoma of Skin	11	91.7	-	-	1	8.3	-	-	-	-	-	-	12	100.0
C44	Other Skin	35	94.6	1	2.7	1	2.7	-	-	-	-	-	-	37	100.0
C45	Mesothelioma	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C46	Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C47+C49	Conn. & Soft Tissue	21	100.0	-	-	-	-	-	-	-	-	-	-	21	100.0
C50	Breast	803	96.5	9	1.1	17	2.0	3	0.4	-	-	-	-	832	100.0
C51	Vulva	4	100.0	-	-	-	-	-	-	-	-	-	-	4	100.0
C52	Vagina	6	100.0	-	-	-	-	-	-	-	-	-	-	6	100.0
C53	Cervix Uteri	145	98.6	1	0.7	1	0.7	-	-	-	-	-	-	147	100.0
C54	Corpus Uteri	142	97.9	2	1.4	1	0.7	-	-	-	-	-	-	145	100.0
C55	Uterus Unspecified	8	100.0	-	-	-	-	-	-	-	-	-	-	8	100.0
C56	Ovary etc.	116	72.0	25	15.5	9	5.6	11	6.8	-	-	-	-	161	100.0
C57	Other Female Genital	3	100.0	-	-	-	-	-	-	-	-	-	-	3	100.0
C58	Placenta	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C60	Penis	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C61	Prostate	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C62	Testis	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C63	Other Male Genital	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C64	Kidney etc.	10	90.9	1	9.1	-	-	-	-	-	-	-	-	11	100.0
C65	Renal Pelvis	2	100.0	-	-	-	-	-	-	-	-	-	-	2	100.0
C66	Ureter	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C67	Bladder	17	100.0	-	-	-	-	-	-	-	-	-	-	17	100.0
C68	Uns.Urinary Organs	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C69	Eye	2	100.0	-	-	-	-	-	-	-	-	-	-	2	100.0
C70-72	Brain, Nervous System	42	100.0	-	-	-	-	-	-	-	-	-	-	42	100.0
C73	Thyroid	222	89.9	4	1.6	20	8.1	1	0.4	-	-	-	-	247	100.0
C74	Adrenal Gland	3	100.0	-	-	-	-	-	-	-	-	-	-	3	100.0
C81	Hodgkins Disease	12	100.0	-	-	-	-	-	-	-	-	-	-	12	100.0
C82-85,C96	NHL	74	78.7	-	-	5	5.3	-	-	-	-	15	16.0	94	100.0
C88	Malig Imn.Prol D	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C90	Multiple Myeloma	11	18.6	-	-	-	-	-	-	-	-	48	81.4	59	100.0
C91	Lymphoid Leuk.	2	4.8	-	-	-	-	-	-	-	-	40	95.2	42	100.0
C92-94	Myeloid Leukaemia	2	3.8	-	-	-	-	-	-	2	3.8	48	92.3	52	100.0
C95	Leukaemia Uns	-	-	-	-	-	-	-	-	-	-	-	-	-	-
O&U	Other and Uns	3	15.0	14	70.0	-	-	3	15.0	-	-	-	-	20	100.0
	All Sites	2284	86.6	103	3.9	66	2.5	31	1.2	2	0.1	151	5.7	2637	100.0

NATIONAL CENTRE FOR DISEASE INFORMATICS AND RESEARCH
NATIONAL CANCER REGISTRY PROGRAMME

(Indian Council of Medical Research)

Hospital Based Cancer Registry

524 HBCR - Malabar Cancer Centre, Kannur

Report Based on Year of Registration : 2023

TABLE 4(a): Number(#) and Proportion(%) of cancers by site (ICD-10) and Broad Treatment Groups - Males

As on: 11/06/2025

ICD 10	Site	Treatment Groups									
		Prior Tmt. Only		Prior & Tmt. at RI		Tmt. Only at RI		No Treatment		Total	
		#	%	#	%	#	%	#	%	#	%
C00	Lip	1	8.3	-	-	9	75.0	2	16.7	12	100.0
C01-02	Tongue	12	9.7	12	9.7	74	59.7	26	21.0	124	100.0
C03-06	Mouth	17	9.5	18	10.1	110	61.5	34	19.0	179	100.0
C07-08	Salivary Gland	5	26.3	6	31.6	8	42.1	-	-	19	100.0
C09	Tonsil	-	-	-	-	1	50.0	1	50.0	2	100.0
C10	Oth. Oropharynx	4	3.7	3	2.8	76	70.4	25	23.1	108	100.0
C11	Nasopharynx	3	30.0	-	-	5	50.0	2	20.0	10	100.0
C12-13	Hypopharynx	4	6.7	2	3.3	40	66.7	14	23.3	60	100.0
C14	Pharynx Unspecified	-	-	-	-	1	100.0	-	-	1	100.0
C15	Oesophagus	6	6.9	4	4.6	42	48.3	35	40.2	87	100.0
C16	Stomach	23	15.1	10	6.6	44	28.9	75	49.3	152	100.0
C17	Small Intestine	3	42.9	-	-	1	14.3	3	42.9	7	100.0
C18	Colon	28	27.7	15	14.9	29	28.7	29	28.7	101	100.0
C19-20	Rectum	25	17.6	14	9.9	60	42.3	43	30.3	142	100.0
C21	Anus & Anal Canal	-	-	1	10.0	6	60.0	3	30.0	10	100.0
C22	Liver	21	12.4	13	7.7	29	17.2	106	62.7	169	100.0
C23-24	Gallbladder etc.	14	42.4	3	9.1	7	21.2	9	27.3	33	100.0
C25	Pancreas	9	20.9	4	9.3	9	20.9	21	48.8	43	100.0
C30-31	Nose, Sinuses etc.	2	22.2	1	11.1	3	33.3	3	33.3	9	100.0
C32	Larynx	13	10.3	7	5.6	81	64.3	25	19.8	126	100.0
C33-34	Lung etc.	43	9.3	21	4.6	171	37.2	225	48.9	460	100.0
C37-38	Other Thoracic Organs	2	33.3	1	16.7	1	16.7	2	33.3	6	100.0
C40-41	Bone	6	23.1	5	19.2	13	50.0	2	7.7	26	100.0
C43	Melanoma of Skin	1	12.5	2	25.0	-	-	5	62.5	8	100.0
C44	Other Skin	17	33.3	7	13.7	20	39.2	7	13.7	51	100.0
C45	Mesothelioma	-	-	-	-	-	-	-	-	-	-
C46	Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
C47+C49	Conn. & Soft Tissue	8	34.8	6	26.1	3	13.0	6	26.1	23	100.0
C50	Breast	-	-	2	50.0	2	50.0	-	-	4	100.0
C51	Vulva	-	-	-	-	-	-	-	-	-	-
C52	Vagina	-	-	-	-	-	-	-	-	-	-
C53	Cervix Uteri	-	-	-	-	-	-	-	-	-	-
C54	Corpus Uteri	-	-	-	-	-	-	-	-	-	-
C55	Uterus Unspecified	-	-	-	-	-	-	-	-	-	-
C56	Ovary etc.	-	-	-	-	-	-	-	-	-	-
C57	Other Female Genital	-	-	-	-	-	-	-	-	-	-
C58	Placenta	-	-	-	-	-	-	-	-	-	-
C60	Penis	1	11.1	3	33.3	3	33.3	2	22.2	9	100.0
C61	Prostate	40	24.4	39	23.8	55	33.5	30	18.3	164	100.0
C62	Testis	5	41.7	2	16.7	4	33.3	1	8.3	12	100.0
C63	Other Male Genital	-	-	-	-	1	100.0	-	-	1	100.0
C64	Kidney etc.	19	33.3	7	12.3	14	24.6	17	29.8	57	100.0
C65	Renal Pelvis	2	66.7	-	-	-	-	1	33.3	3	100.0
C66	Ureter	1	50.0	-	-	1	50.0	-	-	2	100.0
C67	Bladder	27	32.1	25	29.8	12	14.3	20	23.8	84	100.0
C68	Uns.Urinary Organs	-	-	-	-	-	-	-	-	-	-
C69	Eye	1	50.0	-	-	1	50.0	-	-	2	100.0
C70-72	Brain, Nervous System	24	34.3	31	44.3	8	11.4	7	10.0	70	100.0
C73	Thyroid	10	11.8	43	50.6	22	25.9	10	11.8	85	100.0
C74	Adrenal Gland	2	50.0	-	-	-	-	2	50.0	4	100.0
C81	Hodgkins Disease	5	25.0	-	-	13	65.0	2	10.0	20	100.0
C82-85,C96	NHL	26	19.0	11	8.0	52	38.0	48	35.0	137	100.0
C88	Malig Imn.Prol D	-	-	-	-	-	-	-	-	-	-
C90	Multiple Myeloma	15	20.5	6	8.2	32	43.8	20	27.4	73	100.0
C91	Lymphoid Leuk.	6	11.3	2	3.8	22	41.5	23	43.4	53	100.0
C92-94	Myeloid Leukaemia	7	9.2	7	9.2	36	47.4	26	34.2	76	100.0
C95	Leukaemia Uns	-	-	-	-	1	100.0	-	-	1	100.0
O&U	Other and Uns	7	11.7	2	3.3	22	36.7	29	48.3	60	100.0
	All Sites	465	16.1	335	11.6	1144	39.7	941	32.6	2885	100.0

**NATIONAL CENTRE FOR DISEASE INFORMATICS AND RESEARCH
NATIONAL CANCER REGISTRY PROGRAMME**



(Indian Council of Medical Research)
Hospital Based Cancer Registry
524 HBCR - Malabar Cancer Centre, Kannur

Report Based on Year of Registration : 2023

TABLE 4(b): Number(#) and Proportion(%) of cancers by site (ICD-10) and Broad Treatment Groups - Females

As on: 11/06/2025

ICD 10	Site	Treatment Groups									
		Prior Tmt. Only		Prior & Tmt. at RI		Tmt. Only at RI		No Treatment		Total	
		#	%	#	%	#	%	#	%	#	%
C00	Lip	1	9.1	4	36.4	4	36.4	2	18.2	11	100.0
C01-02	Tongue	5	10.6	4	8.5	26	55.3	12	25.5	47	100.0
C03-06	Mouth	7	8.9	10	12.7	50	63.3	12	15.2	79	100.0
C07-08	Salivary Gland	4	33.3	4	33.3	2	16.7	2	16.7	12	100.0
C09	Tonsil	-	-	-	-	-	-	-	-	-	-
C10	Oth. Oropharynx	1	12.5	-	-	5	62.5	2	25.0	8	100.0
C11	Nasopharynx	-	-	-	-	-	-	1	100.0	1	100.0
C12-13	Hypopharynx	-	-	1	6.2	9	56.2	6	37.5	16	100.0
C14	Pharynx Unspecified	-	-	-	-	-	-	-	-	-	-
C15	Oesophagus	4	11.4	2	5.7	17	48.6	12	34.3	35	100.0
C16	Stomach	12	24.0	5	10.0	14	28.0	19	38.0	50	100.0
C17	Small Intestine	1	14.3	3	42.9	1	14.3	2	28.6	7	100.0
C18	Colon	33	30.0	22	20.0	31	28.2	24	21.8	110	100.0
C19-20	Rectum	14	13.9	5	5.0	61	60.4	21	20.8	101	100.0
C21	Anus & Anal Canal	-	-	-	-	3	75.0	1	25.0	4	100.0
C22	Liver	2	6.1	-	-	8	24.2	23	69.7	33	100.0
C23-24	Gallbladder etc.	6	20.7	2	6.9	3	10.3	18	62.1	29	100.0
C25	Pancreas	5	12.8	3	7.7	11	28.2	20	51.3	39	100.0
C30-31	Nose, Sinuses etc.	-	-	2	25.0	5	62.5	1	12.5	8	100.0
C32	Larynx	1	9.1	1	9.1	8	72.7	1	9.1	11	100.0
C33-34	Lung etc.	14	12.7	10	9.1	46	41.8	40	36.4	110	100.0
C37-38	Other Thoracic Organs	1	20.0	-	-	2	40.0	2	40.0	5	100.0
C40-41	Bone	4	40.0	-	-	4	40.0	2	20.0	10	100.0
C43	Melanoma of Skin	5	41.7	3	25.0	2	16.7	2	16.7	12	100.0
C44	Other Skin	10	27.0	6	16.2	13	35.1	8	21.6	37	100.0
C45	Mesothelioma	-	-	-	-	-	-	-	-	-	-
C46	Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
C47+C49	Conn. & Soft Tissue	2	9.5	6	28.6	6	28.6	7	33.3	21	100.0
C50	Breast	122	14.5	162	19.3	398	47.4	158	18.8	840	100.0
C51	Vulva	1	25.0	-	-	1	25.0	2	50.0	4	100.0
C52	Vagina	-	-	1	16.7	4	66.7	1	16.7	6	100.0
C53	Cervix Uteri	12	8.1	10	6.8	92	62.2	34	23.0	148	100.0
C54	Corpus Uteri	24	16.4	39	26.7	68	46.6	15	10.3	146	100.0
C55	Uterus Unspecified	6	75.0	1	12.5	1	12.5	-	-	8	100.0
C56	Ovary etc.	43	25.3	21	12.4	66	38.8	40	23.5	170	100.0
C57	Other Female Genital	1	33.3	1	33.3	1	33.3	-	-	3	100.0
C58	Placenta	-	-	-	-	-	-	-	-	-	-
C60	Penis	-	-	-	-	-	-	-	-	-	-
C61	Prostate	-	-	-	-	-	-	-	-	-	-
C62	Testis	-	-	-	-	-	-	-	-	-	-
C63	Other Male Genital	-	-	-	-	-	-	-	-	-	-
C64	Kidney etc.	5	41.7	1	8.3	2	16.7	4	33.3	12	100.0
C65	Renal Pelvis	1	50.0	1	50.0	-	-	-	-	2	100.0
C66	Ureter	-	-	-	-	-	-	-	-	-	-
C67	Bladder	5	29.4	8	47.1	3	17.6	1	5.9	17	100.0
C68	Uns. Urinary Organs	-	-	-	-	-	-	-	-	-	-
C69	Eye	-	-	-	-	2	100.0	-	-	2	100.0
C70-72	Brain, Nervous System	16	34.8	19	41.3	6	13.0	5	10.9	46	100.0
C73	Thyroid	25	10.1	169	68.1	42	16.9	12	4.8	248	100.0
C74	Adrenal Gland	2	66.7	-	-	-	-	1	33.3	3	100.0
C81	Hodgkins Disease	3	25.0	1	8.3	5	41.7	3	25.0	12	100.0
C82-85,C96	NHL	16	17.0	7	7.4	42	44.7	29	30.9	94	100.0
C88	Malignant Proliferative Disorders	-	-	-	-	-	-	-	-	-	-
C90	Multiple Myeloma	7	11.7	2	3.3	28	46.7	23	38.3	60	100.0
C91	Lymphoid Leuk.	2	4.8	1	2.4	25	59.5	14	33.3	42	100.0
C92-94	Myeloid Leukaemia	7	13.5	2	3.8	28	53.8	15	28.8	52	100.0
C95	Leukaemia Uns.	-	-	-	-	-	-	-	-	-	-
O&U	Other and Uns.	-	-	-	-	10	38.5	16	61.5	26	100.0
	All Sites	430	15.7	539	19.7	1155	42.2	613	22.4	2737	100.0

NATIONAL CENTRE FOR DISEASE INFORMATICS AND RESEARCH
NATIONAL CANCER REGISTRY PROGRAMME

(Indian Council of Medical Research)



Hospital Based Cancer Registry
524 HBCR - Malabar Cancer Centre, Kannur

Report Based on Year of Registration : 2023

TABLE 5(a): Number(#) and Proportion(%) of cancers by site (ICD-10) and Clinical Extent of Disease - Males
(Treatment Only at RI)

As on: 11/06/2025

ICD 10	Site	Clinical Extent of Disease									
		Localised		Regional		Distant		Others		Unknown	
		#	%	#	%	#	%	#	%	#	%
C00	Lip	4	44.4	5	55.6	-	-	-	-	-	-
C01-02	Tongue	39	52.7	35	47.3	-	-	-	-	-	-
C03-06	Mouth	40	36.4	68	61.8	2	1.8	-	-	-	-
C07-08	Salivary Gland	4	50.0	4	50.0	-	-	-	-	-	-
C09	Tonsil	-	-	1	100.0	-	-	-	-	-	-
C10	Oth. Oropharynx	13	17.1	58	76.3	5	6.6	-	-	-	-
C11	Nasopharynx	1	20.0	4	80.0	-	-	-	-	-	-
C12-13	Hypopharynx	7	17.5	31	77.5	2	5.0	-	-	-	-
C14	Pharynx Unspecified	-	-	1	100.0	-	-	-	-	-	-
C15	Oesophagus	5	11.9	18	42.9	19	45.2	-	-	-	-
C16	Stomach	3	6.8	24	54.5	17	38.6	-	-	-	-
C17	Small Intestine	-	-	-	-	1	100.0	-	-	-	-
C18	Colon	5	17.2	12	41.4	12	41.4	-	-	-	-
C19-20	Rectum	11	18.3	38	63.3	11	18.3	-	-	-	-
C21	Anus & Anal Canal	2	33.3	3	50.0	1	16.7	-	-	-	-
C22	Liver	8	27.6	6	20.7	15	51.7	-	-	-	-
C23-24	Gallbladder etc.	2	28.6	3	42.9	2	28.6	-	-	-	-
C25	Pancreas	-	-	-	-	9	100.0	-	-	-	-
C30-31	Nose, Sinuses etc.	-	-	1	33.3	2	66.7	-	-	-	-
C32	Larynx	56	69.1	24	29.6	1	1.2	-	-	-	-
C33-34	Lung etc.	5	2.9	49	28.7	117	68.4	-	-	-	-
C37-38	Other Thoracic Organs	-	-	-	-	1	100.0	-	-	-	-
C40-41	Bone	10	76.9	2	15.4	1	7.7	-	-	-	-
C43	Melanoma of Skin	-	-	-	-	-	-	-	-	-	-
C44	Other Skin	8	40.0	7	35.0	5	25.0	-	-	-	-
C45	Mesothelioma	-	-	-	-	-	-	-	-	-	-
C46	Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
C47+C49	Conn. & Soft Tissue	2	66.7	-	-	1	33.3	-	-	-	-
C50	Breast	1	50.0	-	-	1	50.0	-	-	-	-
C51	Vulva	-	-	-	-	-	-	-	-	-	-
C52	Vagina	-	-	-	-	-	-	-	-	-	-
C53	Cervix Uteri	-	-	-	-	-	-	-	-	-	-
C54	Corpus Uteri	-	-	-	-	-	-	-	-	-	-
C55	Uterus Unspecified	-	-	-	-	-	-	-	-	-	-
C56	Ovary etc.	-	-	-	-	-	-	-	-	-	-
C57	Other Female Genital	-	-	-	-	-	-	-	-	-	-
C58	Placenta	-	-	-	-	-	-	-	-	-	-
C60	Penis	1	33.3	2	66.7	-	-	-	-	-	-
C61	Prostate	11	20.0	10	18.2	34	61.8	-	-	-	-
C62	Testis	1	25.0	1	25.0	2	50.0	-	-	-	-
C63	Other Male Genital	1	100.0	-	-	-	-	-	-	-	-
C64	Kidney etc.	5	35.7	1	7.1	8	57.1	-	-	-	-
C65	Renal Pelvis	-	-	-	-	-	-	-	-	-	-
C66	Ureter	1	100.0	-	-	-	-	-	-	-	-
C67	Bladder	6	50.0	5	41.7	1	8.3	-	-	-	-
C68	Uns. Urinary Organs	-	-	-	-	-	-	-	-	-	-
C69	Eye	-	-	-	-	1	100.0	-	-	-	-
C70-72	Brain, Nervous System	-	-	-	-	-	-	8	100.0	-	-
C73	Thyroid	4	18.2	12	54.5	6	27.3	-	-	-	-
C74	Adrenal Gland	-	-	-	-	-	-	-	-	-	-
C81	Hodgkins Disease	-	-	-	-	-	-	13	100.0	-	-
C82-85,C96	NHL	1	1.9	-	-	-	-	51	98.1	-	-
C88	Malig Imn.Prol D	-	-	-	-	-	-	-	-	-	-
C90	Multiple Myeloma	-	-	-	-	-	-	32	100.0	-	-
C91	Lymphoid Leuk.	-	-	-	-	-	-	22	100.0	-	-
C92-94	Myeloid Leukaemia	-	-	-	-	-	-	36	100.0	-	-
C95	Leukaemia Uns	-	-	-	-	-	-	1	100.0	-	-
O&U	Other and Uns	1	4.5	2	9.1	-	-	19	86.4	-	-
	All Sites	258	22.6	427	37.3	277	24.2	182	15.9	-	-
										1144	100.0

**NATIONAL CENTRE FOR DISEASE INFORMATICS AND RESEARCH
NATIONAL CANCER REGISTRY PROGRAMME**



(Indian Council of Medical Research)
Hospital Based Cancer Registry
524 HBCR - Malabar Cancer Centre, Kannur

Report Based on Year of Registration : 2023

TABLE 5(b): Number(#) and Proportion(%) of cancers by site (ICD-10) and Clinical Extent of Disease - Females
(Treatment Only at RI)

As on: 11/06/2025

ICD 10	Site	Clinical Extent of Disease											
		Localised		Regional		Distant		Others		Unknown		Total	
		#	%	#	%	#	%	#	%	#	%	#	%
C00	Lip	1	25.0	2	50.0	1	25.0	-	-	-	-	4	100.0
C01-02	Tongue	17	65.4	9	34.6	-	-	-	-	-	-	26	100.0
C03-06	Mouth	17	34.0	29	58.0	4	8.0	-	-	-	-	50	100.0
C07-08	Salivary Gland	-	-	1	50.0	1	50.0	-	-	-	-	2	100.0
C09	Tonsil	-	-	-	-	-	-	-	-	-	-	-	-
C10	Oth. Oropharynx	-	-	4	80.0	-	-	1	20.0	-	-	5	100.0
C11	Nasopharynx	-	-	-	-	-	-	-	-	-	-	-	-
C12-13	Hypopharynx	4	44.4	5	55.6	-	-	-	-	-	-	9	100.0
C14	Pharynx Unspecified	-	-	-	-	-	-	-	-	-	-	-	-
C15	Oesophagus	1	5.9	11	64.7	5	29.4	-	-	-	-	17	100.0
C16	Stomach	-	-	7	50.0	7	50.0	-	-	-	-	14	100.0
C17	Small Intestine	-	-	1	100.0	-	-	-	-	-	-	1	100.0
C18	Colon	6	19.4	18	58.1	7	22.6	-	-	-	-	31	100.0
C19-20	Rectum	4	6.6	47	77.0	10	16.4	-	-	-	-	61	100.0
C21	Anus & Anal Canal	-	-	1	33.3	2	66.7	-	-	-	-	3	100.0
C22	Liver	1	12.5	3	37.5	4	50.0	-	-	-	-	8	100.0
C23-24	Gallbladder etc.	1	33.3	1	33.3	1	33.3	-	-	-	-	3	100.0
C25	Pancreas	-	-	3	27.3	8	72.7	-	-	-	-	11	100.0
C30-31	Nose, Sinuses etc.	1	20.0	3	60.0	1	20.0	-	-	-	-	5	100.0
C32	Larynx	7	87.5	1	12.5	-	-	-	-	-	-	8	100.0
C33-34	Lung etc.	2	4.3	12	26.1	32	69.6	-	-	-	-	46	100.0
C37-38	Other Thoracic Organs	-	-	1	50.0	1	50.0	-	-	-	-	2	100.0
C40-41	Bone	2	50.0	2	50.0	-	-	-	-	-	-	4	100.0
C43	Melanoma of Skin	1	50.0	1	50.0	-	-	-	-	-	-	2	100.0
C44	Other Skin	6	46.2	6	46.2	1	7.7	-	-	-	-	13	100.0
C45	Mesothelioma	-	-	-	-	-	-	-	-	-	-	-	-
C46	Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-	-	-
C47+C49	Conn. & Soft Tissue	6	100.0	-	-	-	-	-	-	-	-	6	100.0
C50	Breast	153	38.4	192	48.2	53	13.3	-	-	-	-	398	100.0
C51	Vulva	-	-	1	100.0	-	-	-	-	-	-	1	100.0
C52	Vagina	2	50.0	1	25.0	-	-	1	25.0	-	-	4	100.0
C53	Cervix Uteri	64	69.6	18	19.6	10	10.9	-	-	-	-	92	100.0
C54	Corpus Uteri	47	69.1	18	26.5	3	4.4	-	-	-	-	68	100.0
C55	Uterus Unspecified	1	100.0	-	-	-	-	-	-	-	-	1	100.0
C56	Ovary etc.	14	21.2	23	34.8	29	43.9	-	-	-	-	66	100.0
C57	Other Female Genital	-	-	1	100.0	-	-	-	-	-	-	1	100.0
C58	Placenta	-	-	-	-	-	-	-	-	-	-	-	-
C60	Penis	-	-	-	-	-	-	-	-	-	-	-	-
C61	Prostate	-	-	-	-	-	-	-	-	-	-	-	-
C62	Testis	-	-	-	-	-	-	-	-	-	-	-	-
C63	Other Male Genital	-	-	-	-	-	-	-	-	-	-	-	-
C64	Kidney etc.	1	50.0	-	-	1	50.0	-	-	-	-	2	100.0
C65	Renal Pelvis	-	-	-	-	-	-	-	-	-	-	-	-
C66	Ureter	-	-	-	-	-	-	-	-	-	-	-	-
C67	Bladder	2	66.7	1	33.3	-	-	-	-	-	-	3	100.0
C68	Uns.Urinary Organs	-	-	-	-	-	-	-	-	-	-	-	-
C69	Eye	-	-	2	100.0	-	-	-	-	-	-	2	100.0
C70-72	Brain, Nervous System	-	-	1	16.7	-	-	5	83.3	-	-	6	100.0
C73	Thyroid	23	54.8	13	31.0	6	14.3	-	-	-	-	42	100.0
C74	Adrenal Gland	-	-	-	-	-	-	-	-	-	-	-	-
C81	Hodgkins Disease	1	20.0	-	-	-	-	4	80.0	-	-	5	100.0
C82-85,C96	NHL	-	-	-	-	-	-	42	100.0	-	-	42	100.0
C88	Malig Imn.Prol D	-	-	-	-	-	-	-	-	-	-	-	-
C90	Multiple Myeloma	-	-	-	-	-	-	28	100.0	-	-	28	100.0
C91	Lymphoid Leuk.	-	-	-	-	-	-	25	100.0	-	-	25	100.0
C92-94	Myeloid Leukaemia	-	-	-	-	-	-	28	100.0	-	-	28	100.0
C95	Leukaemia Uns	-	-	-	-	-	-	-	-	-	-	-	-
O&U	Other and Uns	1	10.0	1	10.0	1	10.0	7	70.0	-	-	10	100.0
	All Sites	386	33.4	440	38.1	188	16.3	141	12.2	-	-	1155	100.0

**NATIONAL CENTRE FOR DISEASE INFORMATICS AND RESEARCH
NATIONAL CANCER REGISTRY PROGRAMME**

(Indian Council of Medical Research)



**Hospital Based Cancer Registry
524 HBCR - Malabar Cancer Centre, Kannur**

Report Based on Year of Registration : 2023

TABLE 6(a): Number(#) and Proportion(%) of cancers by site (ICD-10) and Type of Treatment - Males
(Treatment Only at RI)

As on: 11/06/2025

ICD 10	Site	Type of Treatment																				
		Surgery		R-Therapy		C-Therapy		S+R		S+C		R+C		S+R+C		Others		Unknown		Total		
		#	%	#	%	#	%	#	%	#	%	#	%	#	%	#	%	#	%	#	%	
C00	Lip	3	33.3	3	33.3	-	-	1	11.1	-	-	2	22.2	-	-	-	-	-	-	-	9	100.0
C01-02	Tongue	16	21.6	9	12.2	-	-	30	40.5	1	1.4	4	5.4	14	18.9	-	-	-	-	-	74	100.0
C03-06	Mouth	21	19.1	20	18.2	1	0.9	44	40.0	-	-	11	10.0	13	11.8	-	-	-	-	-	110	100.0
C07-08	Salivary Gland	2	25.0	-	-	-	-	5	62.5	-	-	-	-	1	12.5	-	-	-	-	-	8	100.0
C09	Tonsil	-	-	1	100.0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	100.0
C10	Oth. Oropharynx	-	-	34	44.7	-	-	-	-	-	-	42	55.3	-	-	-	-	-	-	-	76	100.0
C11	Nasopharynx	-	-	1	20.0	-	-	-	-	-	-	4	80.0	-	-	-	-	-	-	-	5	100.0
C12-13	Hypopharynx	1	2.5	22	55.0	-	-	-	-	-	-	17	42.5	-	-	-	-	-	-	-	40	100.0
C14	Pharynx Unspecified	-	-	-	-	-	-	-	-	-	-	1	100.0	-	-	-	-	-	-	-	1	100.0
C15	Oesophagus	-	-	22	52.4	1	2.4	1	2.4	4	9.5	13	31.0	1	2.4	-	-	-	-	-	42	100.0
C16	Stomach	5	11.4	6	13.6	9	20.5	-	-	17	38.6	7	15.9	-	-	-	-	-	-	-	44	100.0
C17	Small Intestine	-	-	-	-	-	-	-	-	1	100.0	-	-	-	-	-	-	-	-	-	1	100.0
C18	Colon	8	27.6	1	3.4	5	17.2	-	-	12	41.4	2	6.9	1	3.4	-	-	-	-	-	29	100.0
C19-20	Rectum	7	11.7	11	18.3	5	8.3	4	6.7	6	10.0	4	6.7	23	38.3	-	-	-	-	-	60	100.0
C21	Anus & Anal Canal	-	-	4	66.7	-	-	-	-	-	-	2	33.3	-	-	-	-	-	-	-	6	100.0
C22	Liver	1	3.4	5	17.2	22	75.9	-	-	-	-	1	3.4	-	-	-	-	-	-	-	29	100.0
C23-24	Gallbladder etc.	2	28.6	-	-	2	28.6	-	-	3	42.9	-	-	-	-	-	-	-	-	-	7	100.0
C25	Pancreas	-	-	-	-	9	100.0	-	-	-	-	-	-	-	-	-	-	-	-	-	9	100.0
C30-31	Nose, Sinuses etc.	-	-	1	33.3	-	-	-	-	-	-	2	66.7	-	-	-	-	-	-	-	3	100.0
C32	Larynx	3	3.7	52	64.2	-	-	5	6.2	-	-	18	22.2	3	3.7	-	-	-	-	-	81	100.0
C33-34	Lung etc.	3	1.8	104	60.8	22	12.9	-	-	1	0.6	40	23.4	1	0.6	-	-	-	-	-	171	100.0
C37-38	Other Thoracic Organs	-	-	-	-	1	100.0	-	-	-	-	-	-	-	-	-	-	-	-	-	1	100.0
C40-41	Bone	1	7.7	-	-	2	15.4	-	-	7	53.8	-	-	3	23.1	-	-	-	-	-	13	100.0
C43	Melanoma of Skin	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C44	Other Skin	12	60.0	2	10.0	-	-	4	20.0	-	-	1	5.0	1	5.0	-	-	-	-	-	20	100.0
C45	Mesothelioma	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C46	Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C47+C49	Conn. & Soft Tissue	1	33.3	-	-	-	-	-	-	-	-	-	-	2	66.7	-	-	-	-	-	3	100.0
C50	Breast	-	-	-	-	-	-	-	-	1	50.0	-	-	-	-	1	50.0	-	-	-	2	100.0
C51	Vulva	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C52	Vagina	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C53	Cervix Uteri	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C54	Corpus Uteri	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C55	Uterus Unspecified	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C56	Ovary etc.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C57	Other Female Genital	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C58	Placenta	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C60	Penis	2	66.7	-	-	-	-	-	-	1	33.3	-	-	-	-	-	-	-	-	-	3	100.0
C61	Prostate	1	1.8	2	3.6	3	5.5	-	-	-	-	-	-	-	-	49	89.1	-	-	-	55	100.0
C62	Testis	1	25.0	-	-	-	-	-	-	3	75.0	-	-	-	-	-	-	-	-	-	4	100.0
C63	Other Male Genital	1	100.0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	100.0
C64	Kidney etc.	6	42.9	3	21.4	4	28.6	-	-	-	-	1	7.1	-	-	-	-	-	-	-	14	100.0
C65	Renal Pelvis	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C66	Ureter	1	100.0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	100.0
C67	Bladder	4	33.3	3	25.0	2	16.7	-	-	3	25.0	-	-	-	-	-	-	-	-	-	12	100.0
C68	Uns.Urinary Organs	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C69	Eye	-	-	-	-	1	100.0	-	-	-	-	-	-	-	-	-	-	-	-	-	1	100.0
C70-72	Brain, Nervous System	4	50.0	1	12.5	-	-	1	12.5	-	-	1	12.5	1	12.5	-	-	-	-	-	8	100.0
C73	Thyroid	-	-	2	9.1	-	-	2	9.1	-	-	-	-	-	-	18	81.8	-	-	-	22	100.0
C74	Adrenal Gland	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C81	Hodgkins Disease	-	-	1	7.7	7	53.8	-	-	-	-	5	38.5	-	-	-	-	-	-	-	13	100.0
C82-85,C96	NHL	1	1.9	1	1.9	48	92.3	-	-	1	1.9	1	1.9	-	-	-	-	-	-	-	52	100.0
C88	Malig Imn.Prol D	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C90	Multiple Myeloma	-	-	1	3.1	28	87.5	-	-	-	-	3	9.4	-	-	-	-	-	-	-	32	100.0
C91	Lymphoid Leuk.	-	-	-	-	19	86.4	-	-	-	-	3	13.6	-	-	-	-	-	-	-	22	100.0
C92-94	Myeloid Leukaemia	-	-	-	-	34	94.4	-	-	-	-	1	2.8	-	-	1	2.8	-	-	-	36	100.0
C95	Leukaemia Uns	-	-	-	-	1	100.0	-	-	-	-	-	-	-	-	-	-	-	-	-	1	100.0
O&U	Other and Uns	2	9.1	11	50.0	4	18.2	-	-	-	-	5	22.7	-	-	-	-	-	-	-	22	100.0
	All Sites	109	9.5	323	28.2	230	20.1	97	8.5	61	5.3	191	16.7	64	5.6	69	6.0	-	-	1144	100.0	

O & U : C26, C39, C48, C75, C76, C77, C78, C79, C80, C97

NATIONAL CENTRE FOR DISEASE INFORMATICS AND RESEARCH
NATIONAL CANCER REGISTRY PROGRAMME

(Indian Council of Medical Research)



Hospital Based Cancer Registry

524 HBCR - Malabar Cancer Centre, Kannur

Report Based on Year of Registration : 2023

TABLE 6(b): Number(#) and Proportion(%) of cancers by site (ICD-10) and Type of Treatment - Females
(Treatment Only at RI)

As on: 11/06/2025

ICD 10	Site	Type of Treatment																				
		Surgery		R-Therapy		C-Therapy		S+R		S+C		R+C		S+R+C		Others		Unknown		Total		
		#	%	#	%	#	%	#	%	#	%	#	%	#	%	#	%	#	%	#	%	
C00	Lip	2	50.0	1	25.0	-	-	-	1	25.0	-	-	-	-	-	-	-	-	-	-	4	100.0
C01-02	Tongue	3	11.5	4	15.4	-	-	-	16	61.5	-	-	1	3.8	2	7.7	-	-	-	-	26	100.0
C03-06	Mouth	12	24.0	23	46.0	-	-	-	8	16.0	-	-	3	6.0	4	8.0	-	-	-	-	50	100.0
C07-08	Salivary Gland	-	-	1	50.0	-	-	-	1	50.0	-	-	-	-	-	-	-	-	-	-	2	100.0
C09	Tonsil	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C10	Oth. Oropharynx	-	-	1	20.0	-	-	-	-	-	-	-	4	80.0	-	-	-	-	-	-	5	100.0
C11	Nasopharynx	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C12-13	Hypopharynx	-	-	5	55.6	-	-	-	-	-	-	-	4	44.4	-	-	-	-	-	-	9	100.0
C14	Pharynx Unspecified	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C15	Oesophagus	-	-	13	76.5	-	-	-	-	-	-	-	3	17.6	1	5.9	-	-	-	-	17	100.0
C16	Stomach	1	7.1	1	7.1	6	42.9	-	-	4	28.6	1	7.1	1	7.1	-	-	-	-	-	14	100.0
C17	Small Intestine	-	-	-	-	-	-	-	-	1	100.0	-	-	-	-	-	-	-	-	-	1	100.0
C18	Colon	8	25.8	1	3.2	6	19.4	-	-	16	51.6	-	-	-	-	-	-	-	-	-	31	100.0
C19-20	Rectum	6	9.8	19	31.1	2	3.3	4	6.6	4	6.6	6	9.8	20	32.8	-	-	-	-	-	61	100.0
C21	Anus & Anal Canal	-	-	-	-	1	33.3	-	-	-	-	1	33.3	1	33.3	-	-	-	-	-	3	100.0
C22	Liver	-	-	-	-	7	87.5	-	-	1	12.5	-	-	-	-	-	-	-	-	-	8	100.0
C23-24	Gallbladder etc.	1	33.3	-	-	1	33.3	-	-	1	33.3	-	-	-	-	-	-	-	-	-	3	100.0
C25	Pancreas	4	36.4	-	-	5	45.5	-	-	1	9.1	1	9.1	-	-	-	-	-	-	-	11	100.0
C30-31	Nose, Sinuses etc.	-	-	3	60.0	-	-	2	40.0	-	-	-	-	-	-	-	-	-	-	-	5	100.0
C32	Larynx	-	-	5	62.5	-	-	-	-	-	-	3	37.5	-	-	-	-	-	-	-	8	100.0
C33-34	Lung etc.	2	4.3	7	15.2	14	30.4	-	-	-	-	22	47.8	-	-	1	2.2	-	-	-	46	100.0
C37-38	Other Thoracic Organs	-	-	-	-	1	50.0	1	50.0	-	-	-	-	-	-	-	-	-	-	-	2	100.0
C40-41	Bone	3	75.0	-	-	-	-	-	-	-	-	-	-	1	25.0	-	-	-	-	-	4	100.0
C43	Melanoma of Skin	1	50.0	1	50.0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2	100.0
C44	Other Skin	9	69.2	2	15.4	-	-	1	7.7	-	-	1	7.7	-	-	-	-	-	-	-	13	100.0
C45	Mesothelioma	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C46	Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C47+C49	Conn. & Soft Tissue	2	33.3	2	33.3	-	-	1	16.7	-	-	-	-	1	16.7	-	-	-	-	-	6	100.0
C50	Breast	4	1.0	3	0.8	10	2.5	3	0.8	21	5.3	1	0.3	42	10.6	314	78.9	-	-	-	398	100.0
C51	Vulva	-	-	1	100.0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	100.0
C52	Vagina	1	25.0	-	-	1	25.0	1	25.0	-	-	1	25.0	-	-	-	-	-	-	-	4	100.0
C53	Cervix Uteri	4	4.3	30	32.6	2	2.2	1	1.1	-	-	54	58.7	1	1.1	-	-	-	-	-	92	100.0
C54	Corpus Uteri	21	30.9	1	1.5	4	5.9	18	26.5	7	10.3	-	-	16	23.5	1	1.5	-	-	-	68	100.0
C55	Uterus Unspecified	1	100.0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	100.0
C56	Ovary etc.	8	12.1	1	1.5	12	18.2	1	1.5	42	63.6	-	-	1	1.5	1	1.5	-	-	-	66	100.0
C57	Other Female Genital	-	-	-	-	-	-	-	-	1	100.0	-	-	-	-	-	-	-	-	-	1	100.0
C58	Placenta	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C60	Penis	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C61	Prostate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C62	Testis	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C63	Other Male Genital	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C64	Kidney etc.	1	50.0	-	-	-	-	-	-	-	-	1	50.0	-	-	-	-	-	-	-	2	100.0
C65	Renal Pelvis	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C66	Ureter	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C67	Bladder	2	66.7	1	33.3	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3	100.0
C68	Uns.Urinary Organs	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C69	Eye	1	50.0	-	-	1	50.0	-	-	-	-	-	-	-	-	-	-	-	-	-	2	100.0
C70-72	Brain, Nervous System	1	16.7	-	-	-	-	2	33.3	-	-	1	16.7	2	33.3	-	-	-	-	-	6	100.0
C73	Thyroid	3	7.1	2	4.8	1	2.4	1	2.4	-	-	-	-	3	7.1	32	76.2	-	-	-	42	100.0
C74	Adrenal Gland	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C81	Hodgkins Disease	-	-	-	-	4	80.0	-	-	-	-	1	20.0	-	-	-	-	-	-	-	5	100.0
C82-85,C96	NHL	-	-	1	2.4	33	78.6	1	2.4	-	-	6	14.3	-	-	1	2.4	-	-	-	42	100.0
C88	Malig Imn.Prol D	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C90	Multiple Myeloma	-	-	2	7.1	24	85.7	-	-	1	3.6	1	3.6	-	-	-	-	-	-	-	28	100.0
C91	Lymphoid Leuk.	-	-	-	-	17	68.0	-	-	-	-	8	32.0	-	-	-	-	-	-	-	25	100.0
C92-94	Myeloid Leukaemia	-	-	-	-	27	96.4	-	-	-	-	1	3.6	-	-	-	-	-	-	-	28	100.0
C95	Leukaemia Uns	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
O&U	Other and Uns	4	40.0	2	20.0	3	30.0	1	10.0	-	-	-	-	-	-	-	-	-	-	-	10	100.0
	All Sites	105	9.1	133	11.5	182	15.8	64	5.5	100	8.7	125	10.8	96	8.3	350	30.3	-	-	-	1155	100.0

O & U : C26, C39, C48, C75, C76, C77, C78, C79, C80, C97

NATIONAL CENTRE FOR DISEASE INFORMATICS AND RESEARCH
NATIONAL CANCER REGISTRY PROGRAMME

(Indian Council of Medical Research)



Hospital Based Cancer Registry
524 HBCR - Malabar Cancer Centre, Kannur

Report Based on Year of Registration : 2023

TABLE 7(a): Number(#) and Proportion(%) of cancers by site (ICD-10) and Any Specific Treatment - Males
(Treatment Only at RI)

As on: 29/07/2025

ICD 10	Site	Any S		Any R		Any C		Any H		Others		Unknown		Total	
		#	%	#	%	#	%	#	%	#	%	#	%	#	%
C00	Lip	4	33.3	6	50.0	2	16.7	-	-	-	-	-	-	12	100.0
C01-02	Tongue	61	44.5	57	41.6	19	13.9	-	-	-	-	-	-	137	100.0
C03-06	Mouth	78	40.8	88	46.1	25	13.1	-	-	-	-	-	-	191	100.0
C07-08	Salivary Gland	8	53.3	6	40.0	1	6.7	-	-	-	-	-	-	15	100.0
C09	Tonsil	-	-	1	100.0	-	-	-	-	-	-	-	-	1	100.0
C10	Oth. Oropharynx	-	-	76	64.4	42	35.6	-	-	-	-	-	-	118	100.0
C11	Nasopharynx	-	-	5	55.6	4	44.4	-	-	-	-	-	-	9	100.0
C12-13	Hypopharynx	1	1.8	39	68.4	17	29.8	-	-	-	-	-	-	57	100.0
C14	Pharynx Unspecified	-	-	1	50.0	1	50.0	-	-	-	-	-	-	2	100.0
C15	Oesophagus	6	9.7	37	59.7	19	30.6	-	-	-	-	-	-	62	100.0
C16	Stomach	22	32.4	13	19.1	33	48.5	-	-	-	-	-	-	68	100.0
C17	Small Intestine	1	50.0	-	-	1	50.0	-	-	-	-	-	-	2	100.0
C18	Colon	21	46.7	4	8.9	20	44.4	-	-	-	-	-	-	45	100.0
C19-20	Rectum	40	33.3	42	35.0	38	31.7	-	-	-	-	-	-	120	100.0
C21	Anus & Anal Canal	-	-	6	75.0	2	25.0	-	-	-	-	-	-	8	100.0
C22	Liver	1	3.3	6	20.0	23	76.7	-	-	-	-	-	-	30	100.0
C23-24	Gallbladder etc.	5	50.0	-	-	5	50.0	-	-	-	-	-	-	10	100.0
C25	Pancreas	-	-	-	-	9	100.0	-	-	-	-	-	-	9	100.0
C30-31	Nose, Sinuses etc.	-	-	3	60.0	2	40.0	-	-	-	-	-	-	5	100.0
C32	Larynx	11	10.0	78	70.9	21	19.1	-	-	-	-	-	-	110	100.0
C33-34	Lung etc.	5	2.3	145	67.8	64	29.9	-	-	-	-	-	-	214	100.0
C37-38	Other Thoracic Organs	-	-	-	-	1	100.0	-	-	-	-	-	-	1	100.0
C40-41	Bone	11	42.3	3	11.5	12	46.2	-	-	-	-	-	-	26	100.0
C43	Melanoma of Skin	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C44	Other Skin	17	63.0	8	29.6	2	7.4	-	-	-	-	-	-	27	100.0
C45	Mesothelioma	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C46	Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C47+C49	Conn. & Soft Tissue	3	42.9	2	28.6	2	28.6	-	-	-	-	-	-	7	100.0
C50	Breast	2	50.0	-	-	1	25.0	1	25.0	-	-	-	-	4	100.0
C51	Vulva	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C52	Vagina	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C53	Cervix Uteri	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C54	Corpus Uteri	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C55	Uterus Unspecified	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C56	Ovary etc.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C57	Other Female Genital	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C58	Placenta	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C60	Penis	3	75.0	-	-	1	25.0	-	-	-	-	-	-	4	100.0
C61	Prostate	1	1.2	24	27.9	12	14.0	49	57.0	-	-	-	-	86	100.0
C62	Testis	4	57.1	-	-	3	42.9	-	-	-	-	-	-	7	100.0
C63	Other Male Genital	1	100.0	-	-	-	-	-	-	-	-	-	-	1	100.0
C64	Kidney etc.	6	40.0	4	26.7	5	33.3	-	-	-	-	-	-	15	100.0
C65	Renal Pelvis	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C66	Ureter	1	100.0	-	-	-	-	-	-	-	-	-	-	1	100.0
C67	Bladder	7	46.7	3	20.0	5	33.3	-	-	-	-	-	-	15	100.0
C68	Uns.Urinary Organs	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C69	Eye	-	-	-	-	1	100.0	-	-	-	-	-	-	1	100.0
C70-72	Brain, Nervous System	6	50.0	4	33.3	2	16.7	-	-	-	-	-	-	12	100.0
C73	Thyroid	19	35.2	16	29.6	1	1.9	18	33.3	-	-	-	-	54	100.0
C74	Adrenal Gland	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C81	Hodgkins Disease	-	-	6	33.3	12	66.7	-	-	-	-	-	-	18	100.0
C82-85,C96	NHL	2	3.7	2	3.7	50	92.6	-	-	-	-	-	-	54	100.0
C88	Malig Imn.Prol D	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C90	Multiple Myeloma	-	-	4	11.4	31	88.6	-	-	-	-	-	-	35	100.0
C91	Lymphoid Leuk.	-	-	3	12.0	22	88.0	-	-	-	-	-	-	25	100.0
C92-94	Myeloid Leukaemia	-	-	1	2.7	35	94.6	-	-	1	2.7	-	-	37	100.0
C95	Leukaemia Uns	-	-	-	-	1	100.0	-	-	-	-	-	-	1	100.0
O&U	Other and Uns	2	7.4	16	59.3	9	33.3	-	-	-	-	-	-	27	100.0
	All Sites	349	20.7	709	42.1	556	33.0	68	4.0	1	0.1	-	-	1683	100.0

O & U : C26, C39, C48, C75, C76, C77, C78, C79, C80, C97

**NATIONAL CENTRE FOR DISEASE INFORMATICS AND RESEARCH
NATIONAL CANCER REGISTRY PROGRAMME**



(Indian Council of Medical Research)
Hospital Based Cancer Registry
524 HBCR - Malabar Cancer Centre, Kannur

Report Based on Year of Registration : 2023

TABLE 7(b): Number(#) and Proportion(%) of cancers by site (ICD-10) and Any Specific Treatment - Females
(Treatment Only at RI)

As on: 11/06/2025

ICD 10	Site	Any S		Any R		Any C		Any H		Others		Unknown		Total	
		#	%	#	%	#	%	#	%	#	%	#	%	#	%
C00	Lip	3	60.0	2	40.0	-	-	-	-	-	-	-	-	5	100.0
C01-02	Tongue	21	44.7	23	48.9	3	6.4	-	-	-	-	-	-	47	100.0
C03-06	Mouth	24	34.8	38	55.1	7	10.1	-	-	-	-	-	-	69	100.0
C07-08	Salivary Gland	1	33.3	2	66.7	-	-	-	-	-	-	-	-	3	100.0
C09	Tonsil	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C10	Oth. Oropharynx	-	-	5	55.6	4	44.4	-	-	-	-	-	-	9	100.0
C11	Nasopharynx	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C12-13	Hypopharynx	-	-	9	69.2	4	30.8	-	-	-	-	-	-	13	100.0
C14	Pharynx Unspecified	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C15	Oesophagus	1	4.5	17	77.3	4	18.2	-	-	-	-	-	-	22	100.0
C16	Stomach	6	28.6	3	14.3	12	57.1	-	-	-	-	-	-	21	100.0
C17	Small Intestine	1	50.0	-	-	1	50.0	-	-	-	-	-	-	2	100.0
C18	Colon	24	51.1	1	2.1	22	46.8	-	-	-	-	-	-	47	100.0
C19-20	Rectum	34	29.6	49	42.6	32	27.8	-	-	-	-	-	-	115	100.0
C21	Anus & Anal Canal	1	16.7	2	33.3	3	50.0	-	-	-	-	-	-	6	100.0
C22	Liver	1	11.1	-	-	8	88.9	-	-	-	-	-	-	9	100.0
C23-24	Gallbladder etc.	2	50.0	-	-	2	50.0	-	-	-	-	-	-	4	100.0
C25	Pancreas	5	38.5	1	7.7	7	53.8	-	-	-	-	-	-	13	100.0
C30-31	Nose, Sinuses etc.	2	28.6	5	71.4	-	-	-	-	-	-	-	-	7	100.0
C32	Larynx	-	-	8	72.7	3	27.3	-	-	-	-	-	-	11	100.0
C33-34	Lung etc.	2	2.9	29	42.6	36	52.9	1	1.5	-	-	-	-	68	100.0
C37-38	Other Thoracic Organs	1	33.3	1	33.3	1	33.3	-	-	-	-	-	-	3	100.0
C40-41	Bone	4	66.7	1	16.7	1	16.7	-	-	-	-	-	-	6	100.0
C43	Melanoma of Skin	1	50.0	1	50.0	-	-	-	-	-	-	-	-	2	100.0
C44	Other Skin	10	66.7	4	26.7	1	6.7	-	-	-	-	-	-	15	100.0
C45	Mesothelioma	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C46	Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C47+C49	Conn. & Soft Tissue	4	44.4	4	44.4	1	11.1	-	-	-	-	-	-	9	100.0
C50	Breast	349	29.2	246	20.6	288	24.1	314	26.2	-	-	-	-	1197	100.0
C51	Vulva	-	-	1	100.0	-	-	-	-	-	-	-	-	1	100.0
C52	Vagina	2	33.3	2	33.3	2	33.3	-	-	-	-	-	-	6	100.0
C53	Cervix Uteri	6	4.0	86	57.7	57	38.3	-	-	-	-	-	-	149	100.0
C54	Corpus Uteri	63	50.0	35	27.8	27	21.4	1	0.8	-	-	-	-	126	100.0
C55	Uterus Unspecified	1	100.0	-	-	-	-	-	-	-	-	-	-	1	100.0
C56	Ovary etc.	52	46.4	3	2.7	56	50.0	1	0.9	-	-	-	-	112	100.0
C57	Other Female Genital	1	50.0	-	-	1	50.0	-	-	-	-	-	-	2	100.0
C58	Placenta	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C60	Penis	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C61	Prostate	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C62	Testis	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C63	Other Male Genital	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C64	Kidney etc.	1	33.3	1	33.3	1	33.3	-	-	-	-	-	-	3	100.0
C65	Renal Pelvis	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C66	Ureter	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C67	Bladder	2	66.7	1	33.3	-	-	-	-	-	-	-	-	3	100.0
C68	Uns.Urinary Organs	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C69	Eye	1	50.0	-	-	1	50.0	-	-	-	-	-	-	2	100.0
C70-72	Brain, Nervous System	5	38.5	5	38.5	3	23.1	-	-	-	-	-	-	13	100.0
C73	Thyroid	36	35.0	30	29.1	5	4.9	32	31.1	-	-	-	-	103	100.0
C74	Adrenal Gland	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C81	Hodgkins Disease	-	-	1	16.7	5	83.3	-	-	-	-	-	-	6	100.0
C82-85,C96	NHL	2	3.8	9	17.3	40	76.9	1	1.9	-	-	-	-	52	100.0
C88	Malig Imm.Prol D	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C90	Multiple Myeloma	1	3.3	3	10.0	26	86.7	-	-	-	-	-	-	30	100.0
C91	Lymphoid Leuk.	-	-	8	24.2	25	75.8	-	-	-	-	-	-	33	100.0
C92-94	Myeloid Leukaemia	-	-	1	3.4	28	96.6	-	-	-	-	-	-	29	100.0
C95	Leukaemia Uns	-	-	-	-	-	-	-	-	-	-	-	-	-	-
O&U	Other and Uns	5	45.5	3	27.3	3	27.3	-	-	-	-	-	-	11	100.0
	All Sites	675	28.3	640	26.8	720	30.2	350	14.7	-	-	-	-	2385	100.0

O & U : C26, C39, C48, C75, C76, C77, C78, C79, C80, C97

NATIONAL CENTRE FOR DISEASE INFORMATICS AND RESEARCH
NATIONAL CANCER REGISTRY PROGRAMME

(Indian Council of Medical Research)



Hospital Based Cancer Registry

524 HBCR - Malabar Cancer Centre, Kannur

Report Based on Year of Registration : 2023

TABLE 8(a): Number(#) and Proportion(%) of cancers by site (ICD-10) and Treatment Status at Reporting Institution (Excluding the Cancers Previously Treated) - Males

As on: 11/06/2025

ICD 10	Site	Received		Not Received		Not Accepted		Incomplete		Unknown		Total	
		#	%	#	%	#	%	#	%	#	%	#	%
C00	Lip	9	81.8	1	9.1	-	-	1	9.1	-	-	11	100.0
C01-02	Tongue	74	74.0	16	16.0	8	8.0	2	2.0	-	-	100	100.0
C03-06	Mouth	110	76.4	17	11.8	13	9.0	4	2.8	-	-	144	100.0
C07-08	Salivary Gland	8	100.0	-	-	-	-	-	-	-	-	8	100.0
C09	Tonsil	1	50.0	1	50.0	-	-	-	-	-	-	2	100.0
C10	Oth. Oropharynx	76	75.2	9	8.9	10	9.9	6	5.9	-	-	101	100.0
C11	Nasopharynx	5	71.4	-	-	-	-	2	28.6	-	-	7	100.0
C12-13	Hypopharynx	40	74.1	9	16.7	2	3.7	3	5.6	-	-	54	100.0
C14	Pharynx Unspecified	1	100.0	-	-	-	-	-	-	-	-	1	100.0
C15	Oesophagus	42	54.5	24	31.2	10	13.0	1	1.3	-	-	77	100.0
C16	Stomach	44	37.0	51	42.9	17	14.3	7	5.9	-	-	119	100.0
C17	Small Intestine	1	25.0	3	75.0	-	-	-	-	-	-	4	100.0
C18	Colon	29	50.0	16	27.6	8	13.8	5	8.6	-	-	58	100.0
C19-20	Rectum	60	58.3	27	26.2	11	10.7	5	4.9	-	-	103	100.0
C21	Anus & Anal Canal	6	66.7	2	22.2	1	11.1	-	-	-	-	9	100.0
C22	Liver	29	21.5	83	61.5	14	10.4	9	6.7	-	-	135	100.0
C23-24	Gallbladder etc.	7	43.8	8	50.0	1	6.2	-	-	-	-	16	100.0
C25	Pancreas	9	30.0	17	56.7	1	3.3	3	10.0	-	-	30	100.0
C30-31	Nose, Sinuses etc.	3	50.0	2	33.3	-	-	1	16.7	-	-	6	100.0
C32	Larynx	81	76.4	14	13.2	7	6.6	4	3.8	-	-	106	100.0
C33-34	Lung etc.	171	43.2	171	43.2	38	9.6	16	4.0	-	-	396	100.0
C37-38	Other Thoracic Organs	1	33.3	2	66.7	-	-	-	-	-	-	3	100.0
C40-41	Bone	13	86.7	2	13.3	-	-	-	-	-	-	15	100.0
C43	Melanoma of Skin	-	-	4	80.0	1	20.0	-	-	-	-	5	100.0
C44	Other Skin	20	74.1	5	18.5	2	7.4	-	-	-	-	27	100.0
C45	Mesothelioma	-	-	-	-	-	-	-	-	-	-	-	-
C46	Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-	-	-
C47+C49	Conn. & Soft Tissue	3	33.3	4	44.4	2	22.2	-	-	-	-	9	100.0
C50	Breast	2	100.0	-	-	-	-	-	-	-	-	2	100.0
C51	Vulva	-	-	-	-	-	-	-	-	-	-	-	-
C52	Vagina	-	-	-	-	-	-	-	-	-	-	-	-
C53	Cervix Uteri	-	-	-	-	-	-	-	-	-	-	-	-
C54	Corpus Uteri	-	-	-	-	-	-	-	-	-	-	-	-
C55	Uterus Unspecified	-	-	-	-	-	-	-	-	-	-	-	-
C56	Ovary etc.	-	-	-	-	-	-	-	-	-	-	-	-
C57	Other Female Genital	-	-	-	-	-	-	-	-	-	-	-	-
C58	Placenta	-	-	-	-	-	-	-	-	-	-	-	-
C60	Penis	3	60.0	2	40.0	-	-	-	-	-	-	5	100.0
C61	Prostate	55	64.7	20	23.5	6	7.1	4	4.7	-	-	85	100.0
C62	Testis	4	80.0	1	20.0	-	-	-	-	-	-	5	100.0
C63	Other Male Genital	1	100.0	-	-	-	-	-	-	-	-	1	100.0
C64	Kidney etc.	14	45.2	12	38.7	5	16.1	-	-	-	-	31	100.0
C65	Renal Pelvis	-	-	1	100.0	-	-	-	-	-	-	1	100.0
C66	Ureter	1	100.0	-	-	-	-	-	-	-	-	1	100.0
C67	Bladder	12	37.5	17	53.1	3	9.4	-	-	-	-	32	100.0
C68	Uns. Urinary Organs	-	-	-	-	-	-	-	-	-	-	-	-
C69	Eye	1	100.0	-	-	-	-	-	-	-	-	1	100.0
C70-72	Brain, Nervous System	8	53.3	4	26.7	2	13.3	1	6.7	-	-	15	100.0
C73	Thyroid	22	68.8	7	21.9	2	6.2	1	3.1	-	-	32	100.0
C74	Adrenal Gland	-	-	2	100.0	-	-	-	-	-	-	2	100.0
C81	Hodgkins Disease	13	86.7	2	13.3	-	-	-	-	-	-	15	100.0
C82-85,C96	NHL	52	52.0	38	38.0	3	3.0	7	7.0	-	-	100	100.0
C88	Malig Imn.Prol D	-	-	-	-	-	-	-	-	-	-	-	-
C90	Multiple Myeloma	32	61.5	14	26.9	2	3.8	4	7.7	-	-	52	100.0
C91	Lymphoid Leuk.	22	48.9	16	35.6	1	2.2	6	13.3	-	-	45	100.0
C92-94	Myeloid Leukaemia	36	58.1	17	27.4	1	1.6	8	12.9	-	-	62	100.0
C95	Leukaemia Uns	1	100.0	-	-	-	-	-	-	-	-	1	100.0
O&U	Other and Uns	22	43.1	22	43.1	4	7.8	3	5.9	-	-	51	100.0
	All Sites	1144	54.9	663	31.8	175	8.4	103	4.9	-	-	2085	100.0

O & U : C26, C39, C48, C75, C76, C77, C78, C79, C80, C97

**NATIONAL CENTRE FOR DISEASE INFORMATICS AND RESEARCH
NATIONAL CANCER REGISTRY PROGRAMME**



(Indian Council of Medical Research)
Hospital Based Cancer Registry
524 HBCR - Malabar Cancer Centre, Kannur

Report Based on Year of Registration : 2023

TABLE 8(b): Number(#) and Proportion(%) of cancers by site (ICD-10) and Treatment Status at Reporting Institution (Excluding the Cancers Previously Treated) - Females

As on: 11/06/2025

ICD 10	Site	Received		Not Received		Not Accepted		Incomplete		Unknown		Total	
		#	%	#	%	#	%	#	%	#	%	#	%
C00	Lip	4	66.7	-	-	2	33.3	-	-	-	-	6	100.0
C01-02	Tongue	26	68.4	8	21.1	3	7.9	1	2.6	-	-	38	100.0
C03-06	Mouth	50	80.6	8	12.9	3	4.8	1	1.6	-	-	62	100.0
C07-08	Salivary Gland	2	50.0	2	50.0	-	-	-	-	-	-	4	100.0
C09	Tonsil	-	-	-	-	-	-	-	-	-	-	-	-
C10	Oth. Oropharynx	5	71.4	1	14.3	1	14.3	-	-	-	-	7	100.0
C11	Nasopharynx	-	-	1	100.0	-	-	-	-	-	-	1	100.0
C12-13	Hypopharynx	9	60.0	4	26.7	1	6.7	1	6.7	-	-	15	100.0
C14	Pharynx Unspecified	-	-	-	-	-	-	-	-	-	-	-	-
C15	Oesophagus	17	58.6	9	31.0	2	6.9	1	3.4	-	-	29	100.0
C16	Stomach	14	42.4	15	45.5	4	12.1	-	-	-	-	33	100.0
C17	Small Intestine	1	33.3	1	33.3	-	-	1	33.3	-	-	3	100.0
C18	Colon	31	56.4	17	30.9	6	10.9	1	1.8	-	-	55	100.0
C19-20	Rectum	61	74.4	15	18.3	4	4.9	2	2.4	-	-	82	100.0
C21	Anus & Anal Canal	3	75.0	-	-	1	25.0	-	-	-	-	4	100.0
C22	Liver	8	25.8	21	67.7	2	6.5	-	-	-	-	31	100.0
C23-24	Gallbladder etc.	3	14.3	16	76.2	1	4.8	1	4.8	-	-	21	100.0
C25	Pancreas	11	35.5	17	54.8	2	6.5	1	3.2	-	-	31	100.0
C30-31	Nose, Sinuses etc.	5	83.3	-	-	1	16.7	-	-	-	-	6	100.0
C32	Larynx	8	88.9	1	11.1	-	-	-	-	-	-	9	100.0
C33-34	Lung etc.	46	53.5	32	37.2	5	5.8	3	3.5	-	-	86	100.0
C37-38	Other Thoracic Organs	2	50.0	-	-	-	-	2	50.0	-	-	4	100.0
C40-41	Bone	4	66.7	2	33.3	-	-	-	-	-	-	6	100.0
C43	Melanoma of Skin	2	50.0	2	50.0	-	-	-	-	-	-	4	100.0
C44	Other Skin	13	61.9	7	33.3	1	4.8	-	-	-	-	21	100.0
C45	Mesothelioma	-	-	-	-	-	-	-	-	-	-	-	-
C46	Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-	-	-
C47+C49	Conn. & Soft Tissue	6	46.2	4	30.8	2	15.4	1	7.7	-	-	13	100.0
C50	Breast	398	71.6	75	13.5	30	5.4	53	9.5	-	-	556	100.0
C51	Vulva	1	33.3	2	66.7	-	-	-	-	-	-	3	100.0
C52	Vagina	4	80.0	-	-	1	20.0	-	-	-	-	5	100.0
C53	Cervix Uteri	92	73.0	17	13.5	15	11.9	2	1.6	-	-	126	100.0
C54	Corpus Uteri	68	81.9	14	16.9	-	-	1	1.2	-	-	83	100.0
C55	Uterus Unspecified	1	100.0	-	-	-	-	-	-	-	-	1	100.0
C56	Ovary etc.	66	62.3	24	22.6	9	8.5	7	6.6	-	-	106	100.0
C57	Other Female Genital	1	100.0	-	-	-	-	-	-	-	-	1	100.0
C58	Placenta	-	-	-	-	-	-	-	-	-	-	-	-
C60	Penis	-	-	-	-	-	-	-	-	-	-	-	-
C61	Prostate	-	-	-	-	-	-	-	-	-	-	-	-
C62	Testis	-	-	-	-	-	-	-	-	-	-	-	-
C63	Other Male Genital	-	-	-	-	-	-	-	-	-	-	-	-
C64	Kidney etc.	2	33.3	4	66.7	-	-	-	-	-	-	6	100.0
C65	Renal Pelvis	-	-	-	-	-	-	-	-	-	-	-	-
C66	Ureter	-	-	-	-	-	-	-	-	-	-	-	-
C67	Bladder	3	75.0	1	25.0	-	-	-	-	-	-	4	100.0
C68	Uns.Urinary Organs	-	-	-	-	-	-	-	-	-	-	-	-
C69	Eye	2	100.0	-	-	-	-	-	-	-	-	2	100.0
C70-72	Brain, Nervous System	6	54.5	4	36.4	1	9.1	-	-	-	-	11	100.0
C73	Thyroid	42	77.8	11	20.4	1	1.9	-	-	-	-	54	100.0
C74	Adrenal Gland	-	-	1	100.0	-	-	-	-	-	-	1	100.0
C81	Hodgkins Disease	5	62.5	2	25.0	1	12.5	-	-	-	-	8	100.0
C82-85,C96	NHL	42	59.2	23	32.4	3	4.2	3	4.2	-	-	71	100.0
C88	Malig Imn.Prol D	-	-	-	-	-	-	-	-	-	-	-	-
C90	Multiple Myeloma	28	54.9	18	35.3	1	2.0	4	7.8	-	-	51	100.0
C91	Lymphoid Leuk.	25	64.1	9	23.1	1	2.6	4	10.3	-	-	39	100.0
C92-94	Myeloid Leukaemia	28	65.1	7	16.3	2	4.7	6	14.0	-	-	43	100.0
C95	Leukaemia Uns	-	-	-	-	-	-	-	-	-	-	-	-
O&U	Other and Uns	10	38.5	13	50.0	2	7.7	1	3.8	-	-	26	100.0
	All Sites	1155	65.3	408	23.1	108	6.1	97	5.5	-	-	1768	100.0

O & U : C26, C39, C48, C75, C76, C77, C78, C79, C80, C97

NATIONAL CENTRE FOR DISEASE INFORMATICS AND RESEARCH
NATIONAL CANCER REGISTRY PROGRAMME

(Indian Council of Medical Research)



Hospital Based Cancer Registry
524 HBCR - Malabar Cancer Centre, Kannur

Report Based on Year of Registration : 2023

**TABLE 9(a): Number(#) and Proportion(%) of cancers by site (ICD-10) and Intention to Treat at Reporting Institution
(Excluding the Cancers Previously Treated) - Males**

As on: 11/06/2025

ICD 10	Site	Radical		Palliative		Pain Relief Only		Symptomatic		Unknown		Total	
		#	%	#	%	#	%	#	%	#	%	#	%
C00	Lip	7	77.8	2	22.2	-	-	-	-	-	-	9	100.0
C01-02	Tongue	61	82.4	13	17.6	-	-	-	-	-	-	74	100.0
C03-06	Mouth	82	74.5	28	25.5	-	-	-	-	-	-	110	100.0
C07-08	Salivary Gland	8	100.0	-	-	-	-	-	-	-	-	8	100.0
C09	Tonsil	1	100.0	-	-	-	-	-	-	-	-	1	100.0
C10	Oth. Oropharynx	41	53.9	35	46.1	-	-	-	-	-	-	76	100.0
C11	Nasopharynx	3	60.0	2	40.0	-	-	-	-	-	-	5	100.0
C12-13	Hypopharynx	17	42.5	23	57.5	-	-	-	-	-	-	40	100.0
C14	Pharynx Unspecified	1	100.0	-	-	-	-	-	-	-	-	1	100.0
C15	Oesophagus	11	26.2	31	73.8	-	-	-	-	-	-	42	100.0
C16	Stomach	24	54.5	20	45.5	-	-	-	-	-	-	44	100.0
C17	Small Intestine	-	-	1	100.0	-	-	-	-	-	-	1	100.0
C18	Colon	20	69.0	9	31.0	-	-	-	-	-	-	29	100.0
C19-20	Rectum	43	71.7	17	28.3	-	-	-	-	-	-	60	100.0
C21	Anus & Anal Canal	4	66.7	2	33.3	-	-	-	-	-	-	6	100.0
C22	Liver	7	24.1	22	75.9	-	-	-	-	-	-	29	100.0
C23-24	Gallbladder etc.	5	71.4	2	28.6	-	-	-	-	-	-	7	100.0
C25	Pancreas	-	-	9	100.0	-	-	-	-	-	-	9	100.0
C30-31	Nose, Sinuses etc.	1	33.3	2	66.7	-	-	-	-	-	-	3	100.0
C32	Larynx	68	84.0	13	16.0	-	-	-	-	-	-	81	100.0
C33-34	Lung etc.	18	10.5	153	89.5	-	-	-	-	-	-	171	100.0
C37-38	Other Thoracic Organs	-	-	1	100.0	-	-	-	-	-	-	1	100.0
C40-41	Bone	12	92.3	1	7.7	-	-	-	-	-	-	13	100.0
C43	Melanoma of Skin	-	-	-	-	-	-	-	-	-	-	-	-
C44	Other Skin	16	80.0	4	20.0	-	-	-	-	-	-	20	100.0
C45	Mesothelioma	-	-	-	-	-	-	-	-	-	-	-	-
C46	Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-	-	-
C47+C49	Conn. & Soft Tissue	3	100.0	-	-	-	-	-	-	-	-	3	100.0
C50	Breast	2	100.0	-	-	-	-	-	-	-	-	2	100.0
C51	Vulva	-	-	-	-	-	-	-	-	-	-	-	-
C52	Vagina	-	-	-	-	-	-	-	-	-	-	-	-
C53	Cervix Uteri	-	-	-	-	-	-	-	-	-	-	-	-
C54	Corpus Uteri	-	-	-	-	-	-	-	-	-	-	-	-
C55	Uterus Unspecified	-	-	-	-	-	-	-	-	-	-	-	-
C56	Ovary etc.	-	-	-	-	-	-	-	-	-	-	-	-
C57	Other Female Genital	-	-	-	-	-	-	-	-	-	-	-	-
C58	Placenta	-	-	-	-	-	-	-	-	-	-	-	-
C60	Penis	3	100.0	-	-	-	-	-	-	-	-	3	100.0
C61	Prostate	35	63.6	20	36.4	-	-	-	-	-	-	55	100.0
C62	Testis	4	100.0	-	-	-	-	-	-	-	-	4	100.0
C63	Other Male Genital	1	100.0	-	-	-	-	-	-	-	-	1	100.0
C64	Kidney etc.	7	50.0	7	50.0	-	-	-	-	-	-	14	100.0
C65	Renal Pelvis	-	-	-	-	-	-	-	-	-	-	-	-
C66	Ureter	1	100.0	-	-	-	-	-	-	-	-	1	100.0
C67	Bladder	9	75.0	3	25.0	-	-	-	-	-	-	12	100.0
C68	Uns. Urinary Organs	-	-	-	-	-	-	-	-	-	-	-	-
C69	Eye	-	-	1	100.0	-	-	-	-	-	-	1	100.0
C70-72	Brain, Nervous System	8	100.0	-	-	-	-	-	-	-	-	8	100.0
C73	Thyroid	18	81.8	4	18.2	-	-	-	-	-	-	22	100.0
C74	Adrenal Gland	-	-	-	-	-	-	-	-	-	-	-	-
C81	Hodgkins Disease	13	100.0	-	-	-	-	-	-	-	-	13	100.0
C82-85, C96	NHL	50	96.2	2	3.8	-	-	-	-	-	-	52	100.0
C88	Malig Imm. Prol D	-	-	-	-	-	-	-	-	-	-	-	-
C90	Multiple Myeloma	30	93.8	2	6.2	-	-	-	-	-	-	32	100.0
C91	Lymphoid Leuk.	22	100.0	-	-	-	-	-	-	-	-	22	100.0
C92-94	Myeloid Leukaemia	36	100.0	-	-	-	-	-	-	-	-	36	100.0
C95	Leukaemia Uns	1	100.0	-	-	-	-	-	-	-	-	1	100.0
O&U	Other and Uns	6	27.3	16	72.7	-	-	-	-	-	-	22	100.0
	All Sites	699	61.1	445	38.9	-	-	-	-	-	-	1144	100.0

O & U : C26, C39, C48, C75, C76, C77, C78, C79, C80, C97

NATIONAL CENTRE FOR DISEASE INFORMATICS AND RESEARCH
NATIONAL CANCER REGISTRY PROGRAMME

(Indian Council of Medical Research)



Hospital Based Cancer Registry
524 HBCR - Malabar Cancer Centre, Kannur

Report Based on Year of Registration : 2023

**TABLE 9(b): Number(#) and Proportion(%) of cancers by site (ICD-10) and Intention to Treat at Reporting Institution
(Excluding the Cancers Previously Treated) - Females**

As on: 11/06/2025

ICD 10	Site	Radical		Palliative		Pain Relief Only		Symptomatic		Unknown		Total	
		#	%	#	%	#	%	#	%	#	%	#	%
C00	Lip	3	75.0	1	25.0	-	-	-	-	-	-	4	100.0
C01-02	Tongue	22	84.6	4	15.4	-	-	-	-	-	-	26	100.0
C03-06	Mouth	25	50.0	25	50.0	-	-	-	-	-	-	50	100.0
C07-08	Salivary Gland	1	50.0	1	50.0	-	-	-	-	-	-	2	100.0
C09	Tonsil	-	-	-	-	-	-	-	-	-	-	-	-
C10	Oth. Oropharynx	4	80.0	1	20.0	-	-	-	-	-	-	5	100.0
C11	Nasopharynx	-	-	-	-	-	-	-	-	-	-	-	-
C12-13	Hypopharynx	5	55.6	4	44.4	-	-	-	-	-	-	9	100.0
C14	Pharynx Unspecified	-	-	-	-	-	-	-	-	-	-	-	-
C15	Oesophagus	4	23.5	13	76.5	-	-	-	-	-	-	17	100.0
C16	Stomach	5	35.7	9	64.3	-	-	-	-	-	-	14	100.0
C17	Small Intestine	1	100.0	-	-	-	-	-	-	-	-	1	100.0
C18	Colon	23	74.2	8	25.8	-	-	-	-	-	-	31	100.0
C19-20	Rectum	39	63.9	22	36.1	-	-	-	-	-	-	61	100.0
C21	Anus & Anal Canal	2	66.7	1	33.3	-	-	-	-	-	-	3	100.0
C22	Liver	1	12.5	7	87.5	-	-	-	-	-	-	8	100.0
C23-24	Gallbladder etc.	3	100.0	-	-	-	-	-	-	-	-	3	100.0
C25	Pancreas	3	27.3	8	72.7	-	-	-	-	-	-	11	100.0
C30-31	Nose, Sinuses etc.	2	40.0	3	60.0	-	-	-	-	-	-	5	100.0
C32	Larynx	7	87.5	1	12.5	-	-	-	-	-	-	8	100.0
C33-34	Lung etc.	8	17.4	38	82.6	-	-	-	-	-	-	46	100.0
C37-38	Other Thoracic Organs	1	50.0	1	50.0	-	-	-	-	-	-	2	100.0
C40-41	Bone	4	100.0	-	-	-	-	-	-	-	-	4	100.0
C43	Melanoma of Skin	-	-	2	100.0	-	-	-	-	-	-	2	100.0
C44	Other Skin	11	84.6	2	15.4	-	-	-	-	-	-	13	100.0
C45	Mesothelioma	-	-	-	-	-	-	-	-	-	-	-	-
C46	Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-	-	-
C47+C49	Conn. & Soft Tissue	5	83.3	1	16.7	-	-	-	-	-	-	6	100.0
C50	Breast	360	90.5	38	9.5	-	-	-	-	-	-	398	100.0
C51	Vulva	-	-	1	100.0	-	-	-	-	-	-	1	100.0
C52	Vagina	3	75.0	1	25.0	-	-	-	-	-	-	4	100.0
C53	Cervix Uteri	71	77.2	21	22.8	-	-	-	-	-	-	92	100.0
C54	Corpus Uteri	63	92.6	5	7.4	-	-	-	-	-	-	68	100.0
C55	Uterus Unspecified	1	100.0	-	-	-	-	-	-	-	-	1	100.0
C56	Ovary etc.	58	87.9	8	12.1	-	-	-	-	-	-	66	100.0
C57	Other Female Genital	1	100.0	-	-	-	-	-	-	-	-	1	100.0
C58	Placenta	-	-	-	-	-	-	-	-	-	-	-	-
C60	Penis	-	-	-	-	-	-	-	-	-	-	-	-
C61	Prostate	-	-	-	-	-	-	-	-	-	-	-	-
C62	Testis	-	-	-	-	-	-	-	-	-	-	-	-
C63	Other Male Genital	-	-	-	-	-	-	-	-	-	-	-	-
C64	Kidney etc.	1	50.0	1	50.0	-	-	-	-	-	-	2	100.0
C65	Renal Pelvis	-	-	-	-	-	-	-	-	-	-	-	-
C66	Ureter	-	-	-	-	-	-	-	-	-	-	-	-
C67	Bladder	2	66.7	1	33.3	-	-	-	-	-	-	3	100.0
C68	Uns. Urinary Organs	-	-	-	-	-	-	-	-	-	-	-	-
C69	Eye	2	100.0	-	-	-	-	-	-	-	-	2	100.0
C70-72	Brain, Nervous System	5	83.3	1	16.7	-	-	-	-	-	-	6	100.0
C73	Thyroid	40	95.2	2	4.8	-	-	-	-	-	-	42	100.0
C74	Adrenal Gland	-	-	-	-	-	-	-	-	-	-	-	-
C81	Hodgkins Disease	5	100.0	-	-	-	-	-	-	-	-	5	100.0
C82-85,C96	NHL	39	92.9	3	7.1	-	-	-	-	-	-	42	100.0
C88	Malig Imn.Prol D	-	-	-	-	-	-	-	-	-	-	-	-
C90	Multiple Myeloma	26	92.9	2	7.1	-	-	-	-	-	-	28	100.0
C91	Lymphoid Leuk.	25	100.0	-	-	-	-	-	-	-	-	25	100.0
C92-94	Myeloid Leukaemia	28	100.0	-	-	-	-	-	-	-	-	28	100.0
C95	Leukaemia Uns	-	-	-	-	-	-	-	-	-	-	-	-
O&U	Other and Uns	5	50.0	5	50.0	-	-	-	-	-	-	10	100.0
	All Sites	914	79.1	241	20.9	-	-	-	-	-	-	1155	100.0

O & U : C26, C39, C48, C75, C76, C77, C78, C79, C80, C97

**NATIONAL CENTRE FOR DISEASE INFORMATICS AND RESEARCH
NATIONAL CANCER REGISTRY PROGRAMME**

(Indian Council of Medical Research)



Hospital Based Cancer Registry

524 HBCR - Malabar Cancer Centre, Kannur

Report Based on Year of Registration : 2023

TABLE 10(a): Number(#) and Proportion(%) of cancers by site (ICD-10) and Marital Status - Males

As on: 11/06/2025

ICD 10	Site	Unmarried		Married		Widowed		Divorced		Separated		Others		Unknown		Total	
		#	%	#	%	#	%	#	%	#	%	#	%	#	%	#	%
C00	Lip	-	-	12	100.0	-	-	-	-	-	-	-	-	-	-	12	100.0
C01-02	Tongue	5	4.0	119	96.0	-	-	-	-	-	-	-	-	-	-	124	100.0
C03-06	Mouth	5	2.8	171	95.5	3	1.7	-	-	-	-	-	-	-	-	179	100.0
C07-08	Salivary Gland	1	5.3	18	94.7	-	-	-	-	-	-	-	-	-	-	19	100.0
C09	Tonsil	-	-	2	100.0	-	-	-	-	-	-	-	-	-	-	2	100.0
C10	Oth. Oropharynx	3	2.8	103	95.4	2	1.9	-	-	-	-	-	-	-	-	108	100.0
C11	Nasopharynx	3	30.0	7	70.0	-	-	-	-	-	-	-	-	-	-	10	100.0
C12-13	Hypopharynx	-	-	60	100.0	-	-	-	-	-	-	-	-	-	-	60	100.0
C14	Pharynx Unspecified	-	-	1	100.0	-	-	-	-	-	-	-	-	-	-	1	100.0
C15	Oesophagus	2	2.3	85	97.7	-	-	-	-	-	-	-	-	-	-	87	100.0
C16	Stomach	3	2.0	147	96.7	1	0.7	1	0.7	-	-	-	-	-	-	152	100.0
C17	Small Intestine	-	-	7	100.0	-	-	-	-	-	-	-	-	-	-	7	100.0
C18	Colon	7	6.9	94	93.1	-	-	-	-	-	-	-	-	-	-	101	100.0
C19-20	Rectum	4	2.8	135	95.1	1	0.7	2	1.4	-	-	-	-	-	-	142	100.0
C21	Anus & Anal Canal	-	-	9	90.0	1	10.0	-	-	-	-	-	-	-	-	10	100.0
C22	Liver	7	4.1	160	94.7	2	1.2	-	-	-	-	-	-	-	-	169	100.0
C23-24	Gallbladder etc.	1	3.0	32	97.0	-	-	-	-	-	-	-	-	-	-	33	100.0
C25	Pancreas	2	4.7	41	95.3	-	-	-	-	-	-	-	-	-	-	43	100.0
C30-31	Nose, Sinuses etc.	2	22.2	7	77.8	-	-	-	-	-	-	-	-	-	-	9	100.0
C32	Larynx	1	0.8	124	98.4	1	0.8	-	-	-	-	-	-	-	-	126	100.0
C33-34	Lung etc.	5	1.1	449	97.6	5	1.1	1	0.2	-	-	-	-	-	-	460	100.0
C37-38	Other Thoracic Organs	2	33.3	4	66.7	-	-	-	-	-	-	-	-	-	-	6	100.0
C40-41	Bone	18	69.2	8	30.8	-	-	-	-	-	-	-	-	-	-	26	100.0
C43	Melanoma of Skin	-	-	8	100.0	-	-	-	-	-	-	-	-	-	-	8	100.0
C44	Other Skin	-	-	51	100.0	-	-	-	-	-	-	-	-	-	-	51	100.0
C45	Mesothelioma	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C46	Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C47+C49	Conn. & Soft Tissue	5	21.7	18	78.3	-	-	-	-	-	-	-	-	-	-	23	100.0
C50	Breast	-	-	4	100.0	-	-	-	-	-	-	-	-	-	-	4	100.0
C51	Vulva	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C52	Vagina	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C53	Cervix Uteri	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C54	Corpus Uteri	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C55	Uterus Unspecified	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C56	Ovary etc.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C57	Other Female Genital	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C58	Placenta	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C60	Penis	-	-	9	100.0	-	-	-	-	-	-	-	-	-	-	9	100.0
C61	Prostate	2	1.2	161	98.2	1	0.6	-	-	-	-	-	-	-	-	164	100.0
C62	Testis	5	41.7	7	58.3	-	-	-	-	-	-	-	-	-	-	12	100.0
C63	Other Male Genital	-	-	1	100.0	-	-	-	-	-	-	-	-	-	-	1	100.0
C64	Kidney etc.	2	3.5	54	94.7	1	1.8	-	-	-	-	-	-	-	-	57	100.0
C65	Renal Pelvis	-	-	3	100.0	-	-	-	-	-	-	-	-	-	-	3	100.0
C66	Ureter	-	-	2	100.0	-	-	-	-	-	-	-	-	-	-	2	100.0
C67	Bladder	3	3.6	79	94.0	1	1.2	1	1.2	-	-	-	-	-	-	84	100.0
C68	Uns.Urinary Organs	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C69	Eye	2	100.0	-	-	-	-	-	-	-	-	-	-	-	-	2	100.0
C70-72	Brain, Nervous System	17	24.3	52	74.3	1	1.4	-	-	-	-	-	-	-	-	70	100.0
C73	Thyroid	11	12.9	73	85.9	-	-	1	1.2	-	-	-	-	-	-	85	100.0
C74	Adrenal Gland	3	75.0	1	25.0	-	-	-	-	-	-	-	-	-	-	4	100.0
C81	Hodgkins Disease	9	45.0	11	55.0	-	-	-	-	-	-	-	-	-	-	20	100.0
C82-85,C96	NHL	11	8.0	123	89.8	1	0.7	2	1.5	-	-	-	-	-	-	137	100.0
C88	Malig Imm.Prol D	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C90	Multiple Myeloma	-	-	73	100.0	-	-	-	-	-	-	-	-	-	-	73	100.0
C91	Lymphoid Leuk.	29	54.7	24	45.3	-	-	-	-	-	-	-	-	-	-	53	100.0
C92-94	Myeloid Leukaemia	10	13.2	65	85.5	-	-	1	1.3	-	-	-	-	-	-	76	100.0
C95	Leukaemia Uns	-	-	1	100.0	-	-	-	-	-	-	-	-	-	-	1	100.0
O&U	Other and Uns	3	5.0	57	95.0	-	-	-	-	-	-	-	-	-	-	60	100.0
	All Sites	183	6.3	2672	92.6	21	0.7	9	0.3	-	-	-	-	-	-	2885	100.0

O & U : C26, C39, C48, C75, C76, C77, C78, C79, C80, C97

NATIONAL CENTRE FOR DISEASE INFORMATICS AND RESEARCH
NATIONAL CANCER REGISTRY PROGRAMME



(Indian Council of Medical Research)

Hospital Based Cancer Registry

524 HBCR - Malabar Cancer Centre, Kannur

Report Based on Year of Registration : 2023

TABLE 10(b): Number(#) and Proportion(%) of cancers by site (ICD-10) and Marital Status - Females

As on: 11/06/2025

ICD 10	Site	Unmarried		Married		Widowed		Divorced		Separated		Others		Unknown		Total	
		#	%	#	%	#	%	#	%	#	%	#	%	#	%	#	%
C00	Lip	-	-	7	63.6	4	36.4	-	-	-	-	-	-	-	-	11	100.0
C01-02	Tongue	4	8.5	31	66.0	12	25.5	-	-	-	-	-	-	-	-	47	100.0
C03-06	Mouth	2	2.5	52	65.8	24	30.4	1	1.3	-	-	-	-	-	-	79	100.0
C07-08	Salivary Gland	3	25.0	7	58.3	2	16.7	-	-	-	-	-	-	-	-	12	100.0
C09	Tonsil	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C10	Oth. Oropharynx	-	-	6	75.0	-	-	2	25.0	-	-	-	-	-	-	8	100.0
C11	Nasopharynx	-	-	1	100.0	-	-	-	-	-	-	-	-	-	-	1	100.0
C12-13	Hypopharynx	1	6.2	9	56.2	6	37.5	-	-	-	-	-	-	-	-	16	100.0
C14	Pharynx Unspecified	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C15	Oesophagus	1	2.9	27	77.1	7	20.0	-	-	-	-	-	-	-	-	35	100.0
C16	Stomach	1	2.0	42	84.0	7	14.0	-	-	-	-	-	-	-	-	50	100.0
C17	Small Intestine	-	-	6	85.7	1	14.3	-	-	-	-	-	-	-	-	7	100.0
C18	Colon	5	4.5	87	79.1	17	15.5	1	0.9	-	-	-	-	-	-	110	100.0
C19-20	Rectum	2	2.0	73	72.3	26	25.7	-	-	-	-	-	-	-	-	101	100.0
C21	Anus & Anal Canal	-	-	2	50.0	2	50.0	-	-	-	-	-	-	-	-	4	100.0
C22	Liver	1	3.0	29	87.9	3	9.1	-	-	-	-	-	-	-	-	33	100.0
C23-24	Gallbladder etc.	-	-	22	75.9	7	24.1	-	-	-	-	-	-	-	-	29	100.0
C25	Pancreas	-	-	33	84.6	5	12.8	1	2.6	-	-	-	-	-	-	39	100.0
C30-31	Nose, Sinuses etc.	1	12.5	6	75.0	1	12.5	-	-	-	-	-	-	-	-	8	100.0
C32	Larynx	2	18.2	7	63.6	2	18.2	-	-	-	-	-	-	-	-	11	100.0
C33-34	Lung etc.	4	3.6	87	79.1	17	15.5	2	1.8	-	-	-	-	-	-	110	100.0
C37-38	Other Thoracic Organs	-	-	5	100.0	-	-	-	-	-	-	-	-	-	-	5	100.0
C40-41	Bone	4	40.0	6	60.0	-	-	-	-	-	-	-	-	-	-	10	100.0
C43	Melanoma of Skin	2	16.7	7	58.3	3	25.0	-	-	-	-	-	-	-	-	12	100.0
C44	Other Skin	5	13.5	24	64.9	8	21.6	-	-	-	-	-	-	-	-	37	100.0
C45	Mesothelioma	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C46	Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C47+C49	Conn. & Soft Tissue	3	14.3	15	71.4	3	14.3	-	-	-	-	-	-	-	-	21	100.0
C50	Breast	31	3.7	714	85.0	88	10.5	7	0.8	-	-	-	-	-	-	840	100.0
C51	Vulva	-	-	3	75.0	1	25.0	-	-	-	-	-	-	-	-	4	100.0
C52	Vagina	-	-	4	66.7	2	33.3	-	-	-	-	-	-	-	-	6	100.0
C53	Cervix Uteri	5	3.4	111	75.0	29	19.6	3	2.0	-	-	-	-	-	-	148	100.0
C54	Corpus Uteri	8	5.5	124	84.9	13	8.9	1	0.7	-	-	-	-	-	-	146	100.0
C55	Uterus Unspecified	-	-	8	100.0	-	-	-	-	-	-	-	-	-	-	8	100.0
C56	Ovary etc.	11	6.5	138	81.2	19	11.2	2	1.2	-	-	-	-	-	-	170	100.0
C57	Other Female Genital	-	-	3	100.0	-	-	-	-	-	-	-	-	-	-	3	100.0
C58	Placenta	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C60	Penis	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C61	Prostate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C62	Testis	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C63	Other Male Genital	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C64	Kidney etc.	2	16.7	8	66.7	2	16.7	-	-	-	-	-	-	-	-	12	100.0
C65	Renal Pelvis	-	-	-	-	2	100.0	-	-	-	-	-	-	-	-	2	100.0
C66	Ureter	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C67	Bladder	-	-	13	76.5	4	23.5	-	-	-	-	-	-	-	-	17	100.0
C68	Uns. Urinary Organs	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C69	Eye	1	50.0	1	50.0	-	-	-	-	-	-	-	-	-	-	2	100.0
C70-72	Brain, Nervous System	5	10.9	37	80.4	4	8.7	-	-	-	-	-	-	-	-	46	100.0
C73	Thyroid	13	5.2	207	83.5	24	9.7	4	1.6	-	-	-	-	-	-	248	100.0
C74	Adrenal Gland	1	33.3	2	66.7	-	-	-	-	-	-	-	-	-	-	3	100.0
C81	Hodgkins Disease	1	8.3	10	83.3	-	-	1	8.3	-	-	-	-	-	-	12	100.0
C82-85,C96	NHL	5	5.3	74	78.7	13	13.8	2	2.1	-	-	-	-	-	-	94	100.0
C88	Malignant Prol D	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C90	Multiple Myeloma	4	6.7	46	76.7	9	15.0	1	1.7	-	-	-	-	-	-	60	100.0
C91	Lymphoid Leuk.	18	42.9	18	42.9	6	14.3	-	-	-	-	-	-	-	-	42	100.0
C92-94	Myeloid Leukaemia	11	21.2	37	71.2	4	7.7	-	-	-	-	-	-	-	-	52	100.0
C95	Leukaemia Uns	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
O&U	Other and Uns	1	3.8	22	84.6	3	11.5	-	-	-	-	-	-	-	-	26	100.0
	All Sites	158	5.8	2171	79.3	380	13.9	28	1.0	-	-	-	-	-	-	2737	100.0

O & U : C26, C39, C48, C75, C76, C77, C78, C79, C80, C97

**NATIONAL CENTRE FOR DISEASE INFORMATICS AND RESEARCH
NATIONAL CANCER REGISTRY PROGRAMME**



(Indian Council of Medical Research)
Hospital Based Cancer Registry
524 HBCR - Malabar Cancer Centre, Kannur

Report Based on Year of Registration : 2023

TABLE 12(a): Number(#) and Proportion(%) of cancers by site (ICD-10) and Religion - Males

As on: 11/06/2025

ICD 10	Site	Hindu		Muslim		Christian		Others		Unknown		Total	
		#	%	#	%	#	%	#	%	#	%	#	%
C00	Lip	10	83.3	2	16.7	-	-	-	-	-	-	12	100.0
C01-02	Tongue	77	62.1	32	25.8	15	12.1	-	-	-	-	124	100.0
C03-06	Mouth	116	64.8	48	26.8	15	8.4	-	-	-	-	179	100.0
C07-08	Salivary Gland	12	63.2	5	26.3	2	10.5	-	-	-	-	19	100.0
C09	Tonsil	2	100.0	-	-	-	-	-	-	-	-	2	100.0
C10	Oth. Oropharynx	86	79.6	10	9.3	12	11.1	-	-	-	-	108	100.0
C11	Nasopharynx	4	40.0	6	60.0	-	-	-	-	-	-	10	100.0
C12-13	Hypopharynx	37	61.7	12	20.0	11	18.3	-	-	-	-	60	100.0
C14	Pharynx Unspecified	-	-	1	100.0	-	-	-	-	-	-	1	100.0
C15	Oesophagus	58	66.7	22	25.3	7	8.0	-	-	-	-	87	100.0
C16	Stomach	91	59.9	50	32.9	11	7.2	-	-	-	-	152	100.0
C17	Small Intestine	5	71.4	1	14.3	1	14.3	-	-	-	-	7	100.0
C18	Colon	70	69.3	26	25.7	5	5.0	-	-	-	-	101	100.0
C19-20	Rectum	80	56.3	48	33.8	14	9.9	-	-	-	-	142	100.0
C21	Anus & Anal Canal	7	70.0	3	30.0	-	-	-	-	-	-	10	100.0
C22	Liver	124	73.4	35	20.7	10	5.9	-	-	-	-	169	100.0
C23-24	Gallbladder etc.	16	48.5	12	36.4	5	15.2	-	-	-	-	33	100.0
C25	Pancreas	28	65.1	15	34.9	-	-	-	-	-	-	43	100.0
C30-31	Nose, Sinuses etc.	4	44.4	5	55.6	-	-	-	-	-	-	9	100.0
C32	Larynx	90	71.4	21	16.7	15	11.9	-	-	-	-	126	100.0
C33-34	Lung etc.	241	52.4	179	38.9	40	8.7	-	-	-	-	460	100.0
C37-38	Other Thoracic Organs	1	16.7	4	66.7	1	16.7	-	-	-	-	6	100.0
C40-41	Bone	10	38.5	10	38.5	6	23.1	-	-	-	-	26	100.0
C43	Melanoma of Skin	5	62.5	2	25.0	1	12.5	-	-	-	-	8	100.0
C44	Other Skin	30	58.8	20	39.2	1	2.0	-	-	-	-	51	100.0
C45	Mesothelioma	-	-	-	-	-	-	-	-	-	-	-	-
C46	Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-	-	-
C47+C49	Conn. & Soft Tissue	9	39.1	10	43.5	4	17.4	-	-	-	-	23	100.0
C50	Breast	3	75.0	1	25.0	-	-	-	-	-	-	4	100.0
C51	Vulva	-	-	-	-	-	-	-	-	-	-	-	-
C52	Vagina	-	-	-	-	-	-	-	-	-	-	-	-
C53	Cervix Uteri	-	-	-	-	-	-	-	-	-	-	-	-
C54	Corpus Uteri	-	-	-	-	-	-	-	-	-	-	-	-
C55	Uterus Unspecified	-	-	-	-	-	-	-	-	-	-	-	-
C56	Ovary etc.	-	-	-	-	-	-	-	-	-	-	-	-
C57	Other Female Genital	-	-	-	-	-	-	-	-	-	-	-	-
C58	Placenta	-	-	-	-	-	-	-	-	-	-	-	-
C60	Penis	9	100.0	-	-	-	-	-	-	-	-	9	100.0
C61	Prostate	98	59.8	53	32.3	13	7.9	-	-	-	-	164	100.0
C62	Testis	9	75.0	3	25.0	-	-	-	-	-	-	12	100.0
C63	Other Male Genital	1	100.0	-	-	-	-	-	-	-	-	1	100.0
C64	Kidney etc.	27	47.4	26	45.6	4	7.0	-	-	-	-	57	100.0
C65	Renal Pelvis	1	33.3	2	66.7	-	-	-	-	-	-	3	100.0
C66	Ureter	1	50.0	1	50.0	-	-	-	-	-	-	2	100.0
C67	Bladder	40	47.6	36	42.9	8	9.5	-	-	-	-	84	100.0
C68	Uns.Urinary Organs	-	-	-	-	-	-	-	-	-	-	-	-
C69	Eye	1	50.0	1	50.0	-	-	-	-	-	-	2	100.0
C70-72	Brain, Nervous System	44	62.9	23	32.9	3	4.3	-	-	-	-	70	100.0
C73	Thyroid	46	54.1	30	35.3	9	10.6	-	-	-	-	85	100.0
C74	Adrenal Gland	1	25.0	2	50.0	1	25.0	-	-	-	-	4	100.0
C81	Hodgkins Disease	8	40.0	10	50.0	2	10.0	-	-	-	-	20	100.0
C82-85,C96	NHL	73	53.3	53	38.7	11	8.0	-	-	-	-	137	100.0
C88	Malignant Prol D	-	-	-	-	-	-	-	-	-	-	-	-
C90	Multiple Myeloma	50	68.5	17	23.3	6	8.2	-	-	-	-	73	100.0
C91	Lymphoid Leuk.	34	64.2	17	32.1	2	3.8	-	-	-	-	53	100.0
C92-94	Myeloid Leukaemia	41	53.9	24	31.6	11	14.5	-	-	-	-	76	100.0
C95	Leukaemia Uns	-	-	1	100.0	-	-	-	-	-	-	1	100.0
O&U	Other and Uns	40	66.7	17	28.3	3	5.0	-	-	-	-	60	100.0
	All Sites	1740	60.3	896	31.1	249	8.6	-	-	-	-	2885	100.0

O & U : C26, C39, C48, C75, C76, C77, C78, C79, C80, C97

**NATIONAL CENTRE FOR DISEASE INFORMATICS AND RESEARCH
NATIONAL CANCER REGISTRY PROGRAMME**

(Indian Council of Medical Research)



**Hospital Based Cancer Registry
524 HBCR - Malabar Cancer Centre, Kannur**

Report Based on Year of Registration : 2023

TABLE 12(b): Number(#) and Proportion(%) of cancers by site (ICD-10) and Religion - Females

As on: 11/06/2025

ICD 10	Site	Hindu		Muslim		Christian		Others		Unknown		Total	
		#	%	#	%	#	%	#	%	#	%	#	%
C00	Lip	6	54.5	4	36.4	1	9.1	-	-	-	-	11	100.0
C01-02	Tongue	31	66.0	14	29.8	2	4.3	-	-	-	-	47	100.0
C03-06	Mouth	54	68.4	20	25.3	5	6.3	-	-	-	-	79	100.0
C07-08	Salivary Gland	8	66.7	2	16.7	2	16.7	-	-	-	-	12	100.0
C09	Tonsil	-	-	-	-	-	-	-	-	-	-	-	-
C10	Oth. Oropharynx	4	50.0	3	37.5	1	12.5	-	-	-	-	8	100.0
C11	Nasopharynx	-	-	-	-	1	100.0	-	-	-	-	1	100.0
C12-13	Hypopharynx	10	62.5	4	25.0	2	12.5	-	-	-	-	16	100.0
C14	Pharynx Unspecified	-	-	-	-	-	-	-	-	-	-	-	-
C15	Oesophagus	23	65.7	10	28.6	2	5.7	-	-	-	-	35	100.0
C16	Stomach	31	62.0	19	38.0	-	-	-	-	-	-	50	100.0
C17	Small Intestine	5	71.4	1	14.3	1	14.3	-	-	-	-	7	100.0
C18	Colon	56	50.9	43	39.1	11	10.0	-	-	-	-	110	100.0
C19-20	Rectum	68	67.3	22	21.8	11	10.9	-	-	-	-	101	100.0
C21	Anus & Anal Canal	3	75.0	1	25.0	-	-	-	-	-	-	4	100.0
C22	Liver	19	57.6	10	30.3	4	12.1	-	-	-	-	33	100.0
C23-24	Gallbladder etc.	15	51.7	7	24.1	7	24.1	-	-	-	-	29	100.0
C25	Pancreas	24	61.5	13	33.3	2	5.1	-	-	-	-	39	100.0
C30-31	Nose, Sinuses etc.	5	62.5	2	25.0	1	12.5	-	-	-	-	8	100.0
C32	Larynx	5	45.5	5	45.5	1	9.1	-	-	-	-	11	100.0
C33-34	Lung etc.	73	66.4	33	30.0	4	3.6	-	-	-	-	110	100.0
C37-38	Other Thoracic Organs	3	60.0	1	20.0	1	20.0	-	-	-	-	5	100.0
C40-41	Bone	4	40.0	6	60.0	-	-	-	-	-	-	10	100.0
C43	Melanoma of Skin	8	66.7	3	25.0	1	8.3	-	-	-	-	12	100.0
C44	Other Skin	18	48.6	13	35.1	6	16.2	-	-	-	-	37	100.0
C45	Mesothelioma	-	-	-	-	-	-	-	-	-	-	-	-
C46	Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-	-	-
C47+C49	Conn. & Soft Tissue	11	52.4	8	38.1	2	9.5	-	-	-	-	21	100.0
C50	Breast	495	58.9	267	31.8	78	9.3	-	-	-	-	840	100.0
C51	Vulva	1	25.0	2	50.0	1	25.0	-	-	-	-	4	100.0
C52	Vagina	4	66.7	1	16.7	1	16.7	-	-	-	-	6	100.0
C53	Cervix Uteri	105	70.9	36	24.3	7	4.7	-	-	-	-	148	100.0
C54	Corpus Uteri	105	71.9	31	21.2	10	6.8	-	-	-	-	146	100.0
C55	Uterus Unspecified	3	37.5	5	62.5	-	-	-	-	-	-	8	100.0
C56	Ovary etc.	107	62.9	53	31.2	10	5.9	-	-	-	-	170	100.0
C57	Other Female Genital	2	66.7	1	33.3	-	-	-	-	-	-	3	100.0
C58	Placenta	-	-	-	-	-	-	-	-	-	-	-	-
C60	Penis	-	-	-	-	-	-	-	-	-	-	-	-
C61	Prostate	-	-	-	-	-	-	-	-	-	-	-	-
C62	Testis	-	-	-	-	-	-	-	-	-	-	-	-
C63	Other Male Genital	-	-	-	-	-	-	-	-	-	-	-	-
C64	Kidney etc.	6	50.0	3	25.0	3	25.0	-	-	-	-	12	100.0
C65	Renal Pelvis	2	100.0	-	-	-	-	-	-	-	-	2	100.0
C66	Ureter	-	-	-	-	-	-	-	-	-	-	-	-
C67	Bladder	9	52.9	6	35.3	2	11.8	-	-	-	-	17	100.0
C68	Uns. Urinary Organs	-	-	-	-	-	-	-	-	-	-	-	-
C69	Eye	2	100.0	-	-	-	-	-	-	-	-	2	100.0
C70-72	Brain, Nervous System	31	67.4	13	28.3	2	4.3	-	-	-	-	46	100.0
C73	Thyroid	155	62.5	76	30.6	17	6.9	-	-	-	-	248	100.0
C74	Adrenal Gland	1	33.3	2	66.7	-	-	-	-	-	-	3	100.0
C81	Hodgkins Disease	4	33.3	8	66.7	-	-	-	-	-	-	12	100.0
C82-85, C96	NHL	46	48.9	40	42.6	8	8.5	-	-	-	-	94	100.0
C88	Malig Imm. Prol D	-	-	-	-	-	-	-	-	-	-	-	-
C90	Multiple Myeloma	38	63.3	17	28.3	5	8.3	-	-	-	-	60	100.0
C91	Lymphoid Leuk.	21	50.0	15	35.7	6	14.3	-	-	-	-	42	100.0
C92-94	Myeloid Leukaemia	31	59.6	19	36.5	2	3.8	-	-	-	-	52	100.0
C95	Leukaemia Uns	-	-	-	-	-	-	-	-	-	-	-	-
O&U	Other and Uns	18	69.2	5	19.2	3	11.5	-	-	-	-	26	100.0
	All Sites	1670	61.0	844	30.8	223	8.1	-	-	-	-	2737	100.0

O & U : C26, C39, C48, C75, C76, C77, C78, C79, C80, C97

**NATIONAL CENTRE FOR DISEASE INFORMATICS AND RESEARCH
NATIONAL CANCER REGISTRY PROGRAMME**



(Indian Council of Medical Research)
Hospital Based Cancer Registry
524 HBCR - Malabar Cancer Centre, Kannur

Report Based on Year of Registration : 2023

TABLE 13(a): Number(#) and Proportion(%) of cancers by site (ICD-10) and Education - Males

As on: 11/06/2025

ICD 10	Site	Middle		Secondary		Primary		Literate		College		Others		Unknown		Total	
		#	%	#	%	#	%	#	%	#	%	#	%	#	%	#	%
C00	Lip	4	33.3	2	16.7	4	33.3	2	16.7	-	-	-	-	-	-	12	100.0
C01-02	Tongue	46	37.1	32	25.8	24	19.4	8	6.5	5	4.0	9	7.3	-	-	124	100.0
C03-06	Mouth	71	39.7	29	16.2	39	21.8	17	9.5	6	3.4	17	9.5	-	-	179	100.0
C07-08	Salivary Gland	5	26.3	7	36.8	3	15.8	1	5.3	3	15.8	-	-	-	-	19	100.0
C09	Tonsil	1	50.0	-	-	-	-	1	50.0	-	-	-	-	-	-	2	100.0
C10	Oth. Oropharynx	49	45.4	19	17.6	21	19.4	10	9.3	3	2.8	6	5.6	-	-	108	100.0
C11	Nasopharynx	5	50.0	1	10.0	1	10.0	2	20.0	-	-	1	10.0	-	-	10	100.0
C12-13	Hypopharynx	24	40.0	7	11.7	17	28.3	7	11.7	-	-	5	8.3	-	-	60	100.0
C14	Pharynx Unspecified	-	-	-	-	1	100.0	-	-	-	-	-	-	-	-	1	100.0
C15	Oesophagus	32	36.8	22	25.3	20	23.0	8	9.2	1	1.1	4	4.6	-	-	87	100.0
C16	Stomach	49	32.2	38	25.0	37	24.3	12	7.9	7	4.6	9	5.9	-	-	152	100.0
C17	Small Intestine	2	28.6	2	28.6	2	28.6	1	14.3	-	-	-	-	-	-	7	100.0
C18	Colon	38	37.6	28	27.7	15	14.9	10	9.9	7	6.9	3	3.0	-	-	101	100.0
C19-20	Rectum	49	34.5	34	23.9	27	19.0	12	8.5	11	7.7	9	6.3	-	-	142	100.0
C21	Anus & Anal Canal	4	40.0	2	20.0	1	10.0	-	-	-	-	3	30.0	-	-	10	100.0
C22	Liver	65	38.5	60	35.5	13	7.7	14	8.3	10	5.9	7	4.1	-	-	169	100.0
C23-24	Gallbladder etc.	8	24.2	11	33.3	8	24.2	4	12.1	1	3.0	1	3.0	-	-	33	100.0
C25	Pancreas	12	27.9	17	39.5	7	16.3	1	2.3	6	14.0	-	-	-	-	43	100.0
C30-31	Nose, Sinuses etc.	3	33.3	4	44.4	-	-	-	-	-	-	2	22.2	-	-	9	100.0
C32	Larynx	53	42.1	25	19.8	31	24.6	8	6.3	1	0.8	8	6.3	-	-	126	100.0
C33-34	Lung etc.	179	38.9	94	20.4	102	22.2	47	10.2	12	2.6	26	5.7	-	-	460	100.0
C37-38	Other Thoracic Organs	3	50.0	1	16.7	-	-	1	16.7	-	-	1	16.7	-	-	6	100.0
C40-41	Bone	5	19.2	12	46.2	2	7.7	1	3.8	5	19.2	1	3.8	-	-	26	100.0
C43	Melanoma of Skin	3	37.5	1	12.5	1	12.5	2	25.0	1	12.5	-	-	-	-	8	100.0
C44	Other Skin	18	35.3	11	21.6	8	15.7	7	13.7	2	3.9	5	9.8	-	-	51	100.0
C45	Mesothelioma	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C46	Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C47+C49	Conn. & Soft Tissue	5	21.7	11	47.8	3	13.0	1	4.3	1	4.3	2	8.7	-	-	23	100.0
C50	Breast	2	50.0	1	25.0	1	25.0	-	-	-	-	-	-	-	-	4	100.0
C51	Vulva	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C52	Vagina	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C53	Cervix Uteri	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C54	Corpus Uteri	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C55	Uterus Unspecified	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C56	Ovary etc.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C57	Other Female Genital	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C58	Placenta	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C60	Penis	2	22.2	3	33.3	1	11.1	1	11.1	1	11.1	1	11.1	-	-	9	100.0
C61	Prostate	52	31.7	62	37.8	18	11.0	11	6.7	12	7.3	9	5.5	-	-	164	100.0
C62	Testis	3	25.0	3	25.0	1	8.3	1	8.3	3	25.0	1	8.3	-	-	12	100.0
C63	Other Male Genital	-	-	1	100.0	-	-	-	-	-	-	-	-	-	-	1	100.0
C64	Kidney etc.	17	29.8	22	38.6	8	14.0	2	3.5	3	5.3	5	8.8	-	-	57	100.0
C65	Renal Pelvis	2	66.7	1	33.3	-	-	-	-	-	-	-	-	-	-	3	100.0
C66	Ureter	1	50.0	1	50.0	-	-	-	-	-	-	-	-	-	-	2	100.0
C67	Bladder	33	39.3	22	26.2	13	15.5	7	8.3	4	4.8	5	6.0	-	-	84	100.0
C68	Uns.Urinary Organs	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C69	Eye	-	-	-	-	-	-	-	-	-	-	2	100.0	-	-	2	100.0
C70-72	Brain, Nervous System	22	31.4	24	34.3	3	4.3	5	7.1	7	10.0	9	12.9	-	-	70	100.0
C73	Thyroid	25	29.4	29	34.1	12	14.1	5	5.9	12	14.1	2	2.4	-	-	85	100.0
C74	Adrenal Gland	1	25.0	1	25.0	1	25.0	-	-	-	-	1	25.0	-	-	4	100.0
C81	Hodgkins Disease	2	10.0	10	50.0	3	15.0	-	-	4	20.0	1	5.0	-	-	20	100.0
C82-85,C96	NHL	52	38.0	34	24.8	13	9.5	14	10.2	19	13.9	5	3.6	-	-	137	100.0
C88	Malig.Imm.Prol.D	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C90	Multiple Myeloma	22	30.1	20	27.4	14	19.2	7	9.6	7	9.6	3	4.1	-	-	73	100.0
C91	Lymphoid Leuk.	12	22.6	14	26.4	8	15.1	4	7.5	5	9.4	10	18.9	-	-	53	100.0
C92-94	Myeloid Leukaemia	20	26.3	30	39.5	4	5.3	4	5.3	12	15.8	6	7.9	-	-	76	100.0
C95	Leukaemia Uns	-	-	1	100.0	-	-	-	-	-	-	-	-	-	-	1	100.0
O&U	Other and Uns	25	41.7	20	33.3	10	16.7	3	5.0	1	1.7	1	1.7	-	-	60	100.0
	All Sites	1026	35.6	769	26.7	497	17.2	241	8.4	172	6.0	180	6.2	-	-	2885	100.0

O & U : C26, C39, C48, C75, C76, C77, C78, C79, C80, C97

NATIONAL CENTRE FOR DISEASE INFORMATICS AND RESEARCH
NATIONAL CANCER REGISTRY PROGRAMME



(Indian Council of Medical Research)
Hospital Based Cancer Registry
524 HBCR - Malabar Cancer Centre, Kannur

Report Based on Year of Registration : 2023

TABLE 13(b): Number(#) and Proportion(%) of cancers by site (ICD-10) and Education - Females

As on: 11/06/2025

ICD 10	Site	Middle		Secondary		Primary		Literate		College		Others		Unknown		Total	
		#	%	#	%	#	%	#	%	#	%	#	%	#	%	#	%
C00	Lip	1	9.1	-	-	2	18.2	4	36.4	-	-	4	36.4	-	-	11	100.0
C01-02	Tongue	16	34.0	9	19.1	11	23.4	4	8.5	-	-	7	14.9	-	-	47	100.0
C03-06	Mouth	13	16.5	8	10.1	17	21.5	17	21.5	2	2.5	22	27.8	-	-	79	100.0
C07-08	Salivary Gland	3	25.0	3	25.0	-	-	2	16.7	2	16.7	2	16.7	-	-	12	100.0
C09	Tonsil	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C10	Oth. Oropharynx	2	25.0	2	25.0	2	25.0	2	25.0	-	-	-	-	-	-	8	100.0
C11	Nasopharynx	1	100.0	-	-	-	-	-	-	-	-	-	-	-	-	1	100.0
C12-13	Hypopharynx	8	50.0	1	6.2	2	12.5	1	6.2	-	-	4	25.0	-	-	16	100.0
C14	Pharynx Unspecified	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C15	Oesophagus	8	22.9	7	20.0	10	28.6	5	14.3	-	-	5	14.3	-	-	35	100.0
C16	Stomach	16	32.0	12	24.0	11	22.0	5	10.0	2	4.0	4	8.0	-	-	50	100.0
C17	Small Intestine	2	28.6	2	28.6	1	14.3	1	14.3	-	-	1	14.3	-	-	7	100.0
C18	Colon	32	29.1	29	26.4	22	20.0	15	13.6	7	6.4	5	4.5	-	-	110	100.0
C19-20	Rectum	30	29.7	24	23.8	20	19.8	19	18.8	3	3.0	5	5.0	-	-	101	100.0
C21	Anus & Anal Canal	2	50.0	1	25.0	1	25.0	-	-	-	-	-	-	-	-	4	100.0
C22	Liver	13	39.4	7	21.2	5	15.2	3	9.1	1	3.0	4	12.1	-	-	33	100.0
C23-24	Gallbladder etc.	7	24.1	8	27.6	7	24.1	1	3.4	3	10.3	3	10.3	-	-	29	100.0
C25	Pancreas	11	28.2	6	15.4	10	25.6	7	17.9	2	5.1	3	7.7	-	-	39	100.0
C30-31	Nose, Sinuses etc.	2	25.0	3	37.5	2	25.0	1	12.5	-	-	-	-	-	-	8	100.0
C32	Larynx	7	63.6	1	9.1	2	18.2	-	-	1	9.1	-	-	-	-	11	100.0
C33-34	Lung etc.	31	28.2	33	30.0	20	18.2	14	12.7	4	3.6	8	7.3	-	-	110	100.0
C37-38	Other Thoracic Organs	4	80.0	-	-	1	20.0	-	-	-	-	-	-	-	-	5	100.0
C40-41	Bone	2	20.0	5	50.0	2	20.0	-	-	-	-	1	10.0	-	-	10	100.0
C43	Melanoma of Skin	5	41.7	4	33.3	2	16.7	1	8.3	-	-	-	-	-	-	12	100.0
C44	Other Skin	8	21.6	9	24.3	8	21.6	4	10.8	2	5.4	6	16.2	-	-	37	100.0
C45	Mesothelioma	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C46	Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C47+C49	Conn. & Soft Tissue	6	28.6	7	33.3	3	14.3	1	4.8	3	14.3	1	4.8	-	-	21	100.0
C50	Breast	313	37.3	202	24.0	139	16.5	66	7.9	90	10.7	30	3.6	-	-	840	100.0
C51	Vulva	3	75.0	-	-	1	25.0	-	-	-	-	-	-	-	-	4	100.0
C52	Vagina	3	50.0	2	33.3	-	-	1	16.7	-	-	-	-	-	-	6	100.0
C53	Cervix Uteri	58	39.2	25	16.9	24	16.2	25	16.9	2	1.4	14	9.5	-	-	148	100.0
C54	Corpus Uteri	47	32.2	60	41.1	18	12.3	7	4.8	5	3.4	9	6.2	-	-	146	100.0
C55	Uterus Unspecified	3	37.5	3	37.5	1	12.5	-	-	-	-	1	12.5	-	-	8	100.0
C56	Ovary etc.	46	27.1	44	25.9	27	15.9	21	12.4	18	10.6	14	8.2	-	-	170	100.0
C57	Other Female Genital	1	33.3	1	33.3	1	33.3	-	-	-	-	-	-	-	-	3	100.0
C58	Placenta	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C60	Penis	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C61	Prostate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C62	Testis	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C63	Other Male Genital	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C64	Kidney etc.	6	50.0	2	16.7	2	16.7	-	-	-	-	2	16.7	-	-	12	100.0
C65	Renal Pelvis	1	50.0	-	-	-	-	-	-	1	50.0	-	-	-	-	2	100.0
C66	Ureter	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C67	Bladder	8	47.1	1	5.9	2	11.8	3	17.6	-	-	3	17.6	-	-	17	100.0
C68	Uns.Urinary Organs	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C69	Eye	1	50.0	-	-	-	-	-	-	-	-	1	50.0	-	-	2	100.0
C70-72	Brain, Nervous System	17	37.0	15	32.6	6	13.0	2	4.3	1	2.2	5	10.9	-	-	46	100.0
C73	Thyroid	53	21.4	103	41.5	34	13.7	21	8.5	27	10.9	10	4.0	-	-	248	100.0
C74	Adrenal Gland	1	33.3	1	33.3	-	-	1	33.3	-	-	-	-	-	-	3	100.0
C81	Hodgkins Disease	4	33.3	4	33.3	2	16.7	1	8.3	1	8.3	-	-	-	-	12	100.0
C82-85,C96	NHL	26	27.7	24	25.5	23	24.5	8	8.5	8	8.5	5	5.3	-	-	94	100.0
C88	Malig Imm.Prol D	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C90	Multiple Myeloma	23	38.3	13	21.7	10	16.7	5	8.3	3	5.0	6	10.0	-	-	60	100.0
C91	Lymphoid Leuk.	12	28.6	8	19.0	4	9.5	4	9.5	5	11.9	9	21.4	-	-	42	100.0
C92-94	Myeloid Leukaemia	9	17.3	16	30.8	7	13.5	4	7.7	7	13.5	9	17.3	-	-	52	100.0
C95	Leukaemia Uns	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
O&U	Other and Uns	4	15.4	6	23.1	8	30.8	3	11.5	-	-	5	19.2	-	-	26	100.0
	All Sites	869	31.8	711	26.0	470	17.2	279	10.2	200	7.3	208	7.6	-	-	2737	100.0

O & U : C26, C39, C48, C75, C76, C77, C78, C79, C80, C97

DETAILED INFORMATION-MCC

Table 1: Number of New and Old Cancer Cases

Sex	Old	%	New	%	Total
Female	969	35.4%	1768	64.6%	2737
Male	800	27.7%	2085	72.3%	2885

Table 2: Number and Proportion of System wise & Sex wise Cancer Incidence

System	Male	%	Female	%	Total
Digestive	748	64.5%	412	35.5%	1160
Breast	4	0.5%	840	99.5%	844
Head & Neck	641	77.6%	185	22.4%	826
Hematopoietic&reticuloendothelial	360	58.1%	260	41.9%	620
Respiratory	475	79.4%	123	20.6%	598
Female genital	-	-	485	100%	485
Endocrine	91	26.6%	251	73.4%	342
Male genital	186	100.0%	-	-	186
Urinary tract	146	82.5%	31	17.5%	177
Eye & CNS	72	60.0%	48	40.0%	120
Skin	59	54.6%	49	45.4%	108
Other & Unspecified	54	71.1%	22	28.9%	76
Soft tissue	23	53.5%	20	46.5%	43
Skeletal-bones etc	26	72.2%	10	27.8%	36
Peripheral nervous	-	-	1	100%	1

Table 3: Number (#) and Proportion of System wise habits and family history

System	Smoking	%	Alcohol	%	Pan chewing	%	Family History	%	Total
Digestive	235	20.3%	204	17.6%	121	10.4%	207	17.8%	1160
Breast	10	1.2%	11	1.3%	31	3.7%	232	27.5%	844
Head & Neck	307	37.2%	279	33.8%	247	29.9%	162	19.6%	826
Hematopoietic & reticuloendothelial	69	11.1%	50	8.1%	36	5.8%	87	14.0%	620
Respiratory	220	36.8%	128	21.4%	57	9.5%	68	11.4%	598
Female genital	5	1.0%	7	1.4%	32	6.6%	122	25.2%	485
Endocrine	14	4.1%	13	3.8%	8	2.3%	81	23.7%	342
Male genital	34	18.3%	28	15.1%	13	7.0%	37	19.9%	186
Urinary tract	39	22.0%	20	11.3%	17	9.6%	25	14.1%	177
Eye & CNS	9	7.5%	7	5.8%	5	4.2%	17	14.2%	120
Skin	19	17.6%	11	10.2%	7	6.5%	8	7.4%	108
Other & Unspecified	19	25.0%	15	19.7%	11	14.5%	11	14.5%	76
Soft tissue	2	4.7%	0	0%	0	0%	5	11.6%	43
Skeletal-bones etc	2	5.6%	0	0%	3	8.3%	6	16.7%	36
Peripheral nervous	0	0%	0	0%	0	0%	0	0%	1

Family History/ Hereditary Cancer

Table 4: Numbers (#) and Proportion of Family History with Hereditary Cancers

Site	No. of Patients	%	Total
Breast	232	27.5%	844
colon	54	25.6%	211
ovary	38	22.4%	170
Prostate	33	20.1%	164
Rectum	53	21.8%	243

Ten Leading Cancers - irrespective of Sex

Table 5 : Numbers (#) and Proportion of leading site of cancers- irrespective of sex

Leading site	Male	%	Female	%	Total
Breast	4	0.5%	840	99.5%	844
Lung	460	80.7%	110	19.3%	570
Thyroid	85	25.5%	248	74.5%	333
Mouth	179	69.4%	79	30.6%	258
Rectum	142	58.4%	101	41.6%	243
NHL	137	59.3%	94	40.7%	231
Colon	101	47.9%	110	52.1%	211
Liver	169	83.7%	33	16.3%	202
Stomach	152	75.2%	50	24.8%	202
Tongue	124	72.5%	47	27.5%	171

I Breast Cancer

- Total Number (ICD 10: C50) : 844
- Breast cancer is the first leading cancer among females
- Ist leading cancer among females: 30.7 %
- Peak age group: 50-54 years in females
- Histology: Infiltrating Ductal Carcinoma: 86.9%in females
- Method of diagnosis: Microscopic : 99%in females
- Detailed Microscopic diagnosis: Histology of Primary: 96.5%in females
- Broad treatment group: Treatment only at RI: 47.4% in females
- Clinical extent of disease before treatment (Treatment only at RI): Direct extension with regional nodes : 46.5% in females
- Intention to treat : Curative/Radical(Treatment only at RI): 90.2% in females
- Composite stage : Stage 2: 45.1% in females.

Table 6: Number and Relative Proportion of Breast cancer by five year age group

Breast					
Age	Male	%	Female	%	Total
20-24	0	0.0%	3	0.4%	3
25-29	0	0.0%	9	1.1%	9
30-34	0	0.0%	14	1.7%	14
35-39	0	0.0%	46	5.5%	46
40-44	0	0.0%	91	10.8%	91
45-49	0	0.0%	125	14.9%	125
50-54	1	25.0%	133	15.8%	134
55-59	0	0.0%	118	14.0%	118
60-64	0	0.0%	105	12.5%	105
65-69	2	50.0%	91	10.8%	93
70-74	1	25.0%	62	7.4%	63
>=75	0	0.0%	43	5.1%	43
Total	4	100%	840	100%	844

Table 7: Number and Relative Proportion of Breast cancer by Broad treatment group

Breast					
Broad treatment group	Male	%	Female	%	Total
No treatment	0	0.0%	158	18.8%	158
Prior & Treatment at RI	2	50.0%	162	19.3%	164
Prior Treatment Only	0	0.0%	122	14.5%	122
Treatment only at RI	2	50.0%	398	47.4%	400
Total	4	100%	840	100%	844

Table 8: Number and Relative Proportion of Breast cancer by Clinical extent of disease (Treatment only at RI)

Breast					
Clinical Extent before Treatment	Male	%	Female	%	Total
Direct Extension	0	0.0%	7	1.8%	7
Direct Extension with Regional Nodes	0	0.0%	185	46.5%	185
Distant Metastasis	1	50.0%	50	12.6%	51
Localised	1	50.0%	153	38.4%	154
Too Advanced	0	0%	3	1%	3
Total	2	100%	398	100%	400

Table 9: Number and Relative Proportion of Breast cancer by Composite stage

Breast					
Composite stage	Male	%	Female	%	Total
stage1	0	0.0%	58	6.9%	58
stage2	3	75.0%	379	45.1%	382
stage3	0	0.0%	202	24.0%	202
stage4	1	25.0%	175	20.8%	176
unknown	0	0.0%	26	3.1%	26
Total	4	100%	840	100%	844

Table 10: Number and Relative Proportion of Breast cancer by intention to treat (Treatment Only at RI)

Breast					
Intention to treat	Male	%	Female	%	Total
Curative / Radical	2	100.0%	360	90.2%	362
Palliative	0	0.0%	38	9.5%	38
Total	2	100%	398	100%	400

Table 11: Number and Relative Proportion of Breast cancer by Diagnostic status

Breast					
Diagnostic status	Male	%	Female	%	Total
Microscopically Confirmed	4	100.0%	832	99.0%	836
Suspected (Microscopically / Radiologically)	0	0.0%	8	1.0%	8
Total	4	100%	840	100%	844

Table 12: Number and Relative Proportion of Breast cancer by Detailed Microscopic Diagnosis

Breast					
Method of diagnosis	Male	%	Female	%	Total
Cytology of Metastasis	0	0.0%	3	0.4%	3
Cytology of Primary	0	0.0%	17	2.0%	17
Histology of Metastasis	0	0.0%	9	1.1%	9
Histology of Primary	4	100.0%	803	96.5%	807
Total	4	100%	832	100%	836

Table 13: Number and Relative Proportion of Breast cancer by Morphology

Broad Histological Classification - Breast(ICD10: C50)Number (#) and Relative Proportion (%) of Different Histologic Types(Report from NCDIR/ICMR)

Histologic Type	Females		
	#	%*	%**
Neoplasm Malignant (8000-8005,9990)	17	2	2
Carcinoma (8010-8035)	22	2.6	2.6
Papillary Carcinoma (8050,8260)	3	0.4	0.4
Squamous Cell Carcinoma (8070-8078,8083-8084)	1	0.1	0.1
Adeno carcinoma, NOS(8140-8141, 8143-8147, 8200-8202, 8204, 8210-8211)	5	0.6	0.6
Mucinous Adeno Carcinoma (8430,8480-8482,8490)	17	2	2
Infiltrating Duct Carcinoma (8500-8508,8521,8523)	732	87.8	86.9
Medullary Carcinoma (8510-8514)	1	0.1	0.1
Lobular Carcinoma (8520,8522,8524)	15	1.8	1.8
Paget's Disease (8540-8543)	-	-	-
CystosarcPhyllodes (9020)	5	0.6	0.6
Others	16	1.9	1.9
All Microscopic	834	100	99
Non Microscopic	8	-	1
Total	842	-	100
* All Microscopic ** Total			

II Lung Cancer

- Total Number (ICD 10: C33-34) :570 (19.3% females and 80.7% males)
- 1st leading cancer among males : 15.9% and 7th leading cancer in females : 4%
- Peak age group: 70-74 years in males and 55-69 in females
- Histology: Adenocarcinoma: 27% in males and 38.2% in females
- Method of diagnosis: Microscopic : 84.6% in males and 87.3% in females
- Detailed Microscopic diagnosis: Histology of Primary: 77.1% in males and 75% in females.
- Broad treatment group: Treatment only at RI: 41.8% in females and 37.2% in males
- Clinical extent of disease before treatment (Treatment only at RI) : Distant metastasis: 69.6% in females and 63.2% in males
- Intention to treat (Treatment only at RI) : Palliative: 89.5% in males and 82.6% in females
- Composite stage: Stage 4: 71.1 % in males and 71.8 % in females

Table 14 :Number and Relative Proportion of Lung cancer by five year age group

Lung					
Age	Male	%	Female	%	Total
30-34	2	0.4%	1	0.9%	3
35-39	1	0.2%	1	0.9%	2
40-44	3	0.7%	3	2.7%	6
45-49	12	2.6%	9	8.2%	21
50-54	30	6.5%	16	14.5%	46
55-59	46	10.0%	19	17.3%	65
60-64	88	19.1%	19	17.3%	107
65-69	103	22.4%	19	17.3%	122
70-74	113	24.6%	12	10.9%	125
>=75	62	13.5%	11	10.0%	73
Total	460	100%	110	100%	570

Table 15 : Number and Relative Proportion of Lung cancer by Broad Treatment Groups

Lung					
Broad treatment group	Male	%	Female	%	Total
No treatment	225	48.9%	40	36.4%	265
Prior & Treatment at RI	21	4.6%	10	9.1%	31
Prior Treatment Only	43	9.3%	14	12.7%	57
Treatment only at RI	171	37.2%	46	41.8%	217
Total	460	100%	110	100%	570

Table 16: Number and Relative Proportion of Lung cancer by Clinical Extent of Disease (Treatment only at RI)

Lung					
Clinical Extent before treatment	Male	%	Female	%	Total
Direct Extension	6	3.5%	2	4.3%	8
Direct Extension with Regional Nodes	43	25.1%	10	21.7%	53
Distant Metastasis	108	63.2%	32	69.6%	140
Localised	5	2.9%	2	4.3%	7
Too Advanced	9	5%	0	0%	9
Total	171	100%	46	100%	217

Table 17: Number and Relative Proportion of Lung cancer by histology

Broad Histological Classification - Lung(ICD10: C33-34)Number (#) and Relative Proportion (%) of Different Histologic Types(Report from NCDIR/ICMR)

Histologic Type	Males			Females		
	#	%*	%**	#	%*	%**
Neoplasm Malignant (8000-8005, 9990)	115	29.6	25	35	36.5	31.8
Large Cell Carcinoma (8012, 8013, 8014)	-	-	-	-	-	-
Undiff/Anaplastic Carc. (8020, 8021)	-	-	-	-	-	-
Small Cell Carc. (8041, 8043, 8044, 8045)	40	10.3	8.7	3	3.1	2.7
Squamous Cell Carcinoma (8070-8078, 8084)	85	21.9	18.5	11	11.5	10
Other Carcinomas (8010, 8032, 8033, 8034, 8040, 8042, 8430, 8440, 8480)	17	4.4	3.7	2	2.1	1.8
Adeno Carcinoma (8140, 8141, 8200, 8210, 8240, 8241, 8246, 8250, 8251, 8253, 8254, 8255, 8260, 8310, 8481, 8490, 8560)	124	31.9	27	42	43.8	38.2
Others	8	2.1	1.7	3	3.1	2.7
All Microscopic	389	100	84.6	96	100	87.3
Non Microscopic	71	-	15.4	14	-	12.7
Total	460	-	100	110	-	100
* All Microscopic ** Total						

Table 18: Number and Relative Proportion of Lung cancer by Intention to treat (Treatment only at RI)

Lung					
Intention	Male	%	Female	%	Total
Curative / Radical	18	10.5%	8	17.4%	26
Palliative	153	89.5%	38	82.6%	191
Total	171	100%	46	100%	217

Table 19: Number and Relative Proportion of Lung cancer by Composite stage

Lung					
Composite stage	Male	%	Female	%	Total
stage1	5	1.1%	3	2.7%	8
stage2	6	1.3%	5	4.5%	11
stage3	93	20.2%	18	16.4%	111
stage4	327	71.1%	79	71.8%	406
unknown	29	6.3%	5	4.5%	34
Total	460	100%	110	100%	570

Table 20: Number and Relative Proportion of Lung cancer by Diagnostic status

Lung					
Diagnostic status	Male	%	Female	%	Total
Microscopically Confirmed	389	84.6%	96	87.3%	485
Suspected (Microscopically / Radiologically)	71	15.4%	14	12.7%	85
Total	460	100%	110	100%	570

Table 21 : Number and Relative Proportion of Lung cancer by Detailed Microscopic Diagnosis

Lung					
Method of diagnosis	Male	%	Female	%	Total
Cytology of Metastasis	23	5.9%	6	6.3%	29
Cytology of Primary	16	4.1%	2	2.1%	18
Histology of Metastasis	50	12.9%	16	16.7%	66
Histology of Primary	300	77.1%	72	75.0%	372
Total	389	100%	96	100%	485

III Thyroid

- Total Number (ICD 10: C01-02) : 333
- 2nd leading cancer among females(9.1%)
- Peak age group: 50-54 years in males and 45-49 in females
- Histology : Papillary Adeno carcinoma: 68.2% in males and 65.7 % in females
- Method of diagnosis: Microscopic: 100% in males and 99.6% in females
- Detailed Microscopic diagnosis: Histology of Primary : 84.7% in males and 89.9 % in females
- Broad treatment group: Prior & Treatment at RI:50.6% in males and 68.1 % in females
- Clinical extent of disease before treatment (Treatment only at RI):Direct Extension with Regional Nodes: 54.5% in males and 19% in females
- Intention to treat for new patients : Curative/Radical : 81.8% in males and 95.2% in females
- Composite Stage: Stage 1: 22.4% in males and 38.3 % in females

Table 22: Number and Relative Proportion of Thyroid cancer by Five year age group

Mouth					
Age	Male	%	Female	%	Total
5-9	1	1.2%	1	0.4%	2
15-19	0	0.0%	5	2.0%	5
20-24	3	3.5%	11	4.4%	14
25-29	5	5.9%	8	3.2%	13
30-34	9	10.6%	21	8.5%	30
35-39	2	2.4%	23	9.3%	25
40-44	9	10.6%	30	12.1%	39
45-49	12	14.1%	40	16.1%	52
50-54	13	15.3%	34	13.7%	47
55-59	8	9.4%	25	10.1%	33
60-64	5	5.9%	17	6.9%	22
65-69	5	5.9%	15	6.0%	20
70-74	10	11.8%	10	4.0%	20
>=75	3	3.5%	8	3.2%	11
Total	85	100%	248	100%	333

Table 23: Number and Relative Proportion of Thyroid cancer by Broad Treatment Group

Thyroid					
Broad treatment group	Male	%	Female	%	Total
No treatment	10	11.8%	12	4.8%	22
Prior & Treatment at RI	43	50.6%	169	68.1%	212
Prior Treatment Only	10	11.8%	25	10.1%	35
Treatment only at RI	22	25.9%	42	16.9%	64
Total	85	100%	248	100%	333

Table 24 : Number and Relative Proportion of Thyroid cancer by Clinical extent of disease before treatment (Treatment only at RI)

Thyroid					
Clinical Extent before treatment	Male	%	Female	%	Total
Direct Extension	0	0.0%	5	11.9%	5
Direct Extension with Regional Nodes	12	54.5%	8	19.0%	20
Distant Metastasis	5	22.7%	6	14.3%	11
Localised	4	18.2%	23	54.8%	27
Too Advanced	1	4.5%	0	0.0%	1
Total	22	100%	42	100%	64

Table 25 : Number and Relative Proportion of Thyroid cancer by Composite Stage

Thyroid					
Composite stage	Male	%	Female	%	total
stage 1	19	22.4%	95	38.3%	114
stage 2	11	12.9%	54	21.8%	65
stage 3	18	21.2%	37	14.9%	55
stage 4	30	35.3%	54	21.8%	84
unknown	7	8.2%	8	3.2%	15
Total	85	100%	248	100%	333

Table 26 : Number and Relative Proportion of Thyroid cancer by Intention to treat

Thyroid (Treatment only at RI)					
intention	Male	%	Female	%	count
Curative / Radical	18	81.8%	40	95.2%	58
Palliative	4	18.2%	2	4.8%	6
Total	22	100%	42	100%	64

Table 27 : Number and Relative Proportion of Thyroid cancer by Diagnostic Status

Thyroid					
Diagnostic status	Male	%	Female	%	Total
Microscopically Confirmed	85	100%	247	99.6%	332
Suspected (Microscopically / Radiologically)	0	0.0%	1	0.4%	1
Total	85	100%	248	100%	333

Table 28: Number and Relative Proportion of Thyroid cancer by Detailed Microscopic Diagnosis

Thyroid					
Method of diagnosis	Male	%	Female	%	Total
Cytology of Metastasis	1	1.2%	1	0.4%	2
Cytology of Primary	10	11.8%	20	8.1%	30
Histology of Metastasis	2	2.4%	4	1.6%	6
Histology of Primary	72	84.7%	222	89.9%	294
Total	85	100%	247	100%	332

Table 29 : Number and Relative Proportion of Thyroid cancer by Morphology

WHO Histological Classification - Thyroid(ICD10: C18)Number (#) and Relative Proportion (%) of Different Histologic Types(Report from NCDIR/ICMR)

Histologic Type	Males			Females		
	#	%*	%**	#	%*	%**
Neoplasm Malignant (8000-8005,9990)	3	3.5	3.5	6	2.4	2.4
Other Carcinomas (8010-8012,8022,8030-8035,8041,8337)	1	1.2	1.2	-	-	-
Undifferentiated Carc. (8020,8021)	3	3.5	3.5	7	2.8	2.8
Papillary Carc.NOS (8050)	2	2.4	2.4	4	1.6	1.6
Papillary AdenoCarc. (8260,8341,8344,8350)	58	68.2	68.2	163	66	65.7
Follicular Carcinoma (8290,8330-8335)	12	14.1	14.1	41	16.6	16.5
Mixed Papi&FolliCarc. (8340)	1	1.2	1.2	20	8.1	8.1
Medullary carcinoma (8346,8347,8510,8512)	4	4.7	4.7	5	2	2
Others	1	1.2	1.2	1	0.4	0.4
All Microscopic	85	100	100	247	100	99.6
Non Microscopic	-	-	-	1	-	0.4
Total	85	-	100	248	-	100
* All Microscopic ** Total						

IV Mouth

- Total Number (ICD 10: C03-06) : 258
- 2nd leading cancer among males (6.2%)
- 10th leading cancer among females (2.9%)
- Peak age group: 55-59 years in males and 70-74 years in females.
- Histology : Squamous cell carcinoma : 81% in females and 87.2% in males
- Method of diagnosis: Microscopic: 93.7% in females and 98.9% in males
- Detailed Microscopic diagnosis: Histology of Primary: 97.3 % in females and 98.9% in males.
- Broad treatment group: Treatment Only at RI: 63.3% in females and 61.5% in males
- Clinical extent of disease before treatment (Treatment only at RI): Direct extension with regional nodes :52% in females and 52.7 % in males
- Intention to treat : Curative/Radical: 50% in females and 74.5% in males
- Composite stage : Stage 4 : 57% in males and 65.8 % in females

Table 30 : Number and Relative Proportion of Mouth cancer by Five year age group

Mouth					
Age	Male	%	Female	%	Total
0-4	1	0.6%	0	0.0%	1
15-19	0	0.0%	1	1.3%	1
20-24	0	0.0%	1	1.3%	1
30-34	1	0.6%	1	1.3%	2
35-39	12	6.7%	2	2.5%	14
40-44	14	7.8%	1	1.3%	15
45-49	19	10.6%	4	5.1%	23
50-54	24	13.4%	4	5.1%	28
55-59	27	15.1%	7	8.9%	34
60-64	20	11.2%	10	12.7%	30
65-69	15	8.4%	10	12.7%	25
70-74	21	11.7%	16	20.3%	37
>=75	25	14.0%	22	27.8%	47
Total	179	100%	79	100%	258

Table 31: Number and Relative Proportion of Mouth cancer by Broad treatment group

Mouth					
Broad treatment group	Male	%	Female	%	Total
No treatment	34	19.0%	12	15.2%	46
Prior & Treatment at RI	18	10.1%	10	12.7%	28
Prior Treatment Only	17	9.5%	7	8.9%	24
Treatment only at RI	110	61.5%	50	63.3%	160
Total	179	100%	79	100%	258

Table 32: Number and Relative Proportion of Mouth cancer by Clinical extent of disease before treatment (Treatment only at RI)

Mouth					
Clinical extent before treatment	Male	%	Female	%	Total
Direct Extension	10	9.1%	3	6.0%	13
Direct Extension with Regional Nodes	58	52.7%	26	52.0%	84
Localised	40	36.4%	17	34.0%	57
Too Advanced	2	1.8%	4	8.0%	6
Total	110	100%	50	100%	160

Table 33 : Number and Relative Proportion of Mouth cancer by Composite stage

Mouth					
Composite stage	Male	%	Female	%	Total
stage1	13	7.3%	3	3.8%	16
stage2	22	12.3%	12	15.2%	34
stage3	40	22.3%	10	12.7%	50
stage4	102	57.0%	52	65.8%	154
unknown	2	1.1%	2	2.5%	4
Total	179	100%	79	100%	258

Table 34 : Number and Relative Proportion of Mouth cancer by intention to treat

Mouth (Treatment only at RI)						
Intention	Male	%	Female	%	Total	
Curative / Radical	82	74.5%	25	50.0%	107	
Palliative	28	25.5%	25	50.0%	53	
Total	110	100%	50	100%	160	

Table 35 : Number and Relative Proportion of Mouth cancer by Diagnostic status

Mouth					
Diagnostic status	Male	%	Female	%	Total
Microscopically Confirmed	177	98.9%	74	93.7%	251
Suspected (Clinically / To rule out Malignancy)	1	0.6%	3	3.8%	4
Suspected (Microscopically / Radiologically)	1	0.6%	2	2.5%	3
Total	179	100%	79	100%	258

Table 36 : Number and Relative Proportion of Mouth cancer by Detailed Microscopic Diagnosis

Mouth					
Method of diagnosis	Male	%	Female	%	Total
Cytology of Metastasis	1	0.6%	2	2.7%	3
Cytology of Primary	1	0.6%	0	0.0%	1
Histology of Primary	175	98.9%	72	97.3%	247
Total	177	100%	74	100%	251

Table 37 : Number and Relative Proportion of Mouth cancer by Morphology

Broad Histological Classification - Mouth (ICD10: C03-06) Number (#) and Relative Proportion (%) of Different Histologic Types (Report from NCDIR/ICMR)

Histologic Type	Males			Females		
	#	%*	%**			
Neoplasm Malignant (8000-8005, 9990)	3	1.7	1.7	2	2.7	2.5
Carcinomas (8010-8035, 8041, 8050, 8052)	4	2.3	2.2	2	2.7	2.5
Verrucous Carcinomas (8051)	6	3.4	3.4	2	2.7	2.5
Squamous Cell Carcinoma (8070-8076, 8083-8084)	156	88.1	87.2	64	86.5	81
Adeno Carcinoma (8140, 8200, 8210, 8251, 8260, 8310, 8525, 8550, 8570)	3	1.7	1.7	2	2.7	2.5
Others	5	2.8	2.8	2	2.7	2.5
All Microscopic	177	100	98.9	74	100	93.7
Non Microscopic	2	-	1.1	5	-	6.3
Total	179	-	100	79	-	100
* All Microscopic ** Total						

V. Rectum

- Total Number (ICD 10: C20) : 243
- 6th leading cancer among males and 8th leading cancer in females.
- Peak age group: 70-74 years in males and 65-74 years in females
- Histology : Adenocarcinoma: 85.9% in males and 92.1 % in females
- Method of diagnosis: Microscopic: 96.5% in males and 99 % in females
- Detailed Microscopic diagnosis: Histology of Primary: 97.1% in males and 99% in females
- Broad treatment group: Treatment only at RI : 42.3% in males and 60.4% in females
- Clinical extent of disease before treatment (Treatment only at RI): Direct extension with regional nodes: 58.3% in males and 68.9 % in females
- Intention to treat: Curative/Radical : 71.7% in males and 63.9 % in females
- Composite Stage : Stage 3: 38.7% in males and 61.4 % in females

Table 38: Number and Relative Proportion of Rectum cancer by five year age group

Rectum					
Age	Male	%	Female	%	Total
20-24	1	0.7%	0	0.0%	1
25-29	0	0.0%	1	1.0%	1
30-34	0	0.0%	1	1.0%	1

40-44	7	4.9%	0	0.0%	7
45-49	11	7.7%	10	9.9%	21
50-54	17	12.0%	9	8.9%	26
55-59	15	10.6%	12	11.9%	27
60-64	21	14.8%	12	11.9%	33
65-69	21	14.8%	17	16.8%	38
70-74	24	16.9%	17	16.8%	41
>=75	25	17.6%	22	21.8%	47
Total	142	100%	101	100%	243

Table 39: Number and Relative Proportion of Rectum cancer by Broad treatment group

Rectum					
Broad treatment group	Male	%	Female	%	Total
No treatment	43	30.3%	21	20.8%	64
Prior & Treatment at RI	14	9.9%	5	5.0%	19
Prior Treatment Only	25	17.6%	14	13.9%	39
Treatment only at RI	60	42.3%	61	60.4%	121
Total	142	100%	101	100%	243

Table 40: Number and Relative Proportion of Rectum cancer by Clinical Extent of Disease (Treatment only at RI)

Rectum					
Clinical Extent before treatment	Male	%	Female	%	Total
Direct Extension	3	5.0%	5	8.2%	8
Direct Extension with Regional Nodes	35	58.3%	42	68.9%	77
Distant Metastasis	10	16.7%	8	13.1%	18
Localised	11	18.3%	4	6.6%	15
Too Advanced	1	1.7%	2	3.3%	3
Total	60	100%	61	100%	121

Table 41: Number and Relative Proportion of Rectum cancer by Composite stage

Rectum					
Composite stage	Male	%	Female	%	Total
stage1	6	4.2%	2	2.0%	8
stage2	21	14.8%	7	6.9%	28
stage3	55	38.7%	62	61.4%	117
stage4	42	29.6%	24	23.8%	66
unknown	18	12.7%	6	5.9%	24
Total	142	100%	101	100%	243

Table 42 : Number and Relative Proportion of Rectum cancer by intention to treat

Rectum (Treatment only at RI)					
Intention	Male	%	Female	%	Total
Curative / Radical	43	71.7%	39	63.9%	82
Palliative	17	28.3%	22	36.1%	39
Total	60	100%	61	100%	121

Table 43: Number and Relative Proportion of Rectum cancer by Diagnostic status

Rectum					
Diagnostic status	Male	%	Female	%	Total
Microscopically Confirmed	137	96.5%	100	99.0%	237
Suspected (Microscopically / Radiologically)	5	3.5%	1	1.0%	6
Total	142	100%	101	100%	243

Table 44 : Number and Relative Proportion of Rectum cancer by detailed microscopic diagnosis

Rectum					
Method of diagnosis	Male	%	Female	%	Total
Cytology of Metastasis	1	0.7%	0	0.0%	1
Histology of Metastasis	3	2.2%	1	1.0%	4
Histology of Primary	133	97.1%	99	99.0%	232
Total	137	100%	100	100%	237

Table 45 : Number and Relative Proportion of Rectum cancer by Morphology

WHO Histological Classification - Rectum(ICD10: C19-20)Number (#) and Relative Proportion (%) of Different Histologic Types(Report from NCDIR/ICMR)

Histologic Type	Males			Females		
	#	%*	%**	#	%*	%**
Adenocarcinoma (8140)	122	89.1	85.9	93	93	92.1
Mucinous adenocarcinoma (8480)	5	3.6	3.5	-	-	-
Signet-ring cell carcinoma (8490)	4	2.9	2.8	1	1	1
Squamous cell carcinoma (8070)	-	-	-	1	1	1
Others	6	4.4	4.2	5	5	5
All Microscopic	137	100	96.5	100	100	99
Non Microscopic	5	-	3.5	1	-	1
Total	142	-	100	101	-	100
* All Microscopic ** Total						

VI NHL

- Total Number (ICD 10: C82-85,C96) : 231
- 7th leading cancer among males and 9th leading cancer among females
- Peak age group: 55-59 years in males and 65-69 in females
- Histology : DIFFUSE LARGE B-CELL LYMPHOMA : 32.8% in males and 34 % in females
- Method of diagnosis: Microscopic: 100% in males and females
- Detailed Microscopic diagnosis: Histology of Primary: 78.1% in males and 77.7% in females
- Broad treatment group: Treatment only at RI : 38% in males and 44.7% in females
- Intention to treat : Curative/Radical : 96.2 % in males and 92.9 % in females
- Composite stage : Stage 4: 37.2% in males and 25.5% in females

Table 46: Number and Relative Proportion of NHL cancer by Five year age group

NHL					
Age	Male	%	Female	%	Total
0-4	2	1.5%	0	0.0%	2
5-9	2	1.5%	0	0.0%	2
10-14	1	0.7%	2	2.1%	3
15-19	0	0.0%	2	2.1%	2
20-24	1	0.7%	2	2.1%	3
25-29	1	0.7%	2	2.1%	3
30-34	4	2.9%	1	1.1%	5
35-39	9	6.6%	3	3.2%	12
40-44	14	10.2%	10	10.6%	24
45-49	11	8.0%	6	6.4%	17
50-54	16	11.7%	8	8.5%	24
55-59	19	13.9%	12	12.8%	31
60-64	18	13.1%	10	10.6%	28
65-69	15	10.9%	14	14.9%	29
70-74	17	12.4%	12	12.8%	29
>=75	7	5.1%	10	10.6%	17
Total	137	100%	94	100%	231

Table 47: Number and Relative Proportion of NHL cancer by Broad treatment group

NHL					
Broad Treatment Group	Male	%	Female	%	Total
No treatment	48	35.0%	29	30.9%	77
Prior & Treatment at RI	11	8.0%	7	7.4%	18
Prior Treatment Only	26	19.0%	16	17.0%	42
Treatment only at RI	52	38.0%	42	44.7%	94
Total	137	100%	94	100%	231

Table 48: Number and Relative Proportion of NHLcancer by Composite stage

NHL					
Composite stage	Male	%	Female	%	Total
stage1	10	7.3%	11	11.7%	21
stage2	10	7.3%	17	18.1%	27
stage3	24	17.5%	17	18.1%	41
stage4	51	37.2%	24	25.5%	75
unknown	42	30.7%	25	26.6%	67
Total	137	100%	94	100%	231

Table 49: Number and Relative Proportion of NHLcancer by intention to treat for new patients

NHL					
Intention	Male	%	Female	%	Total
Curative / Radical	50	96.2%	39	92.9%	89
Palliative	2	3.8%	3	7.1%	5
Total	52	100%	42	100%	94

Table 50: Number and Relative Proportion of NHL cancer by Diagnostic status

NHL					
Diagnostic status	Male	%	Female	%	Total
Microscopically Confirmed	137	100.0%	94	100.0%	231

Table 51 : Number and Relative Proportion of NHLcancer by Detailed Microscopic diagnosis

NHL					
Method of diagnosis	Male	%	Female	%	Total
Bone Marrow	29	21.2%	15	16.0%	44
Cytology of Primary	0	0.0%	5	5.3%	5
Histology of Metastasis	1	0.7%	0	0.0%	1
Histology of Primary	107	78.1%	74	78.8%	180
Total	137	100%	94	100%	231

Table 52: Number and Relative Proportion of NHL cancer by Morphology

NHL					
Morphology	Male	%	Female	%	Total
Diffuse Large B-Cell Lymphoma	45	32.8%	32	34.0%	77
Non Hodgkins Lymphoma B Cell	17	12.4%	21	22.3%	38
Polycythemiavera	22	16.1%	6	6.4%	28
Peripheral T Cell Lymphoma	11	8.0%	3	3.2%	14
Myelodysplastic syndrome	3	2.2%	5	5.3%	8
Follicular Lymphoma	15	10.9%	8	8.5%	23
Mantle Cell Lymphoma	4	2.9%	1	1.1%	5
Anaplastic Large Cell Lymphoma	4	2.9%	0	0.0%	4
Marginal Zone B-Cell Lymphoma	2	1.5%	2	2.1%	4
Mycosis Fungoides	2	1.5%	2	2.1%	4
Lymphoma NOS	2	1.5%	2	2.1%	4
Cutaneous T-Cell Lymphoma	2	1.5%	1	1.1%	3
others	8	5.8%	11	11.7%	19
Total	137	100%	94	100%	231

VII Colon

- Total Number (ICD 10: C01-02) : 211
- 6th leading cancer among females
- Peak age group: 60-64 years in males and 65-69 in females
- Histology : Adenocarcinoma: 70.3% in males and 71.8 % in females
- Method of diagnosis: Microscopic: 94.1% in males and 96.4% in females
- Detailed Microscopic diagnosis: Histology of Primary : 92.6% in males and 89.6 % in females
- Broad treatment group: Treatment only at RI :28.7% in males and 28.2% in females
- Clinical extent of disease before treatment (Treatment only at RI):Direct Extension with Regional Nodes: 27.6% in males and 29% in females
- Intention to treat for new patients : Curative/Radical : 69% in males and 74.2% in females
- Composite Stage: Stage 4: 39.6% in males and 43.6 % in females

Table 53: Number and Relative Proportion of Colon cancer by Five year age group

Colon					
Age	Male	%	Female	%	Total
15-19	1	1.0%	1	0.9%	2
20-24	1	1.0%	1	0.9%	2
30-34	2	2.0%	1	0.9%	3
35-39	1	1.0%	3	2.7%	4
40-44	5	5.0%	17	15.5%	22
45-49	5	5.0%	12	10.9%	17
50-54	14	13.9%	11	10.0%	25
55-59	10	9.9%	11	10.0%	21
60-64	18	17.8%	14	12.7%	32
65-69	16	15.8%	21	19.1%	37
70-74	17	16.8%	10	9.1%	27
>=75	11	10.9%	8	7.3%	19
Total	101	100%	110	100%	211

Table 54: Number and Relative Proportion of Colon cancer by Broad treatment group

Colon					
Broad treatment group	Male	%	Female	%	Total
No treatment	29	28.7%	24	21.8%	53
Prior & Treatment at RI	15	14.9%	22	20.0%	37
Prior Treatment Only	28	27.7%	33	30.0%	61
Treatment only at RI	29	28.7%	31	28.2%	60
Total	101	100%	110	100%	211

Table 55: Number and Relative Proportion of Colon cancer by Clinical extent of disease (Treatment only at RI)

Colon					
Clinical extent before treatment	Male	%	Female	%	Total
Direct Extension	4	13.8%	9	29.0%	13
Direct Extension with Regional Nodes	8	27.6%	9	29.0%	17
Distant Metastasis	11	37.9%	7	22.6%	18
Localised	5	17.2%	6	19.4%	11
Too Advanced	1	3%	0	0%	1
Total	29	100%	31	100%	60

Table 56: Number and Relative Proportion of Colon cancer by Composite stage

Colon					
Composite stage	Male	%	Female	%	Total
stage1	7	6.9%	7	6.4%	14
stage2	14	13.9%	12	10.9%	26
stage3	36	35.6%	36	32.7%	72
stage4	40	39.6%	48	43.6%	88
unknown	4	4.0%	7	6.4%	11
Total	101	100%	110	100%	211

Table 57: Number and Relative Proportion of Colon cancer by intention to treat

Colon					
Intention	Male	%	Female	%	Total
Curative / Radical	20	69.0%	23	74.2%	43
Palliative	9	31.0%	8	25.8%	17
Total	29	100%	31	100%	60

Table 58: Number and Relative Proportion of Colon cancer by Diagnostic status

Colon					
Diagnostic status	Male	%	Female	%	Total
Microscopically Confirmed	95	94.1%	106	96.4%	201
Suspected (Microscopically / Radiologically)	6	5.9%	4	3.6%	10
Total	101	100%	110	100%	211

Table 59: Number and Relative Proportion of Colon cancer by Detailed Microscopic Diagnosis

Colon					
Method of diagnosis	Male	%	Female	%	Total
Cytology of Metastasis	0	0.0%	1	0.9%	1
Histology of Metastasis	7	7.4%	10	9.4%	17
Histology of Primary	88	92.6%	95	89.6%	183
Total	95	100%	106	100%	201

Table 60: Number and Relative Proportion of Colon cancer by Morphology

WHO Histological Classification - Colon(ICD10: C18)Number (#) and Relative Proportion (%) of Different Histologic Types(Report from NCDIR/ICMR)

Histologic Type	Males			Females		
	#	%*	%**	#	%*	%**
Adenocarcinoma (8140)	71	74.7	70.3	79	74.5	71.8
Mucinous adenocarcinoma (8480)	9	9.5	8.9	10	9.4	9.1
Signet-ring cell carcinoma (8490)	5	5.3	5.0	3	2.8	2.7
Others	10	10.5	9.9	14	13.2	12.7
All Microscopic	95	100	94.1	106	100	96.4
Non Microscopic	6	-	5.9	4	-	3.6
Total	101	-	100	110	-	100
* All Microscopic ** Total						

VIII Liver

- Total Number (ICD 10: C22) : 202
- 3rd leading cancer among males
- Peak age group: 65-69 years in males and females
- Histology : Hepatocellular carcinoma: 78.7% in males and 33.3% in females
- Method of diagnosis: Microscopic: 38.5% in males and 54.5% in females
- Detailed Microscopic diagnosis: Histology of Primary: 72.3% in males and 44.4% in females
- Broad treatment group: Treatment only at RI : 17.2% in males and 24.2% in females
- Clinical extent of disease before treatment (Treatment only at RI): Distant Metastasis: 41.4% in males and 50% in females.
- Intention to treat: Palliative: 75.9% in males and 87.5 in females.
- Composite Stage: Stage 4 : 46.7% in males and 63.6% in females

Table 61: Number and Relative Proportion of liver cancer by Five year age group

Liver					
Age	Male	%	Female	%	Total
0-4	0	0.0%	1	3.0%	1
5-9	1	0.6%	0	0.0%	1
30-34	0	0.0%	1	3.0%	1
35-39	3	1.8%	2	6.1%	5
40-44	4	2.4%	0	0.0%	4
45-49	3	1.8%	2	6.1%	5

50-54	12	7.1%	4	12.1%	16
55-59	25	14.8%	3	9.1%	28
60-64	34	20.1%	1	3.0%	35
65-69	37	21.9%	8	24.2%	45
70-74	30	17.8%	4	12.1%	34
>=75	20	11.8%	7	21.2%	27
Total	169	100%	33	100%	202

Table 62: Number and Relative Proportion of liver cancer by Broad treatment group

Liver					
Broad Treatment Group	Male	%	Female	%	Total
No treatment	106	62.7%	23	69.7%	129
Prior & Treatment at RI	13	7.7%	0	0.0%	13
Prior Treatment Only	21	12.4%	2	6.1%	23
Treatment only at RI	29	17.2%	8	24.2%	37
Total	169	100%	33	100%	202

Table 63 : Number and Relative Proportion of liver cancer by Clinical extent of disease before treatment (Treatment only at RI)

Liver					
Clinical extent before treatment	Male	%	Female	%	Total
Direct Extension	4	13.8%	0	0.0%	4
Direct Extension with Regional Nodes	2	6.9%	3	37.5%	5
Distant Metastasis	12	41.4%	4	50.0%	16
Localised	8	27.6%	1	12.5%	9
Too Advanced	3	10%	0	0%	3
Total	29	100%	8	100%	37

Table 64: Number and Relative Proportion of liver cancer by composite stage

Liver					
Composite stage	Male	%	Female	%	Total
stage1	4	2.4%	0	0.0%	4
stage2	13	7.7%	1	3.0%	14
stage3	26	15.4%	2	6.1%	28
stage4	79	46.7%	21	63.6%	100
unknown	47	27.8%	9	27.3%	56
Total	169	100%	33	100%	202

Table 65 : Number and Relative Proportion of liver cancer by intention to treat

Liver (Treatment only at RI)					
Intention	Male	%	Female	%	Total
Curative / Radical	7	24.1%	1	12.5%	8
Palliative	22	75.9%	7	87.5%	29
Total	29	100%	8	100%	37

Table 66 : Number and Relative Proportion of liver cancer by Diagnostic status

Liver					
Diagnostic status	Male	%	Female	%	Total
Microscopically Confirmed	65	38.5%	18	54.5%	83
Suspected (Microscopically / Radiologically)	104	61.5%	15	45.5%	119
Total	169	100%	33	100%	202

Table 67 : Number and Relative Proportion of liver cancer by Detailed Microscopicniosis

Liver					
Method of diagnosis	Male	%	Female	%	Total
Cytology of Metastasis	2	3.1%	2	11.1%	4
Cytology of Primary	2	3.1%	1	5.6%	3
Histology of Metastasis	14	21.5%	7	38.9%	21
Histology of Primary	47	72.3%	8	44.4%	55
Total	65	100%	18	100%	83

Table 68: Number and Relative Proportion of liver cancer by Morphology

Liver					
Morphology.	Male	%	Female	%	Total
Hepatocellular carcinoma	133	78.7%	11	33.3%	144
Neoplasm malignant	18	10.7%	13	39.4%	31
Cholangiocarcinoma	11	6.5%	5	15.2%	16
Adenocarcinoma	3	1.8%	2	6.1%	5
Carcinoma	2	1.2%	1	3.0%	3
Embronal sarcoma	1	0.6%	0	0.0%	1
Hemangiosarcoma	1	0.6%	0	0.0%	1
Hepatoblastoma	0	0.0%	1	3.0%	1
Total	169	100%	33	100%	202

IX Stomach

- Total Number (ICD 10: C16) : 202
- Stomach cancer is the 5th leading site among males.
- Peak age group: 60-64 years in females and 65-69 years in males
- Histology : Adenocarcinoma :53.9% in males and 46 % in females
- Method of diagnosis: Microscopic: 94.7% in males and 98% in females
- Detailed Microscopic diagnosis: Histology of Primary: 97.2% in males and 93.9 % in females.
- Broad treatment group: Treatment only at RI: 28.9% in males and 28% in females
- Clinical extent of disease before treatment (Treatment only at RI) : Distant Metastasis: 29.5 % in males and 50 % in females
- Intention to treat : Curative: 54.5% in males and 35.7% in females.
- Composite stage: Stage 4 : 46.7% in males and 50% in females

Table 69: Number and Relative Proportion of Stomach cancer by Five year age group

Stomach					
Age	Male	%	Female	%	Total
25-29	0	0.0%	1	2.0%	1
30-34	0	0.0%	2	4.0%	2
35-39	2	1.3%	4	8.0%	6
40-44	6	3.9%	7	14.0%	13
45-49	10	6.6%	6	12.0%	16
50-54	9	5.9%	4	8.0%	13
55-59	10	6.6%	7	14.0%	17
60-64	29	19.1%	8	16.0%	37
65-69	30	19.7%	4	8.0%	34
70-74	29	19.1%	5	10.0%	34
>=75	27	17.8%	2	4.0%	29
Total	152	100%	50	100%	202

Table 70: Number and Relative Proportion of Stomach cancer by Broad Treatment Group

Stomach			Female	%	Total
Broad Treatment Group	Male	%			
No treatment	75	49.3%	19	38.0%	94
Prior & Treatment at RI	10	6.6%	5	10.0%	15
Prior Treatment Only	23	15.1%	12	24.0%	35
Treatment only at RI	44	28.9%	14	28.0%	58
Total	152	100%	50	100%	202

Table 71 : Number and Relative Proportion of Stomach cancer by Clinical extent of disease before treatment (Treatment only at RI)

Stomach					
Clinical extent before treatment	Male	%	Female	%	Total
Direct Extension	3	6.8%	3	21.4%	6
Direct Extension with Regional Nodes	21	47.7%	4	28.6%	25
Distant Metastasis	13	29.5%	7	50.0%	20
Localised	3	6.8%	0	0.0%	3
Too Advanced	4	9.1%	0	0.0%	4
Total	44	100%	14	100%	58

Table 72: Number and Relative Proportion of Stomach cancer by Composite Stage

Stomach					
composite stage	Male	%	Female	%	Total
stage1	0	0.0%	1	2.0%	1
stage2	14	9.2%	3	6.0%	17
stage3	52	34.2%	13	26.0%	65
stage4	71	46.7%	25	50.0%	96
unknown	15	9.9%	8	16.0%	23
Total	152	100%	50	100%	202

Table 73 : Number and Relative Proportion of Stomach cancer by Intention to treat

Stomach					
Intention	Male	%	Female	%	Total
Curative / Radical	24	54.5%	5	35.7%	29
Palliative	20	45.5%	9	64.3%	29
Total	44	100%	14	100%	58

Table 74: Number and Relative Proportion of Stomach cancer by Diagnostic Status

Stomach					
Diagnostic status	Male	%	Female	%	Total
Microscopically Confirmed	144	94.7%	49	98.0%	193
Suspected (Microscopically / Radiologically)	8	5.3%	1	2.0%	9
Total	152	100%	50	100%	202

Table 75 : Number and Relative Proportion of Stomach cancer by Detailed Microscopic Diagnosis

Stomach					
Method of diagnosis	Male	%	Female	%	Total
Cytology of Metastasis	1	0.7%	1	2.0%	2
Histology of Metastasis	3	2.1%	2	4.1%	5
Histology of Primary	140	97.2%	46	93.9%	186
Total	144	100%	49	100%	193

Table 76 : Number and Relative Proportion of Stomach cancer by Morphology

WHO Histological Classification - Colon(ICD10: C18)Number (#) and Relative Proportion (%) of Different Broad Histological Classification - Stomach(ICD10: C16)Number (#) and Relative Proportion (%) of Different Histologic Types(Report from NCDIR/ICMR)

Histologic Type	Males			Females		
	#	%*	%**	#	%*	%**
Neoplasm Malignant (8000-8005, 9990)	3	2.1	2	3	6.1	6
Carcinomas (8010-8035, 8041, 8070-8072)	14	9.7	9.2	6	12.2	12
Adeno Carcinomas (8140, 8142-8143, 8144, 8145, 8190, 8240, 8241, 8244, 8246, 8310, 8560, 8570)	82	56.9	53.9	23	46.9	46
Mucinous Adeno Carcinoma (8480,8481,8482)	6	4.2	3.9	1	2	2
Signet Ring Cell Carc (8490)	35	24.3	23	14	28.6	28
Others	4	2.8	2.6	2	4.1	4
All Microscopic	144	100	94.7	49	100	98
Non Microscopic	8	-	5.3	1	-	2
Total	152	-	100	50	-	100
* All Microscopic ** Total						

X Tongue

- Total Number (ICD 10: C01-02) : 171
- 9th leading cancer among males
- Peak age group: 50-54 years in males and 65-69 in females
- Histology : Squamous cell Carcinoma: 89.5% in males and 89.4 % in females
- Method of diagnosis: Microscopic: 96.8% in males and 95.7% in females
- Detailed Microscopic diagnosis: Histology of Primary : 98.3% in males and 95.6 % in females
- Broad treatment group: Treatment only at RI :59.7% in males and 55.3% in females
- Clinical extent of disease before treatment (Treatment only at RI):Localised: 52.7% in males and 65.4% in females
- Intention to treat for new patients : Curative/Radical : 82.4% in males and 84.6% in females
- Composite Stage: Stage 4: 40.3% in males and 31.9 % in females

Table 77: Number and Relative Proportion of Tongue cancer by Five year age group

Tongue					
Age	Male	%	Female	%	Total
30-34	4	3.2%	1	2.1%	5
35-39	13	10.5%	2	4.3%	15
40-44	14	11.3%	3	6.4%	17
45-49	8	6.5%	1	2.1%	9
50-54	22	17.7%	3	6.4%	25
55-59	16	12.9%	6	12.8%	22
60-64	13	10.5%	5	10.6%	18
65-69	14	11.3%	7	14.9%	21
70-74	10	8.1%	4	8.5%	14
>=75	10	8.1%	15	31.9%	25
Total	124	100%	47	100%	171

Table 78: Number and Relative Proportion of Tongue cancer by Broad Treatment Group

Tongue					
Broad Treatment Group	Male	%	Female	%	Total
No treatment	26	21.0%	12	25.5%	38
Prior & Treatment at RI	12	9.7%	4	8.5%	16
Prior Treatment Only	12	9.7%	5	10.6%	17
Treatment only at RI	74	59.7%	26	55.3%	100
Total	124	100%	47	100%	171

Table 79 : Number and Relative Proportion of Tongue cancer by Clinical extent of disease before treatment (Treatment only at RI)

Tongue					
Clinical extent before treatment	Male	%	Female	%	Total
Direct Extension	3	4.1%	0	0.0%	3
Direct Extension with Regional Nodes	32	43.2%	9	34.6%	41
Localised	39	52.7%	17	65.4%	56
Total	74	100%	26	100%	100

Table 80: Number and Relative Proportion of Tongue cancer by Composite Stage

Tongue					
composite stage	Male	%	Female	%	Total
stage1	13	10.5%	7	14.9%	20
stage2	36	29.0%	12	25.5%	48
stage3	22	17.7%	12	25.5%	34
stage4	50	40.3%	15	31.9%	65
unknown	3	2.4%	1	2.1%	4
Total	124	100%	47	100%	171

Table 81 : Number and Relative Proportion of Tongue cancer by Intention to treat

Tongue (Treatment only at RI)					
intention	Male	%	Female	%	Total
Curative / Radical	61	82.4%	22	84.6%	83
Palliative	13	17.6%	4	15.4%	17
Total	74	100%	26	100%	100

Table 82 : Number and Relative Proportion of Tongue cancer by Diagnostic Status

Tongue					
Diagnostic status	Male	%	Female	%	Total
Microscopically Confirmed	120	96.8%	45	95.7%	165
Suspected (Clinically / To rule out Malignancy)	3	2.4%	2	4.3%	5
Suspected (Microscopically / Radiologically)	1	0.8%	0	0.0%	1
Total	124	100%	47	100%	171

Table 83 : Number and Relative Proportion of Tongue cancer by Detailed Microscopic Diagnosis

Tongue					
Method of diagnosis	Male	%	Female	%	Total
Cytology of Metastasis	1	0.8%	1	2.2%	2
Cytology of Primary	0	0.0%	1	2.2%	1
Histology of Metastasis	1	0.8%	0	0.0%	1
Histology of Primary	118	98.3%	43	95.6%	161
Total	120	100%	45	100%	165

Table 84 : Number and Relative Proportion of Tongue cancer by Morphology

Broad Histological Classification - Tongue(ICD10: C01-02)Number (#) and Relative Proportion (%) of Different Histologic Types(Report from NCDIR/ICMR)

Histologic Type	Males			Females		
	#	%*	%**	#	%*	%**
Neoplasm Malignant (8000-8005,9990)	2	1.7	1.6	1	2.2	2.1
Carcinomas (8010-8035,8041,8046)	3	2.5	2.4	2	4.4	4.3
Verrucous Carcinomas (8051)	2	1.7	1.6	-	-	-
Squamous Cell Carcinoma (8052, 8070-8076, 8083-8084)	111	92.5	89.5	42	93.3	89.4
Adeno Carcinoma (8140,8200,8525,8560)	2	1.7	1.6	-	-	-
Others	-	-	-	-	-	-
All Microscopic	120	100	96.8	45	100	95.7
Non Microscopic	4	-	3.2	2	-	4.3
Total	124	-	100	47	-	100
* All Microscopic ** Total						

REFERENCES:

1. Isabel dos Santos Silva (1999), Cancer Epidemiology, Principles and Methods IARC Publications, France.
2. Maclellan et al (1978) Cancer Registration and its Techniques IARC Scientific Publications No.21 France.
3. Young J.L (1991) Hospital Based Cancer Registry in Cancer Registration Principles and Methods IARC Publications France.
4. April Fritz, Constance Percy et al. International Classification of Disease for Oncology Third Edition, World Health Organization Geneva 2000.
5. John L. Young, Steven D. Roffers et al, seer summary staging manual 2000 codes and coding instruction
6. Hospital Based Cancer Registry Report, Regional Cancer Centre published by Cancer Epidemiology and Biostatistics, Regional Cancer Centre, Thiruvananthapuram June 2020.



Published by
Malabar Cancer Centre
 [Postgraduate Institute of Oncology Sciences & Research]
 (An Autonomous Institution under Govt. of Kerala)
 Thalassery-670 103, Phone : (+91) 0490 2355881, Fax: 0490 2355880
 Website: www.mcc.kerala.gov.in